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Background: Endurance athletes, in particular triathletes and ultra-distance runners, undergo high 
volumes of intense training in preparation for events. There is recent epidemiological evidence that the 
respiratory tract is the most common system affected by illness in athletes during tournaments. 
Respiratory tract symptoms have also been shown to affect endurance athletes particularly in the post-
event period. However, the prevalence of respiratory related illnesses including respiratory tract 
symptoms, asthma, and allergies in the pre-race period has not been well studied in endurance athletes. 
 
Objective:   The main aims of this dissertation were 1) to review the existing literature focussing on the 
epidemiology, pathogenesis, possible aetiology and management of respiratory tract symptoms, asthma 
and allergies in athletes, and 2) to conduct an investigation to determine the pre-event period prevalence 
(6 weeks and 1 week before an event) and nature of respiratory tract symptoms, asthma and allergies in 
Ironman triathletes and ultra-distance runners. 
 
Methods:  In the first part of the dissertation a review of the literature pertaining to respiratory tract 
symptoms and illness was undertaken. In the second part of the dissertation a cross-sectional descriptive 
study was undertaken in 441 triathletes entering the 2006 and 2007 Ironman Triathlon, and 152 ultra-
distance runners in the 2009 Two Oceans Ultra-marathon. In the 1 to 3 days before the race (registration 
period), participants were requested to complete a validated pre-event medical questionnaire containing 
sections on demographics, training and previous competition, common medical conditions and detailed 
sections on respiratory symptoms in the 6 weeks and 1 week period before the race, as well as asthma 
and allergies experienced. Respiratory symptoms were divided into upper respiratory tract symptoms 
(URTS), lower respiratory tract symptoms (LRTS) and systemic symptoms (SS).  All data obtained 













Results:  The main findings in the experimental section of the dissertation were that 1) triathletes trained 
significantly more hours in the 6 weeks and 1 week before an event than ultra-distance runners, 2) the 
period prevalence (6 weeks before the race) of respiratory tract symptoms was 50% of triathletes and 
35% of ultra-distance runners, 3) upper respiratory tract symptoms and particularly nasal symptoms 
(nasal congestion and rhinorrhoea) were significantly more common in triathletes (21 to 27%) in 
comparison with  ultra-distance runners (12 to 17%), 4) systemic symptoms (especially pyrexia) were 
significantly more common in ultra-distance runners in the 1 week before an event (9.2 vs. 2.4%), 5) the 
point prevalence of self-reported asthma was low in both study groups (ultra-distance runners 3.4% and 
triathletes 8.3%) although symptoms of dry cough, wheezing, shortness of breath and „tight‟ chest were 
reported by 25 to 80% of athletes in both study populations, 6) in most cases the diagnosis of asthma 
was made by means of history taking and a physical examination by a physician, 7)  majority of triathletes 
used beta 2-agonists only as the treatment of choice for asthma symptoms, while ultra-distance runners 
used combinations of corticosteroids and beta 2-agonist inhalers as first line treatment,  8) allergies were 
reported by 34% of triathletes and 22.3% of ultra-distance runners, 9) most allergic symptoms in both 
study groups were confined to the upper respiratory tract with hay fever ranging from 77 to 83% and 
sinusitis 55  to 64.2%, and 10) the most common medication used for allergies by triathletes and ultra-
distance runners, were anti-histamine tablets. 
 
Conclusion:  There is a high period prevalence of respiratory symptoms in triathletes and ultra-distance 
runners in the 6 weeks before an endurance event. Triathletes had a significantly higher prevalence of 
upper respiratory tract symptoms (especially nasal symptoms) in comparison to ultra-distance runners 
which might be related to allergies and a higher training volume.  There also appears to be a lack in 
proper diagnostic evaluation of asthma in these endurance athletes with suboptimal and improper 
treatment of asthma and allergies.  Approximately 10% of ultra-distance runners had systemic symptoms 
in the week before the event, indicating a lack of athlete education on possible risks of exercising with a 














Introduction and scope of thesis 
 
Endurance races such as the Ironman Triathlon (3.8km open water swim, 180km cycle and a 42.2km run) 
and Two Oceans Ultra-marathon (56 km run) are physically and mentally challenging. It is generally 
accepted that, in preparation for these events, endurance athletes are in optimal health, and free of 
disease. It has however been documented that endurance athletes can suffer from a variety of medical 
conditions 1. In particular, a high prevalence of respiratory related conditions (mostly upper respiratory 
tract symptoms) have been reported in endurance athetes, particularly in the post race peroid 2-4.     
 
Historically, respiratory symptoms in endurance athletes were automatically assumed to be of infective 
origin, because a decrease in host immunity as a result of intense exercise has been documented in 
these athletes 5;6. However, in recent studies 7-10 the possibility of an infective cause in these athletes has 
been investigated. The results of these studies show that in many instances, no pathogen could be 
isolated. This led to the quest to find an alternative explanation for the high prevalence of respiratory 
related symptoms in endurance athletes during periods of intense training and competition. Possible non-
infectious hypotheses are that the symptoms are caused by inflammation  and allergy rather than 
infection 7;11;12 or induced by a variety of airway irritants 7;13. 
 
Furthermore, the majority of research studies, to date, have focused on the occurrence of respiratory 
related symptoms in the period following an event 2-4 and little is known about the prevalence of these 
symptoms in the endurance athlete in the pre-event  period. Therefore the aim of this thesis was to 
investigate the prevalence and the nature of respiratory related conditions affecting the respiratory health 












In Chapter 2 of this dissertation, data on the prevalence of respiratory tract symptoms, asthma and 
allergies are reviewed. In particular, the terminology, pathogenesis, diagnosis and the influence of the 
each condition on the performance of the athlete are reviewed. In chapter 3 the results of a research 
study that investigated the prevalence of pre-event respiratory tract symptoms, asthma and allergic 
symptoms are presented. Finally in Chapter 4, the main findings of this dissertation are summarized and 
practical guidelines are presented  to both athletes and sports physicians for the early recognition of 
respiratory tract symptoms and appropriate management of these conditions. This is important to optimise 
the respiratory health of the athlete, and consequently improving the  performance of  endurance athletes.  




























Respiratory health of the endurance athlete: A review of the prevalence of 




It is generally accepted that athletes are healthy individuals and that their bodies are in optimum condition 
to withstand the high stressors of athletic training and competition. This would seem particularly true for 
endurance athletes who spend considerable time training and competing in exhausting and physically 
challenging events. However, contradictory findings exist in the scientific literature when the role of 
exercise and its influence on physical health and wellbeing is investigated.  On the one hand, exercise 
training is promoted to be beneficial in the prevention and management of many chronic diseases,14 and 
moderate intensity exercise may even have a positive effect on immune function and reduced incidence 
of upper respiratory tract symptoms 15. Yet, on the other hand, endurance athletes are at an apparent 
increased risk for developing symptoms of upper respiratory tract infections (URTI) during periods of 
intense training 5. Therefore, a “J-curve” has been suggested to explain the relationship between exercise 
and symptoms of URTI, with moderate and regular exercise improving the ability to protect against these 
symptoms, whilst intense, acute or chronic exercise has been suggested to negatively affect immunity 16. 
 
It is also interesting to note that respiratory related symptoms are the main presenting complaint at 
medical facilities, reported at a number of international sporting events and tournaments.  In a number of 
different studies, focussing on the 2002 Winter Olympic Games 17, the 2008 Winter Olympic Games 18, 
the 2010 FIFA World Cup 19, the 2009 FINA championships 20, and the 2009 IAAF championships 21, 












tournaments. This was only followed by gastrointestinal complaints (ranging from 20 to 26% of all 
consultations). Thus, respiratory complaints in athletes at these tournaments are very common, and 
therefore the understanding, detection, management and prevention of respiratory complaints are 
important for the team physician. The question is raised regarding the possible cause for this seemingly 
disproportionate high occurrence of respiratory illness in athletes. 
 
Historically, following investigation of the cause for increased susceptibility of the athlete to exercise 
related respiratory symptoms, data suggests that the immune system is transiently suppressed after 
prolonged strenuous endurance exercise. This has been suggested as an explanation for the increased 
risk of subsequent infection 5;6;22;23. Indeed, this immune suppression may become more apparent when 
the athlete goes through repeated cycles of high intensity and sustained training, and is often 
accompanied by other stressors to the immune system including lack of sleep, malnutrition, weight loss 
and severe mental stress 5. These stressors are common for the travelling athlete, crossing different time 
zones and competing in major competitions. 
 
The purpose of this Chapter is to review three different clinical entities that affect the respiratory health 
and symptomatology of the athlete, with special attention to the endurance athlete. These include 
respiratory tract symptoms and infections (section 2.4), asthma and asthma-like symptoms (section 2.5) 
and allergies (section 2.6). These clinical entities often have similar clinical manifestations and may 
coexist. This review will mainly focus on the prevalence of these conditions in athletes, but the 
pathophysiology, diagnosis, and the influence on training and performance of each of these clinical 
entities will also be briefly reviewed. A summary will be given at the end of each section and a conclusion 














2.2 Terminology and definitions:  Respiratory tract symptomatology  
 
The respiratory tract can be divided anatomically into the upper respiratory tract (URT) and the lower 
respiratory tract (LRT). Upper respiratory tract symptoms (URTS) are confined to the airway above the 
oropharynx (above the neck) and include “blocked nose”, “runny nose”, a sore throat and swollen 
glands24.  Symptoms such as cough, wheeze and chest pain are related to the lower respiratory tract 
(LRTS) 24. In some instances, systemic symptoms (SS) can accompany respiratory tract symptoms 
(RTS). This is referred to as “flu-like” symptoms and athletes can present with muscle aches, joint pains, 
fever, headache and general fatigue in combination with RTS 24. 
 
In the literature, the terms upper respiratory tract symptoms and upper respiratory tract infections have 
been used somewhat synonymously.  This is also relevant to the lower respiratory tract. The reason for 
this is historical as URT and LRT symptoms have been assumed to be due to infection. However, in a 
laboratory and epidemiological study that reported at least a 30% incidence in URTI, no pathogens could 
be identified 7. The lack of evidence to support an infective cause 7-10 for respiratory tract symptoms, led 
to the possibility of non-infectious hypotheses of URT and LRT symptoms. One of these hypotheses is 
the allergic hypothesis 7;12, and this hypothesis will be further explored in section 2.6. The terminology 
related to asthma and allergies will be outlined in the relevant sections to follow. 
 
 
2.3 Terminology and definitions:  Epidemiology   
 
This review is primarily focused on the prevalence of respiratory related illnesses in the endurance 
athlete.  It is thus important to define the epidemiological terms that will be used throughout the literature 












disease in a population is defined as the total number of cases of the disease in a population at a given 
time or a time period. Prevalence is usually calculated as the total number of cases in the population, 
divided by the total number of individuals in the population and is then expressed per 100 population (%) 
or as a proportion of the population. The prevalence is therefore an estimate of how common a condition 
is within a population at a certain time or over a defined period of time. The term lifetime prevalence 
refers to the proportion of individuals in a population that had the condition at any point in their life (up to 
the time of assessment).  Period prevalence refers to the proportion of individuals in a population that 
had the condition during a specified period, e.g. last 12 months, or last 6 weeks. Period prevalence will be 
used in this dissertation to describe the proportion of athletes suffering from RTS in a period before or 
after an event.  Point prevalence refers to the proportion of individuals that have the condition at a 
specific point in time (on the day of the assessment or measurement) (http://medical-
dictionary.thefreedictionary.com/prevalence). 
 
The term prevalence has to be differentiated from the term incidence, which is defined as the number of 
new conditions/illnesses in a population related to the exposure time (e.g. years, months, days, or hours 
of exposure) (http://medical-dictionary.thefreedictionary.com/incidence). 
 




Historically, it has been assumed that respiratory tract symptoms in athletes, were caused by an infective 
pathogen due a decrease in body‟s immune system as a consequence of intense and prolonged exercise 












cause for RTS 7-10;25. In most instances where this has been studied, no pathogens could be isolated. This 
led to the suggestion that RTS in athletes might also be due to non-infective causes which can include 1) 
allergies 7;11;12;24, 2) inhaled physical or chemical irritants 7;13, and 3) other medical conditions such as 
sinusitis, gastro-oesophageal reflux disorder (GORD), deconditioning, anxiety, cardiac abnormalities and 
vocal cord dysfunction 26. It is clear that other pathophysiological mechanisms should be considered as 
possible causes of respiratory symptoms.  For example, vocal cord dysfunction is often misdiagnosed as 
asthma and presents with increased inspiratory effort, stridor and wheeze. This condition is due to 
functional upper airway obstruction and occurs in 5 to 15 % of all athletes investigated for exercise-
induced  bronchoconstriction 26. 
 
The focus of this dissertation is on respiratory tract symptoms that are suggestive of infections, allergies 
and asthma. Therefore, an in depth discussion of the other medical conditions (listed above) is beyond 
the scope of this review and this dissertation. However, for the sports physician, these conditions must be 
taken into consideration as a part of the differential diagnosis in the athlete presenting with respiratory 
tract symptoms.  
 
2.4.2. Terminology and definitions:  Respiratory tract and systemic symptoms 
 
For the purposes of this review and this dissertation, it is important to define the terminology that relates 
to respiratory tract and systemic symptoms. The following list summarizes the terminology that will be 
used in this dissertation as these relate to the respiratory system: 
 Upper respiratory tract symptoms (URTS):  These symptoms are localised to the nose and 
pharynx, and include „runny nose‟, „blocked nose‟ and sore throat 
24. 
 Lower respiratory tract symptoms (LRTS):  These are symptoms below the pharynx including 












 Systemic symptoms (SS):  Systemic symptoms include fever, headache, joint and muscle pains, 
and general fatigue 24. 
 
2.4.3. Pathogenesis and risk factors for respiratory tract symptoms (RTS) in athletes 
 
Currently, three different hypotheses have been proposed for the aetiology of RTS in athletes and these 
will now be reviewed briefly. To date, the majority of studies have assumed an infective hypothesis for the 
development of RTS in athletes. This hypothesis is based on the observations that an acute exercise bout 
as well as regular exercise training can alter various immune parameters. These alterations occur with 
respect to the systemic immunity 6, cytokines and mucosal immunity 27 in response to exercise. For 
example, salivary immunoglobulin A (IgA) concentration is decreased for several hours after prolonged 
intense exercise 23. This observation has led to the hypothesis that there is an „open window‟ period for a 
few hours after an exercise bout, during which there is decreased host defence 6. During this period of 
decreased host defence, it is hypothesized that bacteria and viruses gain foothold, and cause subclinical 
and clinical respiratory tract infection 5;6. It has also been noted that cortisol concentrations are elevated 
after prolonged exercise. Increased cortisol concentrations have been linked to immunosuppressive 
changes that may be experienced during recovery 5. Data therefore suggest that the immune system is 
transiently suppressed after prolonged endurance exercise. These findings supported the view that host 
protection is compromised after endurance exercise 5. However, in spite of many studies focussing on 
immune changes following exercise, there are no data supporting a direct relationship between changes 
in the immune parameters and the presence of URTS in athletes 28-30. Furthermore, in studies where 
athletes with RTS following endurance events have been investigated, only few could obtain positive viral 
or bacterial cultures to support an infective hypothesis for the RTS 8;10. In summary, there are little data to 
confirm that respiratory tract symptoms in athletes are mostly of infective origin 8-10, indicating that other 













An alternative hypothesis for the pathophysiology of RTS in endurance athletes is to consider allergy 
(atopy). There is good evidence that allergies are very common in elite athletes, and in a number of 
studies it has been documented that the prevalence of atopy in elite athletes is high and ranges from 23 
to 60% 12;31-34. Clinically, symptoms of allergy may mimic those of infections, and it can be difficult to 
differentiate between these causes. Thus, the possibility that RTS in endurance athletes might be related 
to allergies rather than infections, should be considered 11;12. 
 
Finally, the pathogenesis of RTS in endurance athletes may be related to various physical factors that are 
associated with sports participation. Physical factors that may be related to the pathophysiology of RTS in 
endurance athletes could include the high ventilation rate during high intensity exercise, inhalation of cold 
or dry air, increased air turbulence, mouth breathing and increased concentrations of inhaled irritants. 
These physical factors may all be associated with increased risk of developing RTS in athletes 11 8;13. 
When ventilation rate exceeds 30 l/min, there is a tendency towards mouth breathing instead of nasal 
breathing. This may increase the exposure of upper and lower airways to airborne allergens and 
irritants11;12. Increased ventilation rate may also cause cooling and drying of the respiratory mucosa 35. All 
of these mechanisms may increase risk of airway injury and predispose it to illness. Pollutants including 
sulphur dioxide, nitrogen oxide, ozone and airborne particulates may also be contributory factors 36. Other 
factors reported to increase risk of RTS in athletes are female gender, perceived stress, sleep 
deprivation, a lack of awareness about nutrition 37;38 and decreased Vitamin C intake 3. 
 
In summary, there are a number of pathophysiological mechanisms that may be responsible for the 
development of RTS in athletes. There is evidence from recent studies that the traditional infective 
hypothesis for RTS in athletes is not established, and that allergies or other physical factors may be 
important. This information is important for the sports physician as the return to play guidelines following 












aetiology of RTS. The precise diagnosis of the cause of RTS in athletes is therefore important for the 
sports physician.  
 
2.4.4. Diagnostic approach in athletes with respiratory tract symptoms (RTS)  
 
A detailed discussion of the diagnostic approach to respiratory symptoms in athletes is beyond the scope 
of this review. However, a brief overview is important.  As with any clinical condition, a thorough history 
and clinical examination should be performed with special attention to vital signs, and a comprehensive 
pulmonary and ear, nose and throat examination 8. If an allergic component is suspected, skin prick tests 
followed by venous blood samples for allergen specific IgE are indicated.  Specific identification of 
pathogens in the respiratory system can be achieved by performing various diagnostic and laboratory 
tests. Some of these tests are inexpensive and non-invasive, while others may be complex, expensive 
and invasive. Special investigations might include nasopharyngeal and throat swabs, which can be 
analysed using microscopy, culture, and polymerase chain reaction testing for bacterial, viral, chlamydial 
and mycoplasmal respiratory pathogens 7;10. The cells present in sputum can also be investigated for the 
number of neutrophils, eosinophils and lymphocytes present 7. Venous blood samples can be collected 
for a variety of infective markers 8. More invasive procedures include bronchioalveolar lavage and 
bronchial biopsies 7.   
 
2.4.5. Prevalence of respiratory tract symptoms (RTS) in athletes 
 
Respiratory tract symptoms (RTS) suggestive of infections are common in both the general and the 
athletic population.  Any individual (athletes and non-athletes) may have multiple episodes of infections 
pertaining to the respiratory system in one year, which may differ in severity and morbidity. These are 












Furthermore, in athletes, one of the most common non-injury causes for presenting to a sports physician 
during a tournament, is an episode of upper respiratory tract symptoms 19-21 and this was also the most 
common complaint in athletes participating in both the summer and winter Olympic Games 17;18;39. The 
methodology described in these studies differs, and the duration of these tournaments also varied. This 
makes the precise comparison of the true prevalence of RTS during tournaments in athletes difficult. 
Therefore, for the purpose of this review, it is more appropriate to consider the period prevalence (the 
number of cases of a disease which occur during a specified period) of RTS in athletes. Three different 
time periods can be identified where an athlete may develop RTS: 
 Pre-event period: This period refers to the days or few weeks before an event and it is a time period 
that is characterized by intense training and preparation before an event. 
 Period at the time of an event or tournament: This period refers to the time during an event, and most 
studies that have described RTS in athletes in this period, have focussed on the tournament setting 
lasting days or weeks. 
 Post-event period: This period refers to the days or the weeks that follow an event (post-event period) 
and has also received some attention in the literature.   
 
In some studies, the focus has been placed on the volume of training (hours or kilometres) to determine 
its effect of RTS prevalence, while other studies have focused on the type of sport or the time period 
before or after an event.  A summary of the studies where data are available on RTS in these periods will 
now be discussed.  
 
2.4.5.1. Pre-event respiratory tract symptoms (RTS) in athletes 
 
There are very few data on the prevalence of pre-event RTS in athletes (Table 2.1). In one prospective 












episodes” (IE) was recorded in 1694 (340 female and 1354 male) runners finishing the Stockholm 
marathon. In this study, the pre-event period prevalence (3 weeks) of “infectious episodes” was 17% 40. In 
only one other study conducted in our Unit, the period prevalence of upper respiratory tract symptoms 
(URTS) and allergies was documented in the 6 weeks before an Ironman Triathlon. In this study, the pre-
event period prevalence (6 weeks before the event) of RTS was 50%. In this study, there was also an 
association between pre-event RTS and allergies. However, there was no association between pre-event 
RTS and training volume, smoking history, or family history of allergies or asthma (M. Lichaba, Sept 
2006).  
 



















It is important to note that in one other study, data on RTS in athletes were also collected over a period of 
time. However, this period was not related to a specific pre-event period, but rather to a 12-month period 
of training. In this prospective cohort study, 530 male and female runners completed a monthly training 
log over the 12-month period. In this group of runners, the average number of URT “infections” was 1.2 
per person per year. It is important to note that, in this study, the diagnosis of an “infection” was not 
confirmed by laboratory testing. Factors influencing the number of URT “infections” experienced were 
also investigated. In particular, there was a significant interaction between alcohol use and gender with 












































































In summary, the period prevalence (few weeks before an event) of pre-event RTS has, to our knowledge, 
only been reported in two studies. The data from these studies indicate a high period prevalence of RTS 
in endurance athletes in the few weeks before an event (ranging from 17% to 50%). The causes for the 
high prevalence of RTS have not been investigated, although allergies have been linked to RTS in the 
one study. This apparent high prevalence of RTS in the pre-event period has clinical implications for the 
sports physician looking after a group of athletes. This is an area that requires further investigation and is 
one of the areas of focus in the experimental section of this dissertation. 
 
2.4.5.2. Respiratory tract symptoms (RTS) in athletes during events or tournaments 
 
In athletes, respiratory tract symptoms (RTS) can develop during events (that may vary from minutes to 
hours) or during tournaments (that can span over days to weeks). It is clear that there can be a wide 
variation in the duration of events or tournaments.  It is only in recent years, that the pattern of illness in 
athletes participating in tournaments has been investigated (Table 2.2). These studies have focussed 
mainly on elite athletes participating in international tournaments such as the Olympic Games (summer 
and winter), and the World Championships in aquatic events, athletics and football. The data from these 
studies show that 12% of football players suffered from an illness during the 2010 FIFA World Cup19, 
7.1% of athletes reported illness in the 2009 FINA world championships20, 6.8% of athletes suffered from 
an illness during the 2009 IAAF World championships21, and 6.7% of athletes suffered from an illness 
during the 2010 Winter Olympic Games42. In all these studies, respiratory tract illness was the most 













Table 2.2.  The period prevalence of respiratory tract symptoms (RTS) (“illness”) in athletes during 


























In summary, data show that RTS are very common in elite athletes participating in tournaments that last a 
few days to weeks. These studies show that the respiratory tract is a common system that is affected by 
illness in these athletes. However, the precise cause for RTS during tournaments has not been well 
investigated and diagnosis of RTS in all cases was by a clinical diagnosis of the team physician.  
 
2.4.5.3. Post-event respiratory tract symptoms (RTS) in athletes  
 
Post-event RTS in athletes have been investigated in a number of studies. In the majority of these 
studies, post-event respiratory tract symptoms (RTS) in endurance athletes (mainly runners) have been 
recorded in the immediate post-event period up to 2 weeks post-event (Table 2.3). The first study where 
post-event RTS data have been recorded in athletes was a prospective study conducted by Peters and 
Bateman in 1983. In this study, 150 randomly selected Two Oceans marathon runners and individually 



















































































































the day before and 2 weeks after the race. Symptoms of URT “infection” were documented in 33.3% of 
the runners compared to 15.3% of controls (a 2-fold increase) in the 10-14 day post-race period. In 
addition, RTS were more common in those who achieved faster race times. The period prevalence of 
post-event RTS in slow runners was comparable to that in the control subjects 2. 
 
In another study by the same investigators, the role of daily vitamin C supplementation (600mg) in 
reducing post-race upper respiratory tract symptoms (URTS) was studied using a double-blind-placebo-
controlled study design. In this study 92 ultra-marathon runners competing in an ultra-marathon event and 
92 control runners were recruited. This post event period prevalence or URTS was 33% in athletes on 
vitamin C supplements compared to 68% in athletes in the placebo group (p<0.05) 3. 
 
In one other large epidemiological study, 2311 marathon runners were randomly selected 8 days before 
competing in the Los Angeles Marathon (LAM) 4. The relationship between self-reported “infectious 
episodes” (IE), training data and participation to the LAM were evaluated by means of a questionnaire.  
Athletes varied widely in running ability and training habits. The period prevalence (1 week) of post-event 
IE was 12.9% in the runners compared with only 2.2% in a control running group that did not participate in 
the race. In addition, runners who trained >96km per week had an increased risk of post-event IE (double 
the odds ratio of developing symptoms) compared with runners training <32km per week 4.  
 
In the previously mentioned prospective cohort study (section 2.4.5.1) in 1694 (340 female and 1354 
male) runners where the period prevalence of pre-event “infectious episodes” (IE) 3 weeks before a race 
were investigated, post-event data were also recorded 40. In this study, the pre-race period (3 weeks) 
prevalence of an IE of 17% was similar to the post-event period prevalence of IE of 19%. There was also 
no difference between male and female athletes. It is of interest to note in this study that the post-event 
prevalence of IE was 16% in runners who began the race in a healthy state. In the group of runners who 












increased risk for post-event IE was related to pre-event IE, as healthy athletes before the race had no 
increase in self reported IE after a race. Furthermore, pre-event training, gender, social status, training 
volume or running time could not explain the difference in post-event IE. It was however documented that 
faster finishing times, especially in younger athletes, could pose a risk for post-event IE 40.   
 
These studies all indicate that endurance athletes have a high period prevalence of self-reported RTS in 
the 2-week period following events. Factors that are associated with the post-event RTS are increased 
training volume, increased exercise intensity and the presence of pre-event RTS. In one study, it appears 
that Vitamin C supplementation was associated with a decrease in post-event RTS. 
 
 




































































































































































2.4.5.4. Summary: Period prevalence of RTS in athletes 
 
In this review on the period prevalence of RTS in athletes it is clear that RTS are common in the pre-
event period, during tournaments, and in the post-endurance event period. Data are strongest in ultra- 
marathon runners, in the post-event period 2;3 and in elite athletes during tournaments. The pre-event 
period has not received much attention, despite the fact that pre-event RTS may be associated with 
increased risk of post-event RTS 40.  Also of note is the fact that very few studies have investigated the 
prevalence of RTS in triathletes 10;22;23.  
 
Triathletes are a unique group of endurance athletes because the demand of training (volume and 
intensity) is spread across three disciplines. It has been suggested that triathletes are at a higher risk of 
development of URTS 22 due to increased physical stress during training and competition compared to 
runners, cyclists or swimmers. In one study, the effect of competing in a half-ironman triathlon (mean time 
6.5hr) on the cell-mediated immunity was investigated by Bruunsgaard et al (2007). The results of this 
study showed that delayed-type hypersensitivity (DTH) reaction was suppressed in 60% of triathletes 2 
days after the competition compared to the controls. This was the first study to show that the increased 
physical demands of training for and competing in a triathlon can decrease in vivo cell-mediated immunity 
and predispose these athletes to a higher risk of RTS 22.  
 
In summary RTS are common in athletes during the pre-event period but there are very few studies that 
have focussed on this period. In one study, pre-event RTS were possibly related to allergies, but this 
requires further investigation. Secondly, during events or tournaments the period prevalence of RTS is 
lower, but RTS did account for most symptoms of illnesses seen by attending team physicians. Finally, 
post-event RTS are very common, and may be related to pre-event RTS as well as intensity and duration 
of the exercise performed during the competition. RTS in athletes need to be recognised and appropriate 












2.4.6. Clinical Implications: The effect of RTS on training and performance 
 
As outlined above, it appears that athletes seem more prone to develop RTS in the period of intense 
training 5.  This usually occurs in the period prior to a race or event. During this period, the sports 
physician has to give the athlete sound advice regarding continuation or withdrawal from exercise training 
and racing. Unfortunately, there are few clear guidelines to assist the physician with return to play, 
especially with respect to the intensity and time interval at which exercise may be resumed 35. 
 
Clinical guidelines to assist the sports physician in providing advice to the athlete presenting with RTS 
have been suggested 35. These guidelines have been called the “neck check” and are primarily there to 
differentiate localized from regional or systemic symptoms and signs. If symptoms or signs are above the 
neck (e.g. “runny nose”, nasal congestion, or sore throat), with no below the neck symptoms (e.g. cough, 
fever, malaise or gastrointestinal symptoms), it has been suggested that the athlete may train for 10 min 
at half the normal intensity level. If the symptoms then do not worsen, the workout can be continued as 
tolerated. If symptoms worsen following the 10 minute trial, training should be suspended until symptoms 
have resolved 35. 
 
The distinction between localized and regional/systemic symptoms and signs is important. It has been 
shown that not all episodes of illness have a detrimental effect on the athlete‟s performance. A study in 
college students investigating experimental rhinovirus infection found no negative effects of this viral 
infection on pulmonary function tests, VO2 max values or performance during sub maximal exercise 
testing. The authors however mentioned that the rhinovirus does not cause viremia, and symptoms are 













It is however important to consider the possible serious consequences of certain infections in athletes 43. 
In some cases, lower respiratory tract symptoms or systemic symptoms may be an indication of systemic 
viral or bacterial illness. These may present with systemic signs or symptoms such as fever that can 
affect an athlete‟s ability to train and compete. Fever has been shown to impair mental cognition, 
pulmonary perfusion and concentric muscle strength 35. It also increases systemic metabolism and 
insensible fluid loss thereby increasing the body‟s requirements for caloric intake, oxygen and fluids. It 
has a negative effect on performance, can increase the risk for injury 44 and may predispose an athlete to 
heat illness e.g. heat stroke. 
 
However, the most serious consequence of performing exercise training in the presence of a systemic 
illness, is the risk of myocarditis, which is a potential life threatening condition in exercising athletes 43. 
Myocarditis is mostly caused by viruses, notably the Coxsackie virus. Symptoms associated with this 
condition are shortness of breath, chest pain, tachycardia at rest and systemic symptoms like fever and 
general body pains 24;43. Furthermore, some viruses, in particular the Ebstein Barr virus, which is the 
responsible organism for infectious mononucleosis, can cause prolonged symptoms 35;43. This infection 
commonly occurs in the 15-24 year age group, and more than 90% of the population demonstrate 
antibody titres by the age of 30 years 35.  Although infectious mononucleosis is seldom fatal and is usually 
self-limiting, recovery may take up to 6 to 8 weeks. Symptoms of anorexia, fatigue and nausea are often 
present, and this may complicate recovery. A highly trained athlete may take as long as 3 months to 
attain pre-illness fitness levels following infectious mononucleosis 35. It has also been shown in several 
case histories that sudden and unexplained decreases in athletic performance could be traced to recent 
URTI or a subclinical viral infection 5. In some athletes, a debilitating state known as “post viral fatigue” 
can also occur after a viral infection. Symptoms include easy fatigability, lethargy and myalgia and these 
can persist for several months 5. It is therefore important to identify these illnesses and to give appropriate 













In summary, RTS in the exercising individual have a number of important clinical considerations. Firstly, 
the sports physician needs to make an accurate diagnosis to determine if the causes are infective or non-
infective. Without the use of special investigations (that also require some time before results are known) 
this is a challenge to the sports physician. Secondly, clinical decisions have to be made regarding training 
or participation in competitions. Currently, distinguishing between localized and regional/systemic 
symptoms and signs are used in this decision (“neck check”). Thirdly, there are the potential life-
threatening and long-term complications of infective causes of RTS in athletes. All these considerations 
are against a backdrop of data showing that RTS are very common in the pre-event period, during 
tournaments and following events. Appropriate measures to prevent RTS and to manage RTS in athletes 
are therefore important to consider.  
 
2.4.7. Prevention and management of RTS in athletes 
 
Athletes should be aware of possible ways to decrease the risk or spread of infection. This is an area that 
has not been studied well. In one recent study, some preventative measures were shown to be effective 
in reducing respiratory tract illness in a team travelling to the winter Olympic Games 45. In this study, the 
measures that were introduced included the following; 1) basic hygiene (hand washing), 2) the use of 
alcohol hand gel and 3) to minimise close contact with ill individuals, 4) athletes with respiratory problems 
and subjected to heavy training loads, were accommodated in single rooms and 5) it was suggested that 
all athletes should be vaccinated prior to the training season and before travelling abroad 45.  
 
The role of certain supplements in reducing RTS in athletes has also been investigated.  A double-blind –
placebo-controlled study was conducted to evaluate the role of vitamin C supplementation in the 14 day 
post-race period in a group of ultra-marathon runners. The results of this study show that 33% of vitamin 
C supplemented runners reported URTS compared to 68% in the placebo group. The study concluded 












Whilst this effect has not been shown in all studies 46;47, it has been suggested by some authors that 
because Vitamin C is an antioxidant, it reduces the risk of RTS by clearing free oxygen radicals which are 
produced by heavy exertion 5. Finally, there is recent evidence that the use of probiotics may modulate 
the immune response to training, thus reducing the duration and severity of RTS in endurance 
athletes48;49. 
 
The prevention and treatment of respiratory illnesses thus require a combined effort of athletes, 
physicians, coaches and administrators. It is the athlete‟s responsibility to report RTS immediately to the 
medical staff and to comply with the physician‟s recommendations. This measure may result in 
diminished impact of respiratory illness on training and general wellbeing of the athlete. 
 
2.4.8. Summary: Respiratory tract symptoms (RTS) in athletes 
 
 RTS are common in both the general and the athletic populations and have traditionally been 
attributed to infection. 
 RTS are more prevalent after a period of high intensity and prolonged exercise or training. This has 
been traditionally thought to be due to the “open window” hypothesis of decreased immunity. 
 The decrement in the immune status is usually only temporary. 
 An infective cause for RTS in athletes has not been proven and hence there is a need to consider 
alternative hypotheses for the cause of RTS in athletes. 
 RTS and allergic symptoms can often coexist. 
 Respiratory tract infection can at times be prolonged with negative long-term consequences. 
 Some preventative measures can be effectively taken to decrease infection exposure and 
susceptibility. 












 The majority of studies on RTS in athletes have been in runners and few studies documented RTS 
experienced by triathletes. 
 Future studies on the prevalence of RTS, allergies and asthma in a defined study population might be 
of benefit to assess co-existence of these conditions. This may help explain the aetiology of RTS, 
which may have similar clinical manifestations.   
 
 




Athletes may experience increased respiratory workload as a normal physiological response to the body‟s 
increased demand for oxygen during bouts of exercise. Under normal conditions, the respiratory system 
is able to adapt to the higher oxygen demand for increased cell metabolism and respiration. However, 
there are conditions in which the body fails to respond appropriately. 
 
Asthma, exercise-induced bronchoconstriction (EIB) and airway hyper responsiveness (AHR) are 
common respiratory conditions found in both the athletic, as well as in the general population 50. These 
conditions exist due to an abnormal response of the respiratory system to increased ventilation or other 
“triggers” and may present with symptoms of chest tightness, breathlessness, wheezing, phlegm, 
dyspnoea and cough 51. In questioning athletes regarding respiratory symptoms, they may use a variety 














2.5.2 Terminology and definitions:  Asthma and asthma-like symptoms 
 
Airway hyper-responsiveness (AHR) occurs when airways constrict more than the normal response 
when exposed to physical stimuli (cold air and exercise), chemical substances (methacholine and 
histamine), or sensitising agents (allergens) in sensitised individuals 50. Exercise-induced 
bronchoconstriction (EIB) is the transient airway narrowing that occurs in individuals with hyper-reactive 
airways, during or following vigorous physical activity, which results in a decrease in pulmonary function 
52. When this narrowing of airways occurs in response to exercise in a known asthmatic individual, this 
phenomenon is best described as exercise-induced asthma (EIA) 53. Both of these conditions are 
characterized by respiratory symptoms including cough, breathlessness, and tightness of the chest, 
wheezing, chest pain and excess mucus production. These symptoms might result in fatigue, poor 
performance, and poor recovery from exercise 26;54. Asthma is a clinical syndrome characterised by an 
increased response of the trachea and bronchi to a variety of stimuli 55. It is a common, chronic disease in 
both the athletic population and sedentary individuals and is associated with intermittent episodes of 
airflow obstruction, that is at least partially reversible 56. 
 
It is clear that EIB, AHR and asthma, may all present with similar symptoms. It is however important to 
understand the pathogenesis of these conditions, as this will determine the appropriate management. 
 
2.5.3 Pathogenesis of asthma and asthma-like symptoms in athletes 
 
Many theories exist for the development of asthma and the higher prevalence of asthma-like symptoms in 
the athletic population. The first of these theories is the osmotic theory (airway dehydration theory). 
Inspired air needs to be humidified and therefore water loss occurs from the airways during exercise can 












mediators including prostaglandins, leukotrienes, and histamine, which stimulate smooth muscle, causing 
contraction and change in the permeability of the airway vasculature. The ability to return water to the 
airway surface is likely to be different for healthy and inflamed lower and upper airways 57. 
 
The second theory is the thermal theory or airway cooling theory. This theory proposes a purely 
mechanical cause of airway narrowing 57. Airway cooling causes vasoconstriction of the bronchial 
vasculature, followed by reactive hyperaemia which causes vascular leakage and airway oedema 57. With 
an increase in ventilation rate during higher intensity exercise, mouth breathing replaces nasal breathing 
resulting in decreased heating of inspired air 12. 
 
A third theory relates to epithelial injury and inflammation. Cooling and dehydration of the air can also 
cause airway epithelial injury. There is some evidence that there is an increase in the number of 
neutrophils in sputum, and this is suggestive of epithelial injury 58. The severity of EIB in asthmatic 
athletes appears to be related to the epithelial cell numbers in sputum at baseline 59. The response to 
airway injury involves exudation of bulk plasma as part of the restorative process. In elite athletes 
exercising in cold weather conditions, this process of epithelial injury and repair would occur repetitively 
during the season. It was proposed that AHR and EIB could develop for the first time after repeated 
exposure 52, due to the effect of plasma-derived products on the contractile properties of airway smooth 
muscle (ASM) 57. This concept was supported by the finding that airway responsiveness returned to 
normal out of season and after retirement of sport 57. 
 
Hyperventilation during exercise also induces mechanical stress that is thought to increase local 
inflammatory processes in the airways 50. Furthermore, it exposes the airways to increased 
concentrations of allergens, pollutants, or other particles suspended in the air. Outdoor exercise can 












neutrophilic airway inflammation, and this in turn, cause increased airway smooth muscle 
responsiveness57. 
 
Swimmers are particularly prone to develop AHR due to inhalation of chlorine gas in chlorinated pools.  A 
study conducted in Spain, measured concentrations of chlorine gas above the water surface 60. It was 
calculated that if a swimmer trains for 2 hours, exposure to chlorine gas was in excess of 4 to 6gm during 
that period. This exceeded the recommended exposure of 4 to 7gm for a worker per 8-hour shift in the 
United States. This exposure to chlorine gas may increase airflow obstruction and increase bronchial 
responsiveness 60. This finding may explain the high prevalence of asthma-like symptoms in swimmers. 
 
Atopy also appears to be a significant risk factor for the development of asthma. In a study investigating 
logistic regression models of asthma in athletes, it was found that when atopy and sport participation 
were combined as risk factors, the relative risk of asthma increased 97-fold in atopic swimmers, 42-fold in 
atopic long distance runners; and 25-fold in atopic speed and power athletes, compared with non-atopic 
controls 61. 
 
Besides the environmental triggers for EIB and asthma, a genetic component for the development of 
asthma has also been suggested. It has been shown that, if one or more family members have atopy 
and/or asthma, a child born into this family has a far greater risk of developing asthma 50. 
 
It is thus evident that the aetiology of asthma-like symptoms is multi-factorial but that the common 
underlying pathology is inflammation of the airways with an abnormal response to certain triggers and 
increased ventilation.  It is also important to note that symptoms of asthma may mimic that of respiratory 












2.5.4. Diagnosis of asthma in athletes 
 
Asthma is a clinical syndrome and therefore a thorough history and physical examination are the 
cornerstones of the diagnosis of asthma. Clinical assessment in combination with special investigations 
are used in the diagnosis of asthma 56. In the history taking, the physician should take special note of 
symptoms exacerbated by triggers, sensitivity to drugs including aspirin or non steroidal anti-
inflammatories as well as a history of allergies and atopic conditions 51 56. The physician should also 
enquire about associated symptoms of sinusitis, gastro-oesophageal reflux disorder, and anxiety 
disorders as these can be contributing factors 26.  
 
 
In the physical examination of the respiratory system, the athlete should be assessed for prolonged 
expiratory time and wheeze, decreased air movements and hyperexpansion of the chest cavity, as well 
as the use of accessory muscle use with respiration 56. Athletes should be assessed both at rest and after 
exercise, as some of the symptoms may only become apparent with physical exertion.  
  
Various special investigations can aid in the diagnosis of asthma and these should be used appropriately 
for the confirmation of this condition. Pulmonary Function Testing (PFT) or clinical spirometry, which 
measures the amount (volume) and speed (flow) of air that can be exhaled and inhaled, forms the gold 
standard of testing. Resting PFT is performed by asking the athlete to inhale the deepest possible breath 
and then to exhale quickly and forcefully 56. The forced expiratory flow in the first second (FEV1) is then 
compared to the entire volume of air that can be expelled in a forced expiration, and this measurement is 
known as the forced vital capacity (FVC) 56. Airflow obstruction (asthma) is present if FEV1/FVC < 0.7 or 













To assess for EIB, baseline PFT is performed and the athlete is then requested to perform an 8-minute 
exercise test (running or cycling) at an exercise intensity where 90% of predicted maximum heart rate is 
reached within 2 minutes after the start of the exercise. PFT tests are repeated at 5, 10 and 30 minutes 
after the cessation of the exercise test. If the FEV1 decreases by at least 10% from baseline values, the 
post-exercise challenge test for EIB is considered positive 26. 
 
Athletes who have airflow obstruction on PFT are given 2-4 puffs of a short-acting bronchodilator e.g. 
salbutamol 26, and PFT are repeated after 10-15 minutes.  A reversible airflow obstruction is defined when 
an improvement of >12% or >0.2L in baseline FEV1 26;56. It should be noted that peak flow meters should 
not be used in the diagnostic evaluation of asthma as spirometry is much more accurate (3% vs.10%) 
and FEV1  is less effort-dependant than peak flow measurements 56. 
If the physician still suspects asthma or EIB, but has failed to demonstrate bronchoconstriction, he/she 
may assess the athlete for hyper-responsive airways by conducting bronchial provocation tests 
(BPTs)62;63. 
 
Direct BPTs include the methacholine and histamine challenge tests. These are very useful tests to 
evaluate for asthma 62. Methacholine stimulates the airway smooth muscle directly and interpretation is 
based on the provocational concentration (PC) of methacholine that causes a 20% decrease in baseline 
FEV1 (PC20) 56;62. A normal methacholine challenge test is a decrease in the FEV1 by 20% at a 
methacholine concentration of >16mg/mL, while the same response at a methacholine concentration of 
<4mg/ml is considered a confirmatory test of AHR 56. Histamine has a shorter half-life than methacholine 
but unfortunately has a greater side effect profile e.g. voice changes, headache and flushing, dizziness, 














Indirect testing for AHR includes exercise challenge tests (test of choice to evaluate for EIB) 62, eucapnic 
voluntary hyperpnoea (EVH) and inhalation of hyperosmolar aerosols e.g. hypertonic saline and 
mannitol26;63. These challenge tests cause the release of mediators from inflammatory cells which in turn, 
stimulate bronchoconstriction 26.  
 
2.5.5 Prevalence of asthma and asthma-like symptoms in athletes 
 
For the purposes of this review, the prevalence of asthma will be considered as either lifetime prevalence 
(ever diagnosed asthma; also known as total asthma) or point prevalence (current asthma). Studies 
documenting the prevalence of asthma and asthma-like symptoms investigated different variables, e.g. 
the influence of training and environment on symptoms, the prevalence of asthma in different sports and 
differences among genders. The main focus of this component of the literature review will be on the 
prevalence of asthma in endurance athletes as this will be studied in the experimental section of this 
dissertation. However, where appropriate, studies conducted in the general athletic population will also be 
mentioned (Table 2.4). 
 
Asthma is common in both athletes and sedentary individuals. In the general population, 5-10% of 
individuals suffer from this condition 50. In the athletic population, however, the prevalence of diagnosed 
asthma is higher and has been reported to vary from 14 to 28%. Furthermore, the prevalence of EIA (23-
35%) and AHR (23-52%) is even higher 50. Possible explanations for the higher prevalence of these 
conditions among athletes include the higher physical demand (and thus trigger mechanism) on the 
respiratory system compared with sedentary counterparts.  Another hypothesis is that the high levels of 
exercise (duration, frequency and intensity) may cause a change in the contractile properties of airway 
smooth muscle (ASM) and this may contribute to the development of asthma in previously unaffected 












A study of 424 elite athletes (18-29 years), from the Queensland Academy of Sport was conducted to 
determine if the prevalence of asthma was different in the elite athlete population compared to an age-
matched non-athletic population. The athletes included in this study represented 19 different sports 
disciplines and participants completed a questionnaire regarding respiratory symptoms experienced over 
a 12-month period. The lifetime prevalence of asthma in this group of athletes was 26% 65. Current 
asthma (point prevalence) was experienced by 12% of athletes compared to 11% in the control 
population.  Medication was used by 9% of athletes with a current history of asthma. The type of sport 
was independently related to the risk of having current asthma and the highest prevalence of current 
asthma was among endurance athletes. The point prevalence (current asthma) within this group was 
22%, and the lifetime prevalence was 36% compared to 29% in the control group 65.  
 
In another descriptive study among Danish elite athletes, 329 athletes participating in different sports 
completed a self-administered questionnaire 66. Symptoms over a 12-month period were recalled and the 
authors documented that 55% of athletes reported asthma-like symptoms, of which cough and wheeze 
were the most common. In this study, 16% of athletes were previously diagnosed with asthma, while 14% 
had a current diagnosis of asthma but only 7% were taking medication. Endurance athletes had a higher 
prevalence of current asthma, when compared to the other athletes. Indeed, asthma-like symptoms 
occurred in 74% of the endurance athletes and yet only 15% used medication for these symptoms. Within 
the endurance sports, 93% of swimmers reported asthma- like symptoms, 57% had a current diagnosis of 
asthma and 50% used asthma medication. This study shows that many athletes have asthma-like 
symptoms without a formal diagnosis of asthma. Therefore, objective measures are needed to diagnose 
asthma and facilitate appropriate treatment 66. 
 
There is an apparent discrepancy between symptoms of asthma that are experienced by athletes and a 
formal diagnosis of asthma. In a study in competitive swimmers the prevalence of AHR to methacholine 












diagnosed asthma in swimmers was only 8% 64. Therefore, it was suggested that these differences could 
be due to the fact that symptoms are either well tolerated by athletes, or the symptoms are denied or not 
perceived as requiring medical assessment 50.  
 
In 2003, a review was conducted to determine the possible reasons for the above-mentioned 
discrepancies 67. In this report, EIB and AHR were measured by objective methods (exercise challenge 
test and broncho-provocation challenge tests respectively). The authors found that the prevalence of self-
reported or physician-diagnosed asthma in athletes is usually lower than if it was diagnosed using AHR or 
EIB. This review reported a discrepancy between subjective and objective assessment of airway 
dysfunction.  Possible explanations for these differences were; 1) AHR is a transient and reversible result 
of supra-physiological stimulus to prolonged and intense exercise, 2) the possibility that AHR might be 
asymptomatic and therefore is not reported by athletes, 3) asthma is under-diagnosed in athletes due to 
poor perception of symptoms, adaptation to nociceptive stimuli, or underreporting of symptoms and 4) 
under diagnosis by physicians due to misinterpretation of symptoms or the lack of objective 
measurements 67. 
 
A further review of the prevalence of asthma and AHR in different sports (including sprinting, football, 
basketball and other track and field events) revealed the prevalence of physician-diagnosed asthma, EIA 
and AHR to range from 8 to 21%. This study did not report the prevalence in endurance athletes 50. 
However, some studies reported higher point prevalence (current asthma) in endurance athletes (17-
22%) in comparison to team sports (7%) or speed and power sport types (5-8%) 65;68. This was confirmed 
by findings with respect to athletes participating in the 1996 Summer Olympics in which the prevalence of 
asthma was higher in endurance sports like cycling, swimming and rowing 34. Yet another study on the 
prevalence of asthma and bronchial hyper-responsiveness indicated a higher prevalence in endurance 













In 1998, a total of 162 athletes (49 power athletes, 71 long-distance runners and 42 swimmers) were 
compared to a control group of 45 subjects 61. Both groups were studied by completing a respiratory 
symptom questionnaire, skin prick testing, resting flow-volume spirometry, and a histamine challenge test. 
Of the swimmers, 50% were atopic and 36% displayed AHR in response to histamine challenge tests. 
Current asthma was found in 26% of swimmers and previous physician-diagnosed asthma occurred in 
29%. The adjusted risk of total asthma was nearly 6-fold in swimmers when compared to controls.  When 
atopy and swimming were combined as risk factors in the multivariate analysis, the risk of asthma in 
atopic swimmers was 96-fold as compared with non-atopic control subjects without atopy 61.  
 
It is evident from a number of studies that asthma and asthma-like symptoms are more prevalent in 
swimmers compared to athletes from other sport disciplines 61;66. An interesting phenomenon studied in a 5-
year prospective study was the effect of discontinuing high level swimming on airway inflammation, bronchial 
hyper-responsiveness and asthma 70. 42 elite Finnish national team swimmers completed a questionnaire 
and had resting spirometry, histamine challenge testing and skin prick testing performed at baseline and at 
follow up. Of these, 16 (38%) swimmers had continued their competitive career at the time of follow up 
(active swimmers), whilst 26 (62%) had stopped competing more than 3 months prior to follow up (past 
swimmers). Bronchial hyper-responsiveness at baseline was documented in 7 (44%) of active swimmers 
compared to 8 (31%) of past swimmers. When the same test was performed at follow up, 8 (50%) of active 
swimmers had bronchial hyper-responsiveness in contrast to only 3 (12%) of the past swimmers. Current 
asthma was found in 5 (31%) of active swimmers at baseline and 6 (23%) of past swimmers. At follow up 
there was an increase to 7 (44%) of active swimmers compared to only one (4%) past swimmers with current 
asthma 70. The results of this study suggests that asthma may result from high intensity and prolonged 
exercise and that the condition is partly reversible on cessation of an active sports career 70. 
 
The possibility of gender differences with respect to prevalence of AHR, physician-diagnosed asthma and 












One hundred athletes (group 1) underwent a methacholine challenge test (PC20<16mg/ml) to assess 
prevalence of AHR, and a second group of 698 subjects (group 2) completed a questionnaire to assess 
prevalence of physician-diagnosed asthma (PDA). Both groups also completed a questionnaire regarding 
exercise related respiratory symptoms. In group 1, 60% of female athletes had AHR to methacholine 
compared to only 21.5% of male athletes. However, it is of interest that there were no gender differences 
in the prevalence of AHR within the control group of sedentary individuals.   Respiratory symptoms during 
exercise were also reported more often in females compared with males (19.4% vs. 12.2%). However, in 
this study, the prevalence of physician-diagnosed asthma was similar between female and male athletes 
(17.1 % vs. 15.4%) 71. Female athletes therefore seem to experience respiratory symptoms more often 
with exercise compared to males, although the diagnosis of asthma seems to be similar among the 
genders. It should be noted that there was no uniform diagnostic testing for establishing the diagnosis of 
asthma among subjects and across studies. This factor may need to be considered for more accurate 
investigation for possible gender differences in PDA in future studies. It is of further interest that after 
adjusting for age and body mass index, or even for airway calibre and lung volume, the gender difference 
for AHR still remains higher in females 71;72. 
 
Possible explanations for the observed gender difference are; 1) that the menstrual cycle, and therefore 
hormonal status, is associated with changes in the airway. Females in their mid-luteal phase (day 21 of 
menstruation), demonstrated more severe EIB and a more frequent use of bronchodilator medication.  
This finding has been attributed to the higher levels of progesterone during this phase 73, 2) female 
athletes demonstrate a more sensitive perception or better recognition of symptoms and may therefore 
report symptoms more often than their male counterparts 71, and 3) females may perceive the presence 
of these symptoms, or the reporting thereof as a sign of weakness.  They may also choose to ignore it 
due to fear that it may be potentially limiting for performance development 71. They may therefore not 
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a PDA, Physician diagnosed asthma; bICS, Inhaled corticosteroids; c IBA, Inhaled beta 2-agonists;  dLDR, Long- 




2.5.5.1 Summary:  Point prevalence of asthma in athletes 
 
In summary, it is evident that there is a high reported prevalence of asthma in athletes but that there is 
also great discrepancy between asthma-like symptoms experienced and the actual diagnosis of asthma, 
AHR or EIB.  Secondly, the need to make a proper diagnosis by means of a thorough history, physical 
examination and appropriate special investigations, should be emphasized. Thirdly, the prevalence of 
asthma is higher in the endurance athletes but these studies were mainly conducted on swimmers, 












asthma-like symptoms are often sub-optimal or inappropriate.  The impact of asthma and training will 
performance will now be reviewed. 
 
2.5.6 Influence of asthma-like symptoms on training and performance 
 
Asthma and EIB may pose a challenge for the training and competing athlete, but may not necessarily 
influence athletic performance if it is well controlled. It is interesting to note that Olympic athletes at Salt 
Lake City, Athens and Torino, who used beta 2-agonists for asthma-like symptoms, won more individual 
medals than their counterparts without asthma at each Games 53. Most of these medals were for 
endurance events during winter competitions. There are two possible theories to explain this observation; 
1) either endurance athletes develop asthma after achieving success as an elite athlete or 2) having a 
chronic disease (in this instance asthma) and competing at a high level may represent as a 
“psychological” training stimulus for the elite athlete 
53.   
 
However, in view of the above findings, concerns have been raised that the use of beta 2-agonist inhalers 
(bronchodilators) could enhance athletic performance. However, to date studies have shown no 
significant increase in physical performance with the use of inhaled short- or long acting beta 2-agonists, 
inhaled corticosteroids or inhaled anticholinergics 69;74. However, the use of oral salbutamol remains 
prohibited as it does increase strength 75. As from 1 January 2011, an “Abbreviated therapeutic use 
exemption (ATUE)” is no longer required for the use of salbutamol or salmeterol {www.wada-ama.org}. 
Athletes should however still report in writing all medication/substances ingested/inhaled in the 7 days 
prior to the test, on the Doping Control form. In addition, urine concentrations of beta-2 stimulants may 
not exceed 1000ng/ml as this would indicate supra-therapeutic doses. However, it should be noted that at 
present, terbutaline and formeterol are prohibited, and use of these agents require completion, 












All forms of corticosteroids by means of oral, intramuscular or intravenous routes are also prohibited 
(http://www.wada-ama.org).   
 
It is therefore evident that asthma, AHR and EIB, if adequately managed, do not have to prevent an 
athlete from achieving performance goals. However, this is dependent on early recognition of symptoms, 
confirmation with diagnostic testing, and the implementation of appropriate treatment within anti-doping 
regulations.   
 
2.5.7 Summary: Prevalence of asthma and asthma-like symptoms in athletes 
  
 Asthma, EIB and AHR are commonly observed in both the general and athletic population. 
 Endurance athletes tend to have a higher prevalence of asthma-like symptoms compared to other 
athletes.  
 Swimmers have a high prevalence of AHR and EIB. This is thought to be due to high exposure to 
chlorine derivatives. It could also be that athletes with asthma traditionally chose swimming as the 
sport of preference. 
 Respiratory symptoms are more prevalent in females than male athletes but physician-diagnosed 
asthma is similar in both genders. 
 The pathogenesis of asthma is multifactorial. Some risk factors can be altered or avoided; others 
cannot be changed e.g. genetic predisposition. 
 Asthma appears to be reversible after the cessation of high-level sports. 
 Athletes with rhinitis should be screened for asthma and asthmatic athletes should have allergy 
testing as these conditions often co-exist. 
 There is a great discrepancy between asthma-like symptoms experienced and diagnosis made – 
physicians should be vigilant to perform appropriate diagnostic testing. 























The athletic population often suffer from allergic conditions and the prevalence of allergic conditions has 
been increasing over the past 20 years 76. Allergies can manifest as a variety of clinical entities, some of 
which can be potentially debilitating. In the lung, allergies may cause bronchoconstriction or asthma; in 
the skin, urticaria; in the nose, rhinitis and in the eyes, allergy can manifest as conjunctivitis 37. The 
manifestations of allergic symptoms depends on the type of allergen, the length of exposure and the 
atopic tendency of the individual 37. As most endurance training occurs outdoors, it is evident that 
athletes, and in particular the endurance athlete, might have a higher exposure to allergens during 
periods of prolonged training.  
 
 
The most common clinical manifestations of allergic disorders in the athletic population are allergic rhinitis 
and conjunctivitis 77. Allergic rhinitis usually presents in the 6 to 25 year age group, and is important to 
note that most elite athletes belong to this age group 77. Allergic conjunctivitis is a localised manifestation 
of allergies and may present with redness and itching of the eyes, tearing and at times photophobia and 
swelling 77. Allergic conditions of the skin present as allergic contact dermatitis (ACD) and irritant contact 
dermatitis (ICD), the symptoms and signs of which are very similar and both are treated topical 
corticosteroids and avoidance of triggers 78. Allergies can however also present systemically, as in the 












life threatening and requires immediate medical intervention 37. An in depth discussion of each of these 
conditions is beyond the scope of this review. 
 
Allergic symptoms can however at times be subtle and athletes may only complain of poor quality sleep, 
poor exercise performance, fatigue, headaches or even depression and anxiety 12;37. Allergies are 
therefore likely to be under-diagnosed and under-treated possibly due to the fact that they are often under 
reported 77. On the other hand, athletes may have more obvious symptoms including nasal congestion 
and sneezing, post nasal drip, rhinorrhoea, cough and itchiness of the ears, throat or nose 37;77. 
 
Allergic conditions may make an athlete more prone to other clinical conditions influencing their 
respiratory health, including infection. Allergic rhinitis can often precede the onset of asthma and can 
therefore represent a predisposing condition for the development of asthma 79. These two conditions can 
also frequently coexist 69;80. The WHO-ARIA (Allergic rhinitis nd its impact on asthma) therefore 
recommended to investigate asthmatics for rhinitis and to test subjects with rhinitis, for asthma 81.  
 
It is important to note that allergic conditions that affect the respiratory tract may have the same clinical 
presentation as symptoms of URTI and it may be difficult to differentiate between these two conditions 24. 
This highlights the need to consider non-infectious causes for RTS as discussed in the previous section. 
 
2.6.2. Terminology and definitions:  Allergies in athletes 
 
As mentioned, allergic conditions have a wide array of clinical manifestations and affect various systems.  
For the purpose of this review, the main focus will be on allergies pertaining to the respiratory tract.  
Allergic rhinitis is clinically defined as a symptomatic allergic disorder of the nose. Exposure to an 












This condition can be subdivided into intermittent allergic rhinitis (IAR) or persistent allergic rhinitis 
(PER) and the symptoms can be graded from “moderate” or “severe” 81. In some instances, referral is 
made to “allergic rhinoconjunctivitis” 
11, which implies rhinitis in conjunction with allergic conjunctivitis.   
 
2.6.3. Pathophysiology of allergies in athletes 
 
Recent evidence suggests that chronic exercise training can lead to changes in the innate and adaptive 
immunity 82. This includes the tendency of T-helper lymphocytes to proliferate into the T-helper type 2 
(Th2) phenotype 83, which are responsible for the allergic reaction that could predispose an athlete to 
allergic rhinitis and upper respiratory tract symptoms 31;37. 
 
Allergens occur from multiple sources, including the environment (e.g. pollen, dust and mold), insects, 
foods and a variety of drugs 37. Aeroallergens like tree, grass and weed pollen, are seasonal, while mold 
and dust, are non-seasonal aeroallergens 84. Exposure to these allergens, results in the secretion of 
specific immunoglobulin E (IgE) antibodies which in turn causes acute, recurrent or chronic 
inflammation37. As previously described, an athlete can greatly increase ventilation (up to 200L/min) 
during exercise 37. For this reason, the athlete is more exposed to allergens, poor quality air and 
particulate matter during the exercise bout. Clinically, this exposure may present in the respiratory tract, 
skin or systemic symptoms and can have a profound effect on exercise tolerance.   
 
Allergic rhinitis is characterized by swelling of the nasal mucosa as a result of IgE-mediated release of 
cytokines. These promote infiltration of the mucosa with inflammatory cells, and the athletes then 
presents with nasal congestion, sneezing, rhinorrhoea, itching of the nose or a post nasal drip 37. Swelling 
of the nasal mucosa also compromises drainage of the related anatomical systems, and this may result in 












disturbances and resultant fatigue, which have negative effects on training performance and quality of life 
of the athlete 12. “Blocked” nasal passages are also undesirable for a sprinting athlete who is dependent 
on both nasal and mouth breathing for optimal performance 12. 
 
Localized allergic symptoms may also have remote consequences. For example, a post nasal drip due to 
allergic rhinitis, may also affect the function of the vocal cords. During exertion with an increase in body 
temperature, the viscosity of mucus decreases, allowing it to reach the vocal cords and subsequently a 
reflex increase in bronchial hyperreactivity 85. 
 
The upper respiratory tract acts as a filter and humidifier of inhaled air 12. Any alternation to the upper 
airway function, would therefore alter lower respiratory function 12. This may lead lower respiratory tract 
symptoms including wheeze, cough and breathlessness. It is thus evident that allergies may have 
systemic consequences, and therefore it is important to recognize these conditions and manage them 
appropriately. 
 
2.6.4. Diagnosis of allergies in athletes 
 
Optimal management starts with the clinician making an accurate diagnosis and identification of factors 
that may trigger allergic symptoms 11. In the first instance, a thorough history and physical examination 
should be conducted with special attention given to the respiratory tract, skin and ear, nose and throat 
systems 77. It is important to consider that symptoms may be seasonal or intermittent and thus it may not 
be present at the time of examination 81. 
 
Special investigations for allergies can include skin prick (SPT) and intradermal testing, which are 












wheal or flare response occurs 15 minutes after allergen contact 37. If the skin response is decreased or 
inconclusive, a radioallergosorbent (RAST) can be performed on a serum sample. This test detects 
specific IgE antibodies with comparable specificity and sensitivity to skin-prick testing 86. When an allergic 
pathogenesis is thought to be the cause for upper respiratory tract symptoms, the „gold standard‟ practice 
should include the SPT and measurement of allergen specific IgE in serum 31. 
 
 
Symptoms similar to that of allergic rhinitis, can manifest in conditions such as aspirin sensitivity, side- 
effects to medications, vasomotor rhinitis, misuse of topical decongestants (rhinitis medicamentosa) as 
well as in mechanical factors including deviated nasal septum or foreign body 81. These factors should 
always be considered in the differential diagnosis of any allergic type manifestation.  Due to the high 
prevalence of asthma in atopic athletes, it may be advisable to screen atopic patients for asthma 11;80;81;87. 
The diagnostic tests for asthma have already been described in this review. 
 
Furthermore, it has been suggested that allergy testing should form a standard part of the pre-season 
screening or periodic health assessment of all athletes 31;77, as many may have symptoms, but never 
seek proper medical advice or investigation. This may aid in appropriate prophylaxis, the avoidance of 
triggers and lead to better athletic performance 11;37;88. 
 
2.6.5. Prevalence of allergies in athletes 
 
Allergic rhinitis is a common condition with an apparent high prevalence among elite competitive 
athletes11;34.This condition remains one of the most common reasons for a visit to local pharmacist or 
medical practitioner 11. A number of studies have been conducted to determine the prevalence of allergies 













On evaluation, the type of sport and the presence of allergic symptoms show some interesting trends 
emerge. Sports participants in aquatic sports such as swimming, rowing and diving, were more likely to 
have allergic rhinoconjunctivitis compared to non-aquatic sports 11. This is of particular interest because, 
in Australia, there has been a tendency to encourage children suffering from asthma to participate in 
aquatic activities 11. This advice could explain the higher prevalence of asthma and possible associated 
atopic symptoms in this group. In contrast to this, the least likely athletes to show atopic tendencies were 
equestrians. This is however thought to be due to “natural selection” 
11.   
 
 
A group of 214 Australian elite athletes, preparing for the Sydney Olympics in 2000, was studied for the 
prevalence of allergic symptoms. Allergy testing for common aeroallergens and the most prevalent 
pollens were conducted and the impact of allergic symptoms on the quality of life was also assessed. 
Furthermore, athletes diarized their daily symptoms for 8 weeks during the pollen season. In this study, 
56% of athletes had a self-reported history of symptoms of allergy compared to a 41% prevalence of 
current symptoms of allergic rhinoconjunctivitis (AR/C) that was confirmed by positive allergen tests.  
Seasonal AR/C was documented in 29% of athletes, and was also confirmed with positive skin test. In 
this group of athletes, 21% suffered from asthma. Swimmers and divers were the group of athletes most 
likely to show allergic sensitization.  Allergic athletes had a higher symptom score and lower quality of life 
ratings during the pollen season compared with non-allergic athletes. It is of interest to note that even 
after the pollen count decreased, allergic athletes showed no improvement in their nasal symptoms. This 
phenomenon has been termed the “priming effect” 33.  
 
 
These findings were compared to the findings in a survey study on the prevalence of atopy in 81 South 
African Olympic athletes preparing for the same Olympic Games. In the South African study, participants 
completed a detailed allergy questionnaire, were examined for physical signs of atopy and underwent a 












(SAR) 32. This was far more than the currently believed allergy prevalence of 30% in the general South 
African population 32. 
 
 
In 2006, a questionnaire-based study on the prevalence of allergic and asthma-like symptoms was 
conducted on 63 British track and field athletes. In this study, 60% of athletes reported symptoms of hay 
fever in the past of which only 8% had specific clinical allergy testing to confirm the diagnosis. Despite 
having symptoms that could possibly affect performance and health in general, only few athletes pursued 
further clinical confirmation of their symptoms 31. This could also be due to the fact that athletes are poor 
at recognizing symptoms as being caused by allergy 11. Since then, the author implemented an active 
allergy screening program in British track and field athletes 31.  
 
 
Atopy has also been associated with other conditions of the respiratory tract e.g. asthma.  A survey of 
162 athletes competing in summer events was conducted to determine the prevalence and the risk 
factors for asthma and increased bronchial responsiveness (study population and asthma prevalence 
discussed in previous section) 61. Atopy by SPT was documented in 77 (48%) of athletes compared to 16 
(36%) of controls. Pollen allergy was more common in athletes than in controls.  In relation to respiratory 
symptoms, atopic athletes showed significantly greater bronchial responsiveness and asthma than non-
atopic athletes. Furthermore, a strong association was made between increased bronchial 
responsiveness and the severity of atopic tendency in these elite athletes 61.   
 
 
A higher prevalence of allergic conditions in endurance athletes, was observed in a cross-sectional 
survey on 446 Finnish national level athletes 12.  A representative sample of 1504 Finnish young adults 
served as controls. All participants completed a questionnaire regarding symptoms of asthma and 












endurance athletes indicated having physician-diagnosed allergic rhinitis compared to only 20.4% of 
speed and power athletes and 20.2% of controls. There was no significant difference in allergic rhinitis 
between summer and winter sports. In the group of athletes reporting allergic rhinitis, 34.7% also had a 
clinical diagnosis of asthma. The use of anti-allergic medication use was reported in 33.3% of endurance 
athletes, 15.7% of speed and power athletes and 15.6% of controls. This study clearly indicated the 
higher prevalence of allergies in the endurance sports, but also emphasized the lack of appropriate 








































































































2.6.6. The effect of allergies on athletic performance  
 












63 track and 




8% had specific 
clinical allergy 
























































































48% atopy in 
athletes 































conditions may lead to a cascade of effects, which negatively impact the physical wellbeing and the 
physical performance of the athlete. Allergic disease may present with inflammatory response manifesting 
in asthma, rhinitis, urticaria and conjunctivitis, thus affecting multiple systems 37. Allergic rhinitis can cause 
rhinorrhoea, nasal obstruction and sinus pressure and this in turn may have a negative effect on sleep, 
resulting in fatigue and tiredness and ultimately affecting the athlete‟s recovery and performance 
12;33. 
Allergic rhinitis may even have a negative effect on cognitive processing, as tests in subjects with allergic 
rhinitis revealed decrements in reaction time, vigilance and attention when the individual is exposed to 
pollen 89. 
 
2.6.7. Prevention and management of allergies in athletes 
 
Prevention and optimal treatment of allergies in athletes is dependent on the correct diagnosis, and 
identification of triggering factors 11. Yet, many athletes may be ignorant as to their allergic symptoms and 
the origin/nature of their allergic triggers 31;77. It has already been suggested that allergic screening be 
included in the periodic health examination of athletes in order to prevent complications of allergies, and 
to optimize management. 
 
 
Management of allergic rhinitis can be divided into non-pharmacologic and pharmacologic treatment. 
Non-pharmacological interventions include the following; 1) the avoidance of allergens, although this is 
not always feasible for the athlete training outdoors 77, 2) saline nasal irrigation has been shown to be 
effective and safe in cleansing the nasal mucosa of allergens 90, and 3) external nasal dilators can also be 
used and in one study, have been shown to decrease submaximal exercise-perceived exertion, 
ventilation, oxygen use and heart rate in comparison to not using nasal dilators 91. 












corticosteroids 11;31;88. Corticosteroids have a strong anti-inflammatory action and attenuate the release of 
cytokines, antigen presenting cells and cellular infiltration within the nasal mucosa 11. Regular 
prophylactic use of intranasal corticosteroids, is effective in reducing symptoms of sneezing, nose itching, 
rhinorrhoea and nose “blockage” 
11;88. A meta-analysis showed intranasal corticosteroids to be superior to 
systemic anti-histamines in the treatment of allergic rhinoconjunctivitis 92.  
 
 
Other medication to consider are the oral non-sedating anti-histamines e.g. fexofenadine, which have 
demonstrated minimal disruptive effects on the central nervous system and can be used as a second line 
of treatment 93. Another drug to consider is ipratropium bromide and although it has no effect on 
sneezing, it is effective in the control of watery rhinorrhoea. It is therefore more effective in winter sports 
where watery rhinorrhoea due to cold air exposure is more prevalent 11. 
 
 
Athletes with allergic rhinitis without clinical evidence of asthma may often have increased nonspecific 
bronchial hyper-responsiveness. It is interesting to note, that treating rhinitis by means of intranasal 
corticosteroids, may also alleviate asthma-like symptoms and it can also decrease nonspecific bronchial 
reactivity that is associated with seasonal pollen exposure 87. This re-emphasizes the need to have a high 
index of suspicion for co-existing respiratory illnesses in the presence of allergic disorders. 
 
 
In treating allergic conditions, sports physicians should take extra care to make sure they comply with the 
WADA guidelines. The 2011 guidelines state that pseudoephedrine is prohibited in-competition if the 
urine concentration exceeds 150 micrograms per ml. Although the use of this agent is not recommended 
as effective management of allergy in athletes, athletes sometimes use it as an over-the-counter 
decongestant.  Finally, it is important to note that all glucocorticosteriods are prohibited when these are 












sometimes used in the treatment of allergies by general practitioners. However, the use of intranasal 
corticosteroids is not prohibited and does not require a Therapeutic Use Exemption (www.wada-ama.org).  
 
 
2.6.8. Summary:  Allergies in athletes 
 
 Allergic conditions are very common in athletes, especially endurance athletes. 
 Allergic symptoms may mimic other conditions of the respiratory tract. 
 Allergies and asthma may co-exist and therefore athletes with allergies should be tested for asthma 
and asthmatic athletes should be screened for allergies. 
 Athletes tend to be ignorant about atopic conditions and may be unaware of the influence these 
conditions may have on quality of daily life and athletic performance. 
 Allergy screening should be considered part of the periodic health evaluation of athletes. 
 Special care should be taken in prescribing anti-allergic medication of high level athletes in 
compliance with WADA regulations. 
 
 
2.7. Summary: Respiratory symptoms, asthma and allergies in athletes  
 
 
In this Chapter, respiratory symptoms, asthma and allergies in athletes were reviewed. These conditions 
can affect the physical wellbeing of the athlete, can negatively affect performance, particularly during the 
preparation for an event (pre-event period) and in some cases may cause life threatening illness such as 
myocarditis. Symptoms from these respiratory illnesses can often co-exist and may have similar clinical 
presentations. The prevalence of these conditions, which can influence the respiratory health of the 
endurance athlete, and in particular the triathlete and ultra-distance runner, has not been studied well in 












respiratory illnesses, particularly in the pre-event period. This is the focus of the experimental component 









































Prevalence of pre-event respiratory illness and symptoms in Ironman Triathletes 




The Ironman Triathlon is an ultra-endurance race comprising of a 3.8km open water swim, a 180km cycle 
and a 42.2km run. In the past few years, it was held during the summer months at the eastern coastal 
town of Port Elizabeth in South Africa. The Two Oceans ultra-marathon, on the other hand, is an ultra-
distance road running race of 56km, which is usually held in March or April in Cape Town, South Africa. 
Athletes regard both these two ultra-distance events as ultimate tests of their physical and mental 
endurance. Despite the fact that it is generally accepted by both athletes and health professionals that 
individuals participating in these events are largely free of illness, it has been noted that these endurance 
athletes can suffer from a variety of medical conditions during training before, during, or after the event 1. 
 
 
Therefore, in recent years, there has been an increasing focus on not only injury prevention, but also on 
protecting the health of the athlete. More specifically, a number of recently published studies have shown 
that the respiratory system is the system most likely affected by illness, particularly during sports 
tournaments 17-19. Furthermore, it has been shown that upper respiratory tract (URT) complaints are very 
common, especially after endurance races 2;3;5. It has also been noted that upper respiratory tract 
symptoms (URTS) are also common during periods of increased training load and intensity and a “J-
curve” has been suggested to explain the relationship between exercise and upper respiratory tract (URT) 
symptoms. Data suggest that moderate intensity and regular exercise is associated with protection 
against URT symptoms, while high intensity, acute or chronic exercise, such as during training and 












most studies in endurance athletes have focussed on post-event URT symptoms 2-4;40 and only few 
studies addressed pre-event URT symptoms 4;40{Lichaba 2006}.  
 
Until recently, it was suggested that respiratory symptoms in athletes during training (pre-event) and post-
event were caused by pathogens (infective hypothesis) due to a decrease in host immunity as a result of 
intense or prolonged exercise 5. However, this hypothesis has recently been challenged, particularly 
because an infective pathogen could seldom be isolated in athletes with these symptoms 7-10. These 
findings led to the suggestion that alternative processes could be involved in the pathogenesis of 
respiratory symptoms in endurance athletes.  One of the alternative hypotheses that have been proposed 
as an explanation of the common occurrence of respiratory tract symptoms in endurance athletes is the 
allergic hypothesis 7. 
 
 
In recent years there is increasing evidence suggesting that allergies are very common among athletes, 
particularly in endurance athletes 11;12;31;32;77. Allergic rhinitis can present with symptoms including nasal 
congestion and rhinorrhoea and these may mimic symptoms of respiratory tract infection. Other clinical 
entities that may also mimic symptoms of respiratory tract infection include asthma and asthma-like 
symptoms. Asthma classically pres nts with coughing, wheezing and shortness of breath and these same 
symptoms can also occur during respiratory tract infections 26;51. 
 
 
It is thus clear that symptoms of respiratory tract illness are apparently very common in endurance 
athletes in the post-event period, and that these symptoms may not always be due to an infection. The 
presence of allergies and asthma may contribute to the development of both post- and pre-event 
respiratory tract symptoms of the athlete, and in particular, the endurance athlete 77. However, the 
prevalence of respiratory tract symptoms, particularly in the pre-event period has not been investigated 












The primary aim of this study is to document the pre-event point prevalence of respiratory tract symptoms 
in two groups of endurance athletes.  A secondary aim is to document the nature of respiratory related 





3.2.1 Type of study 
 




For this study, participants were recruited from two groups of endurance athletes – Ironman triathletes 
and ultra-distance runners. All the triathletes participating in the 2006 and 2007 „Spec-Savers ‟Ironman 
Triathlons (3.8km open water swim, 180km cycle and 42.2km run) in Port Elizabeth, South Africa and 
ultra-distance runners participating in the 2009 Old Mutual Two Oceans ultra-marathon (56km road run) 
in Cape Town, South Africa, were considered as potential participants for this study. There were in total 
1136 (85% males and 15% females) entrants in the Ironman Triathlon held in March 2006, 1566 (75% 
males and 25% females) entrants in the Ironman Triathlon of April 2007, and 5824 (77% male and 23% 













Two months before the events, information pertaining to the study was posted on the official race 
websites. The website content included information about study procedures (Appendix A), the informed 
consent form (Appendix B) and copies of the questionnaires (Appendix C) to be completed. Before these 
studies commenced, the protocols were approved by the Human Research and Ethics Committee of the 
Faculty of Health Sciences at the University of Cape Town (REC ref. 425/2005, REC ref. 002/2007 and 
REC ref. 066/2009) (Appendix D), as well as the general organizing committees of the 2006 and 2007 
„Spec-savers‟ Triathlon and the 2009 Old Mutual Two Oceans Ultra-marathon.  
 
Potential participants for the studies were recruited during registration in the 3 days prior to each event. At 
all three events, research „stations‟ were established in close proximity to the registration desk and 
athletes were informed about the study at registration. Those who agreed to participate were then 
accompanied to the research area where voluntary staff gave further information regarding the study and 
the procedure to follow.  Once athletes gave written informed consent, they were handed a questionnaire 
and encouraged to complete it on site. Alternatively, athletes were allowed to take the questionnaire with 
them and to return it the next day, or the morning of the race day (less than 10% of questionnaires were 
returned in this way). 
 
One hundred and fifty-two ultra-distance runners and 470 triathletes completed the questionnaire. 
Twenty-nine triathletes completed both the 2006 and the 2007 questionnaires, and for triathletes who 
completed the questionnaire in both years, only the data from 2007 were used in this study. Therefore, 
the final participants in the study were 441 triathletes (279 from 2006 and 162 from 2007) and 152 ultra-
distance runners (2009).  The response rates for each event were as follows: 26.5% of the triathlete 














3.2.3. Pre-event medical questionnaire 
 
This study made use of previously validated pre-event medical questionnaires which were modified and 
used 94-96. The questionnaires for the two Ironman events and the Two Oceans were very similar, with 
only a few changes made to the questions regarding training relevant to the specific event. The pre-event 
questionnaire for the Ironman event consisted of 28 pages and that of Two Oceans contained 25 pages. 
The main differences were related to cycling and swimming training for the Ironman triathlon, which was 
not relevant to the Two Oceans participants. The remaining sections included details of the athlete‟s 
medical history. The sections of the questionnaires relevant to this study were therefore very similar in all 
three events (Ironman 2006, 2007 and Two Oceans 2009).   
 
In this particular study, information from the following sections were used:  1) demographic details 
including age, gender, weight and height, 2) racing and training history of the 15 weeks and 1 week 
period prior to the event (training distances for running only and hours spent training for all disciplines in 
the Ironman triathletes compared to hours  running in ultra-distance running), including personal best 
times in 10km, 21.1km and 42.2km running races, 3) lifestyle habits, particularly smoking history and 4) 
personal general medical history. In the general medical history, the athlete was asked to report any 
history of symptoms experienced in 14 different medical conditions.  
 
3.2.3.1. General questions regarding respiratory tract illness 
For the purposes of this study, the focus was to obtain information on the following three main questions 
in the general medical history that were related to respiratory tract illness: 1) “In the 6 weeks before this 
race did you suffer from any symptoms of flu (fever, sore throat, blocked or runny nose, cough, wheeze, 
muscle aches and pains)?” 2) “Have you ever in your triathlon/running career suffered from symptoms of 












history of allergies to medication, plant material or animal material?” 3) “Do you currently suffer from 
asthma including exercise induced asthma, or symptoms of asthma such as shortness of breath, 
wheezing, or chronic coughing?”  Throughout the questionnaire, layman‟s terms were used e.g. flu-like 
symptoms were used instead of respiratory symptoms, and fever, “blocked nose”, “runny nose”, muscle 
aches and joint pains were used instead of pyrexia, nasal congestion, rhinorrhoea, myalgia and arthralgia 
respectively. If the athlete reported symptoms of a specific condition in the general medical section, they 
were then requested to complete a more detailed section on the relevant medical condition in a different 
section of the questionnaire.  
 
3.2.3.2. Detailed questions on respiratory tract illness 
In a detailed section on respiratory symptoms, athletes were requested to complete details on a) 
symptoms of respiratory tract illness in the period (6 weeks and 1 week) before the events, b) history of 
asthma, and c) history of allergies. 
 
a. Symptoms of respiratory tract illness in the period (6 weeks and 1 week) before the events 
Athletes were asked to report symptoms of upper respiratory tract (URTS) illness including sore throat, 
„blocked‟ or „runny‟ nose, lower respiratory tract symptoms (LRTS) (cough and wheeze), and systemic 
symptoms (SS) (fever, joint pains and muscle aches) and a category was provided for „other‟ symptoms.  
All symptoms were reported in time frames of 6 weeks and one week before the race. 
 
b. Asthma 
In the detailed section on asthma, athletes were requested to report the following; if they are currently 
suffering from asthma and for how many years they suffered from it as well as the method by which the 












and a history of previous hospital admissions for asthma in the past 12 months.  In addition, athletes were 
asked to report current symptoms experienced, type and frequency of medication use and if they 
obtained a TUE (therapeutic use exemption) for the use of medication, if applicable.  
 
c. Allergies 
The detailed section on allergies contained questions regarding the duration of allergies, current and past 
types of allergy (hay fever, sinusitis, skin allergies, eye allergies, allergies to plant material, animal, food 
and medication).  Athletes were requested to report the use of medication (corticosteroid nasal spray/ 
inhaler, anti-histamine tablets, corticosteroid and anti-histamine creams and other inhalers or creams).  
Information regarding current symptoms experienced (sneezing, itchy „runny‟ nose, headaches, itchy 
palate, streaming eyes, itchy eyes, „blocked „nose, post-nasal drip, coughing, fatigue, wheezing and poor 
sleep) as well as seasonal variation in allergies (by calendar month) was obtained. 
 
3.2.4. Statistical analysis of data   
 
All the data from the questionnaires were entered onto an Excel spreadsheet Microsoft 2011 (Redmond, 
Washington, USA).  Data were analysed using the STATISTICA 10.0 (Stat-soft Inc, Tulsa, Oklahoma, 
USA) and GraphPad InStat 2.05a (GraphPad Software Inc, San Diego, California, USA) statistical 
programs. 
 
All numerical data were presented by the mean ± standard deviation, with the number of subjects with 
non missing data who answered the relevant question in parenthesis.  A one-way analysis of variance 
(ANOVA) was used to determine any significant differences between groups.  Where the overall F values 












differences were.  Categorical data are expressed as frequencies, and significant differences between the 
groups were analyzed using the Pearson‟s chi-square or Fisher‟s exact tests.  The numbers of subjects or 




3.3.1. General characteristics (age, anthropometry, and gender) of the study population 
The general characteristics of the triathletes and ultra-distance runners are depicted in Table 3.1. 
 
Table 3.1. Characteristics (age, anthropometry, and gender) of the study population of 









Values are expressed as average ± standard deviation, with the number of subjects (n) in parentheses. 
a For the athletes that completed both the 2006 and 2007 events, only the 2007 data were included in the combined 
Ironman values. 
b Self reported height in centimetres. 
c Self reported weight in kilograms. 
d Body mass index calculated as weight in kilogram divided by height in metre squared. 
The Ironman triathletes were significantly taller and weighed more than the ultra-distance runners, but 









p-Value IM vs. UD 
Age 
(years) 
38.6 ± 8.6 
(403) 




178.0 ± 8.2 
(401) 




75.1 ± 11.3 
(424) 




23.7 ± 2.6 
(397) 

















groups. The majority of participants in both groups were male with no significant difference in the % 
males between the two groups. 
 
3.3.2. Training history of the triathletes and ultra-distance runners 15 weeks and 1 week 
before the event 
 
The training history of the triathletes and ultra-distance runners is depicted in Table 3.2.  The training 
distances (km) for the 15 weeks and the 1 week before the events only include the running component of 
the triathletes so that these distances could be compared to those of the ultra-distance runners.  
However, the total hours spent training for the triathlete group, is the combined hours of training 


















































p-Value IM vs. 
UD 
Days training/week past 15 
weeks 
5.7 ± 0.9 
(404) 
4.6 ± 1.4 
(146) <0.001 
Running km/week past 15 
weeks 
46.4 ± 17.8 
(406) 
54.2 ± 26.8 
(144) <0.001 
Hours running/week past 15 
weeks 
4.6 ± 2.0 
(391) 
8.1 ± 12.0 
(138) <0.001 
Total hours training/week past 
15 weeks 
15.2 ± 4.7 
(414) 
6.6 ± 3.6 
(138) <0.001 
Running km in week before 13.3 ± 11.4 (393) 
27.4 ± 26.4 
(148) <0.001 
Running hours in week before 1.4 ± 2.0 (404) 
5.2 ± 12.4 
(139) <0.001 
Total hours training in week 
before 
4.7 ± 5.1 
(441) 
3.8 ± 4.0 
(139) <0.001 
Values are expressed as average ± standard deviation, with the number of subjects (n) in parentheses. 




In the 15 weeks before the event, the ironman triathletes had a significantly greater training volume (spent 
significantly more days and more hours training) than the ultra-distance runners. It should be noted that 
this includes all disciplines for the triathlon namely running, cycling and swimming.  However, the ultra-
distance runners ran significantly longer distances and spent more hours running in the 15 weeks before 
the event. Similarly, in the 1-week period before the events, triathletes trained significantly more hours 
while the ultra-distance runners ran significantly longer distances and spent more hours running.  
 
 




The self reported personal best times ever achieved for a 10km, 21.1km and 42.2km as well as the self 












Table 3.3.  Personal best times ever achieved and the personal best times for a 10km, 21.1km and 





























Values are expressed as average ± standard deviation, with the number of subjects (n) in parentheses. 




In assessing the “running caliber” of the Ironman triathletes and the ultra-distance runners, there were no 
significant differences in the self reported personal best times ever achieved or the personal best times 
achieved for a 10km, 21.1km and 42.2km running race in the 15 weeks before the events. 
 
 
3.3.4. Smoking habits of Ironman triathletes compared to ultra-distance runners 
 

















p-Value IM vs. UD 




10 km 42.7 ± 6.9 (361) 
42.8 ± 10.1 
(115) 0.916 
21.1 km 91.1 ± 16.9 (374) 
101.4 ± 35.5 
(128) 0.066 
42.2 km 213.7 ± 33.5 (319) 
216.6 ± 46.2 
(135) 0.456 
Personal best (PB) in 
past 15 weeks 
(minutes) 
 
10 km 47.2 ± 8.6 (166) 
47.3 ± 10.2 
(63) 0.937 
21.1 km 108.0 ± 17.9 (201) 
112.8 ± 41.8 
(91) 0.173 
42.2 km 231.7 ± 40.1 (114) 


























Values are presented as frequencies (%) with the number of participants with non-missing or valid data (n) in 
parentheses. 





In comparing the smoking history in both groups of athletes, the majority of the athletes in both groups 
never smoked and there was no significant difference between the number of triathletes and ultra-
distance runners that were (then) currently smoking.  Furthermore, there were no significant differences in 
the duration of smoking or the number of cigarettes smoked per day among the current smokers or the 
amount of years since cessation of smoking in the „ex-smoker‟ group of athletes. 
 
 
3.3.5. Period prevalence (%) of respiratory tract symptoms in the Ironman triathletes and 
ultra-distance runners in the 6 weeks before the events 
 
 
The period prevalence (%) (6 weeks before the race) of respiratory tract symptoms in the two groups of 










p-Value IM vs. UD 
Never smoked 70.6 (438) 73.7 (152) 0.697 
Ex-smoker 26.5 (438) 23.0 (152) 0.451 
Current smoker 3.0 (438) 3.3 (152) 0.789 
Smoking duration (years) 11.0 ± 6.8 (101) 
13.9 ± 9.6 
(22) 0.094 
Number of cigarettes/day 15.5 ± 11 (118) 
13.4 ± 13.8 
(37) 0.359 
Number of years since 
smoking cessation 
10.9 ± 8.3 
(107) 













Table 3.5. The period prevalence (%) (6 weeks before the race) of respiratory tract symptoms in 


















































Values are presented as frequencies (%) with the number of participants with non-missing or valid data (n) in 
parentheses. 
a For the athletes that completed both the 2006 and 2007 events, only the 2007 data were included in the combined 
Ironman values.  
 
In the 6 weeks before the event, the period prevalence of URTS, nasal congestion and rhinorrhoea was 
















All respiratory tract 




All URTS 40.5 (407) 29.0 (152) 0.012 
Nasal congestion 20.9 (407) 12.5 (152) 0.028 
Rhinorrhoea 26.8 (407) 17.1 (152) 0.020 




All LRTS 17.7 (407) 13.8 (152) 0.274 
Cough 15.5 (407) 12.5 (152) 0.422 
Wheezing 5.2 (407) 2.6 (152) 0.253 
Systemic symptoms 
(SS) 
All SS 15.2 (407) 17.1 (152) 0.589 
Pyrexia 9.6 (407) 11.2 (152) 0.635 
Arthralgia 4.2 (407) 7.2 (152) 0.189 
Myalgia 7.6 (407) 8.6 (152) 0.724 
LRTS and SS All LRTS and SS 25.6 (407) 24.3 (152) 0.769 
6 week „any‟ 
symptom  46.3 (421) 34.2 (152) 0.010 
6 week „other‟ 












no significant difference in the period prevalence of LRTS and SS between the two groups of endurance 
athletes.  There was also a significantly higher period prevalence of „any‟ or „other‟ symptoms.  These 
categories allowed the participant to fill in symptoms they experienced but that were not listed. Symptoms 
additionally reported by athletes were swollen lymph nodes, headaches, sinus, exhaustion, malaise, and 
„fluid in right lung‟. 
 
 
3.3.6. Period prevalence (%) of respiratory tract symptoms in the Ironman triathletes and 
ultra-distance runners in the 1 week before the event 
 
The period prevalence (%) of respiratory tract symptoms in Ironman triathletes and ultra-distance runners 










































Table 3.6.  The period prevalence (%) (1 week before the event) of respiratory tract symptoms in 
Ironman triathletes compared to ultra-distance runners 
 
 












































Values are presented as frequencies (%) with the number of participants with non-missing or valid data (n) in 
parentheses. 
a For the athletes that completed both the 2006 and 2007 events, only the 2007 data were included in the combined 
Ironman values.  
 
 
In the week before the event, ultra-distance runners reported a significantly higher period prevalence of 
all SS, and specifically pyrexia, compared with the Ironman triathletes. There were no significant 




















All URTS 20.1 (417) 15.1 (152) 0.176 
Nasal congestion 10.1 (417) 5.9 (152) 0.138 
Rhinorrhoea 10.8 (417) 8.6 (152) 0.532 




All LRTS 7.0 (417) 6.6 (152) 0.875 
Cough 5.3 (417) 5.9 (152) 0.835 
Wheezing 3.1(417) 0.7 (152) 0.127 
Systemic symptoms 
(SS) 
All SS 2.4 (417) 9.2 (152) <0.001 
Pyrexia 1.2 (417) 5.3 (152) 0.008 
Arthralgia 0.7 (417) 2.6 (152) 0.086 
Myalgia 1.2 (417) 2.6 (152) 0.257 
LRTS and SS All LRTS and SS 8.4 (417) 13.8 (152) 0.055 
1 week „any‟ 
symptom  25.0 (424) 21.7 (152) 0.416 
1 week „other‟ 












that over 9% of ultra-distance runners reported systemic symptoms in the week before the event and this 
finding has significant clinical implications.  
 
  
3.3.7.   Point prevalence (%) and characteristics of asthma in Ironman triathletes and 
ultra-distance runners 
 
The self-reported point prevalence of asthma (% athletes) was 7.1% for all the athletes (41/581), 8.3% for 
triathletes (36/435) and 3.4% for ultra-distance runners (5/146).  In the 41 athletes who reported current 
asthma, the methods used to make the diagnosis of asthma in the two study groups are depicted in Table 
3.7.  It should be noted that, the sample size of athletes who reported a current history of asthma, was too 
small to allow comparison between triathletes and ultra-distance runners. 
 
 

























Values are presented as frequencies (%) with the number of subjects (n) in parentheses. 
a LFT, Lung function test 
* Self diagnosed     
 ¥ Diagnosed by means of X-Ray (according to subject)    
     
 












Physician history and examination 61.0 (25) 58.3 (21) 80.0 (4) 
LFTa without exercise 34.1 (14) 33.3 (12) 40.0 (2) 
LFT with exercise 24.4 (10) 25.0 (9) 20.0 (1) 
Methacholine challenge test 0 0 0 
Eucapnic hyperventilation test 4.9 (2) 5.6 (2) 0 












The diagnosis of asthma in both groups was most commonly made by history taking and conducting a 
physical examination. The second most common method of diagnosing was by means of a lung function 
test without exercise, followed by a lung function test with exercise. No athletes in these 2 groups were 
diagnosed by means of a methacholine challenge test and two athletes had a eucapnic hyperventilation 
test. One athlete in the triathletes group made a self-diagnosis and one athlete in the ultra-distance 
runners group reported that the diagnosis was made by means of an X-Ray. 
 
 
The occurrence of asthma symptoms in relation to exercise in Ironman triathletes and ultra-distance 
runners with a current history of asthma is depicted in Table 3.8.  
 
 



















The Ironman triathletes with a current history of asthma, experienced asthma symptoms mostly related to 
exercise and the minority experienced symptoms at rest. The ultra-distance runners experienced asthma 
symptoms mostly at anytime, with no relation to exercise, followed by symptoms which occur mostly 
during exercise.   
 
The symptoms experienced by Ironman triathletes and ultra-distance runners with a current history of 
asthma are shown in Table 3.9. 
 
 











Any time but not with 
exercise 31.7 (13) 27.8 (10) 60.0 (3) 
Any time and with exercise 34.1 (14) 36.1 (13) 20.0 (1) 












Table 3.9.  Current symptoms of asthma experienced by athletes in both study groups 
  
 





















Values are presented as frequencies (%) with the number of subjects (n) in parentheses. 
Ω Pain at ribs 
 
 
In the triathlete group, the most common symptoms experienced by athletes with a current history of 
asthma were shortness of breath and wheezing, followed by a tight chest, dry cough, chest pain and 
„other‟ symptoms.  The ultra-distance runners reported mostly wheezing; followed by tight chest, dry 
cough, and chest pain, with the minority reporting shortness of breath and „other‟ symptoms. 
 
 
The medication currently used by Ironman triathletes and ultra-distance runners with a history of asthma 
























Wheezing 58.5 (24) 55.6 (20) 80.0 (4) 
Tight chest 46.3 (19) 44.4 (16) 60.0 (3) 
Dry Cough 29.3 (12) 25.0 (9) 60.0 (3) 
Chest pain 9.8 (4) 2.8 (1) 60.0 (3) 
Shortness of breath 58.5 (24) 61.1 (22) 40.0 (2) 








































The most common anti-asthmatic medication used by Ironman triathletes was salbutamol inhalers, 
followed by a corticosteroid inhaler, a combination of corticosteroid and bronchodilator inhaler, and long-
acting beta 2-agonists fenoterol and salmeterol. Few athletes reported using bronchodilator tablets and 
leukotriene receptor antagonists. In the ultra-distance runners, the combination of corticosteroid and 
bronchodilator inhalers was most frequently used. Two of the five asthmatic runners used the short acting 
beta 2-agonist salbutamol only and one athlete made use of corticosteroid tablets for the control of 
asthma symptoms. Only one athlete in both the triathletes and the ultra-distance runner groups had a 
therapeutic use exemption (TUE) which was obtained for the use of the relevant anti-asthmatic 
medication (table not shown). 
 











Corticosteroid inhaler 22.0 (9) 25.0 (9) 0 
Salbutamol (Ventolin, 
Asthavent) 61.0 (25) 63.9 (23) 40.0 (2) 
Salmeterol (Serevent) 2.4 (1) 2.8 (1) 0 
Fenoterol (Berotec) 4.9 (2) 5.6 (2) 0 
Corticosteroid and 
bronchodilator 29.3 (12) 22.2 (8) 80.0 (4) 
Corticosteroid tablets 2.4 (1) 0 20.0 (1) 
Bronchodilator tablets 2.4 (1) 2.8 (1) 0 
Leukotriene receptor 
antagonist ( Singulair) 2.4 (1) 2.8 (1) 0 












3.3.11. Point prevalence and characteristics of allergies in Ironman triathletes and ultra-
distance runners 
 
The self reported point prevalence (%) of allergies in both groups was high, but in Ironman triathletes 
(34.0%) it was significantly higher than in ultra-distance runners (22.3%) (p=0.011). The type of allergies 
that endurance athletes experienced is depicted in Table 3.11. 
 
 
Table 3.11. Current allergy manifestation in Ironman triathletes and ultra-distance runners 
 
 






























Values are presented as frequencies (%) with the number of participants with non-missing or valid  
data (n) in parentheses. 
a For the athletes that completed both the 2006 and 2007 events, only the 2007 data were included in the 












p-Value IM vs. UD 
Nasal manifestation 
(hay fever) 77.8 (126) 83.3 (30) 0.503 
Sinusitis 64.2 (120) 55.0 (20) 0.432 
Lung manifestation  
(wheezing) 17.0 (112) 33.3 (12) 0.233 
Skin manifestation 21.1 (114) 38.5 (13) 0.171 
Eye manifestation 18.9 (111) 25.0 (12) 0.701 
Plant material trigger 21.4 (112) 16.7 (12) 1.000 
Food material trigger 14.8 (115) 23.1 (13) 0.427 
Animal material trigger 27.3 (110) 23.1 (13) 1.000 
Medication trigger 31.8 (22) 0 (13) 0.031 












There was no significant difference between the prevalence of different types of allergic manifestations 
(hay fever, sinusitis, allergic type asthma, skin allergies and allergies to plant material, food and animals) 
among athletes in both study groups.  However, significantly more Ironman triathletes reported allergies 
to medication compared with the ultra-distance runners. 
 
The type of specific allergies for which medication was taken in the two groups of endurance is shown in 
Table 3.12. 
 
Table 3.12.  The type of allergy manifestation for which medication was taken by Ironman 
triathletes and ultra-distance runners 
 


























Values are presented as frequencies (%) with the number of participants with non-missing or valid data (n) in 
parentheses. 
a For the athletes that completed both the 2006 and 2007 events, only the 2007 data were included in the combined 




There were no significant differences between the two groups for allergies that required medication. The 











runners (UD)  
p-Value IM vs. UD 
Nasal manifestation (hay 
fever) 62.8 (51) 50.0 (20) 0.326 
Sinusitis 66.7 (51) 35.7 (14) 0.062 
Lung manifestation  
(wheezing) 45.7 (35) 25.0 (12) 0.310 
Skin manifestation 23.1 (26) 36.4 (11) 0.442 
Eye manifestation 16.7(24) 0 (11) 0.285 
Plant material trigger 17.4 (23) 8.3 (12) 0.640 
Food material trigger 4.5 (22) 8.3 (12) 1.000 












Table 3.13.  Medication used by Ironman triathletes and ultra-distance runners for allergy 
symptoms 
    








p-Value IM vs. UD 
Corticosteroid nasal spray 48.4 (31) 35.7 (14) 0.428 
Corticosteroid nasal inhaler 30.4 (23) 16.7 (12) 0.450 
Antihistamine tablets 74.0 (50) 46.7 (15) 0.047 
Corticosteroid cream 11.1 (18) 25.0 (12) 0.364 
Anti-histamine cream 11.8 (17) 23.1 (13) 0.628 
Other inhaler/tablets/cream 57.1 (35) 38.5 (13) 0.250 
Values are presented as frequencies (%) with the number of participants with non-missing or valid data (n) in 
parentheses. 
a For the athletes that completed both the 2006 and 2007 events, only the 2007 data were included in the combined 




The most common medication used by both groups, was anti-histamine tablets and the use of these 
tablets was significantly higher in Ironman triathletes compared to ultra-distance runners.  Less than 50% 
of athletes in both study groups made use of corticosteroid nasal spray/inhaler. 
 
 
The current allergic symptoms that endurance athletes in the study population experienced are depicted 




































































Values are presented as frequencies (%) with the number of participants with non-missing or valid data (n) in 
parentheses. 
a For the athletes that completed both the 2006 and 2007 events, only the 2007 data were included in the combined 




The Ironman triathlete group reported significantly more symptoms of post nasal drip, sneezing, nasal 













p-Value IM vs. UD 
Sneezing 91.3 (69) 68.2 (22) 0.007 
Itchy palate 61.8 (34) 41.7 (12) 0.227 
Itchy eyes 80.4 (56) 46.2 (13) 0.011 
Post nasal drip 91.7 (72) 58.2 (17) 0.001 
Itchy runny nose 83.6 (55) 78.3 (23) 0.573 
Streaming eyes 55.2 (29) 25.0 (12) 0.098 
Nasal congestion 80.8 (52) 42.9 (14) 0.005 
Coughing 36.0 (25) 38.5 (13) 0.881 
Headache 71.1 (38) 28.6 (14) 0.010 
Fatigue 42.9 (21) 30.8 (13) 0.718 
Poor sleep 57.7 (26) 25.0 (12) 0.086 














The focus of this study was the pre-event period prevalence (6 weeks and 1 week before an event) and 
the nature of the symptoms of respiratory tract illness in endurance athletes. In particular, the areas that 
were studied were pre-event point prevalence and nature of respiratory tract symptoms, asthma, and 
allergies in two groups of endurance athletes.  
 
The first group of main findings were that; 1) respiratory tract symptoms in endurance athletes are 
common in the pre-event period, 2) upper respiratory tract symptoms, and in particular nasal symptoms 
are more common in triathletes in the 6 weeks before an event, and 3) systemic symptoms were present 
in almost 10% of ultra-distance runners, 1 week before an endurance event.   
 
The second group of main findings of this study were related to asthma. The point prevalence of self-
reported asthma was low in both the triathletes and the ultra-distance runners. However, clinically 
significant findings pertaining to asthma in these athletes were; 1) that the diagnosis of asthma was 
mostly made by history taking and physical examination by a physician without the diagnostic assistance 
of any special investigations, and 2) most asthmatic athletes used beta 2-agonists only for the treatment 
of asthma, rather than inhaled corticosteroids or combination therapy. 
 
The third group of main findings in this study pertain to allergic conditions in our study population. In 
general; 1) the point prevalence of self-reported allergies was high in both triathletes and ultra-distance 
runners and 2) in fact it was significantly higher in triathletes compared with ultra-distance runners, 3) 
nasal symptoms (nasal congestion and postnasal drip) were more commonly reported by triathletes in 












the first choice in the treatment of allergic symptoms in triathletes and ultra-distance runners rather than 
the use of topical corticosteroids.   
 
Pre-event period prevalence of respiratory tract symptoms in endurance athletes 
 
A novel finding from this study was that the period prevalence of respiratory tract symptoms in the 6 
weeks before a race was high in endurance athletes.  Specifically, about 50% of triathletes and 35% of 
the ultra-distance runners reported respiratory tract symptoms in the 6 week period before the events. 
More specifically, upper respiratory tract symptoms were more prevalent during this period in the 
triathletes (40.5%) compared to the ultra-distance runners (29.0%). The most common upper respiratory 
symptoms were nasal symptoms including nasal congestion (ranging from 12 to 21%) and rhinorrhoea 
(17 to 27%), the higher percentage pertaining to the triathlete group. 
 
To date, most studies of the prevalence of respiratory tract symptoms in athletes have been conducted 
during the post-race period. The results of this study are novel and could only be compared to post-event 
prevalence data. In these studies conducted during the post-event period, the period prevalence of RTS 
in the 10-14 days post-event ranged from 12.9% to 68% 2-4;40. 
 
Our study was not designed to document the possible causes of pre-event RTS. However, we could 
speculate that the high prevalence of pre-event RTS in athletes 6 weeks before the event might be 
related to training load in preparation for the event. Our data on the training history 15 weeks before the 
race, show that the triathletes spent more hours training (15.2 ± 4.7 hours per week) compared to the 
ultra-distance runners (6.6 ± 3.6 hours per week) and even in the week before the race, triathletes spent 












endurance runners focused only on one training discipline (running) there was no significant difference in 
the “running caliber” between the two study groups. 
 
It has been suggested that athletes are more susceptible to develop respiratory tract symptoms in periods 
of increased training load (volume and intensity). The relationship between training load and risk of RTS 
has been depicted as a “J-curve”, indicating that  moderate training load and regular exercise improve the 
body‟s ability to protect against infection, while high training loads decrease this protection 16. It is 
postulated that intense exercise weakens the body‟s defence mechanism against infection and this might 
result in the “open window” period causing a higher susceptibility for infection 
24. However, despite this 
hypothesis of infection as a cause of symptoms, studies indicate that pathogens are rarely isolated in 
athletes presenting with post-event respiratory symptoms 7-10. This raises the question of the possibility of 
other aetiological hypotheses for RTS, including allergy as a possible cause for symptomatology. 
 
The period prevalence in the one week period before the race is important from a clinical perspective, as 
this reflects a period where tapering of training volume is common, and that athletes need to be in optimal 
health in preparation for the event. RTS in this period are also clinically important as decisions regarding 
participation in the event have to be made in athletes suffering from any RTS. In athletes presenting with 
RTS, return to play guidelines have been formulated 35. Specifically, the clinical criteria for return to play 
are based on documenting localized upper respiratory tract symptoms vs. lower respiratory tract 
symptoms, or systemic symptoms. In current guidelines it is stated that the presence of any systemic 
symptoms or LRT symptoms constitute a contra-indication to exercise. This is known as the “neck 
check”
35. In our study, the period prevalence of systemic symptoms in the week before the event was 
9.2% in the ultra-distance running group. This was significantly higher than the 2.4% reported by the 
triathlete group. In particular, it should be noted that 5.3% of the ultra-distance runners reported pyrexia. 
These data indicate that a significant proportion of athletes, in particular runners, reported systemic 












noted that these were self-reported symptoms and were not confirmed by clinical examination or special 
investigations. However, this is clearly an area that does require further investigation. We suggest that 
studies should be conducted to determine the exact nature and cause of these symptoms. If athletes do 
suffer from acute active infections during this period, they should be educated regarding the risk of 
participation whilst ill.  
 
Asthma in endurance athletes 
 
The main findings regarding asthma in this study were that the point prevalence of asthma and asthma-
like symptoms in endurance athletes was low, but it was higher in triathletes (8.3%) than in ultra-distance 
runners (3.4%). These prevalence data are lower when they are compared to that reported in most other 
studies where the prevalence of current asthma was reported as ranging from 7% to 26% 51;61;65;66;71. 
However, these studies were not exclusively on endurance athletes and a higher prevalence of asthma 
was recorded, particularly in swimmers 61. 
 
In our study, it was also evident that asthma is mostly diagnosed by means of history taking and 
examination without the assistance of results from special investigations. In the literature, it is well 
established that there is a great discrepancy between symptoms of asthma and the actual diagnosis 64;67. 
The data from our study is therefore likely to reflect potential under-diagnosis of asthma and this may 
result in ineffective treatment.  Athletes should therefore be properly informed and physicians should be 
encouraged to perform the necessary special investigations to confirm the appropriate diagnosis of RTS. 
 
Our data indicate that triathletes reported most asthma-like symptoms while exercising. In the triathletes, 
shortness of breath and wheezing, were the most common symptoms of asthma while the ultra-distance 












with no specific relation to exercise. In treating these symptoms, most triathletes (63.9%) made use of a 
short-acting beta 2-agonist (salbutamol) only, a quarter (25.0%) made use of a corticosteroid inhaler and 
22.2% of triathletes used a combination of a corticosteroid and beta 2-agonist inhaler. In contrast, 80% of 
the ultra-distance runners used the combination inhaler (corticosteroid and beta 2-agonist) as first-line 
treatment, and 40% used salbutamol only. One athlete made use of oral corticosteroid tablets to control 
asthma symptoms. 
 
Optimal treatment of asthma aims at reducing bronchial hyper-responsiveness and to maintain control 
over disease activity 69. Anti-inflammatory treatment in the form of inhaled corticosteroids is currently the 
most important and effective treatment of asthma and EIA and effectiveness of the drug increases as 
treatment duration progresses 69. Short-acting beta 2-agonists (e.g. salbutamol) have a rapid onset of 
action and are effective for the immediate relief of bronchoconstriction. However, regular use of beta 2-
agonists result in decreased effectiveness, a phenomenon known as tolerance 69. 
 
Allergies in endurance athletes 
 
In our study there was a high point prevalence of self-reported allergic symptoms in endurance athletes 
(34.0% of triathletes and 22.3% of ultra-distance runners). In particular, allergic nasal symptoms (hay 
fever and sinusitis) were common. This finding is similar to that reported in the literature 12;31-33.   
 
Furthermore, our data show that there was a particularly high point prevalence of allergic symptoms in the 
upper respiratory tract with hay fever ranging from 77.8 to 83.3% and sinusitis between 55.0 and 64.2%. 
Ultra-distance runners reported a higher point prevalence of hay fever while sinusitis was more prevalent 
in the triathletes. Despite the high point prevalence of these allergic symptoms, only 62.8% of triathletes 












ultra-distance runners received treatment for sinusitis. Furthermore, the most common medication used in 
both groups was oral anti-histamine tablets. 
 
These findings do raise some concern and emphasize the need for further investigation.  It was evident 
that despite the high prevalence of allergy related symptoms, the majority of symptomatic athletes do not 
receive any treatment, or are treated inappropriately with systemic anti-histamines (tablets) rather than 
using topical corticosteroids. In a systemic review, intranasal corticosteroids produced significantly greater 
relief than oral anti-histamines of nasal discharge, sneezing, nasal blockage, nasal itch and post nasal 
drip 92. Another study on the use of intranasal budesonide for the treatment of seasonal allergic 
rhinoconjunctivitis, indicated significant improvement of symptoms, quality of life and performance on 
treatment with this topical corticosteroid 88. Despite this knowledge, athletes still make use of oral anti-
histamines as the first choice in the treatment of allergic symptoms 12. 
 
In British track and field athletes, it has been noted that 60% of athletes reported symptoms of hay fever 
but only 8% underwent any specific form of clinical allergy testing 31. This may raise yet another question 
regarding possible ignorance on behalf of the athlete, which makes effective management of allergic 
conditions an even greater challenge for the sports physician. 
 
Strengths and limitations of our study 
 
The study described above was cross-sectional in nature and the study tool used was a previously 
validated questionnaire. The following limitations therefore need to be discussed. Firstly, all data 
regarding RTS, asthma and allergies are self-reported by athletes and are therefore based on recall over 
a period of weeks. We could not verify the presence of reported infection, asthma or allergies by means 












study would have benefited from specific management interventions at the registration/start/finish of the 
event, e.g nasal swabs before and after the event  to document possible pathogens as a cause for 
respiratory symptoms.  Secondly, due to the nature of this descriptive study, no cause-effect relationships 
could be established. Thirdly, we acknowledge the possibility of selection bias with respect to recruitment 
of the study population, and the low response rate (particularly in the running group). It is possible that, 
the lengthy questionnaire might have been a reason that would explain the low response rate. Finally, as 
mentioned previously, the data pertaining to asthma and asthma-like symptoms in triathletes and ultra-
distance runners could not be compared due to the small sample sizes.  
 
However, there were also important strengths to be considered in the present study. Firstly, there was 
overall a large sample size. Secondly, we made use of questionnaires that had been previously validated. 
Thirdly, although this is a descriptive study, it focussed on a novel approach to determine the period 
prevalence of pre-event respiratory tract illness in two groups of endurance athletes. The findings are of 
clinical relevance to these groups of athletes for future advice and appropriate care. Finally, these 
findings regarding the prevalence of the different respiratory illnesses and the possible impact on the 
respiratory health of the endurance athlete, will direct future investigations in this clinically important area 




In summary, to our knowledge this is the first study that compared the period and point prevalence of 
respiratory illnesses (respiratory tract symptoms, asthma and allergies) between 2 groups of endurance 
athletes (triathletes and ultra-distance runners). These data revealed a higher prevalence of respiratory 
symptoms, particularly in the triathletes compared to the ultra-distance runners. There was also a very 












not optimally treated. Another finding and cause for concern is the lack of appropriate diagnosis of 
asthma-like symptoms, and the finding that these symptoms seem to be treated sub-optimally.  
 
We also documented that approximately 10% of ultra-distance runners reported systemic symptoms in 
the one week period before the race. This finding highlighted the need for more athlete education 
regarding respiratory health and athletes should be made aware of the possible risks of exercising while 
suffering from acute systemic illness. The “neck check” can be used as a general guideline for athletes on 
how to approach training in the presence of respiratory symptoms 35. 
 
In conclusion, the results of our study show that endurance athletes, and in particular triathletes, in 
preparation for a race, report a high frequency of respiratory related symptoms, especially nasal 
symptoms which appear to be related to allergy. We also identified the lack of specific diagnostic testing 
and the need for appropriate pharmacological management of illnesses influencing the respiratory health 


























The focus of this dissertation was on respiratory tract symptoms and illnesses in endurance athletes. In 
particular, the prevalence of respiratory tract symptoms, asthma and symptoms of allergies was studied in 
two groups of endurance athletes.  
 
4.2. Summary: Respiratory tract symptoms (RTS) in endurance athletes 
 
In Chapter 2, a review of the literature was undertaken in which we indicated that there was a high 
prevalence of RTS in the athletic population, especially in the period following an event or competition. 
However, it was also evident from this review that little was known about the prevalence of respiratory 
symptoms, asthma and allergies in the pre-event period, particularly in the endurance athlete (Table 2.1). 
A cross-sectional study was therefore undertaken to investigate the period prevalence of RTS in 
triathletes and ultra-distance runners in the 6-week period before an event (Chapter 3). The main findings 
of this study were; 1) RTS were very common in endurance athletes during the pre-event period (6 weeks 
and 1 week before the event), 2) the 6-week period prevalence of nasal symptoms before an event was 
significantly higher in triathletes compared with ultra-distance runners , 3) the pre-event respiratory 
symptoms might be related to a higher training volume and higher prevalence of allergies in the 
triathletes, and 4) systemic symptoms were present in 10% of ultra-distance runners and were 












have contributed to the knowledge of respiratory tract symptoms (RTS) in endurance athletes in the pre-
event period is depicted in Table 4.1. 
 
Table 4.1.  The pre-event period prevalence of respiratory tract symptoms (RTS) (“illness”) in 
athletes  
 
a RTS, Respiratory tract symptoms; bUTRS, Upper respiratory tract symptoms;  cSS, Systemic symptoms 
 
   
4.3. Summary: Prevalence of asthma in endurance athletes 
 
In Chapter 2 (section 2.5) of this dissertation, a review on asthma and asthma-like symptoms in athletes 
was presented. The main findings from this review were that prevalence of asthma was high in endurance 
athletes but little was known about the prevalence of asthma in particularly the endurance triathlete and 


































































































































asthma and the actual diagnosis of asthma in athletes. Finally, data from the review also emphasised the 
under-treatment of asthma related symptoms. 
 
In Chapter 3, the results of a study on asthma and asthma like symptoms in two groups of endurance 
athletes (triathletes and ultra-distance runners) were presented. The main findings of this study on 
asthma in the pre-event period were; 1) that the point prevalence of asthma-like symptoms ranged from 
25 to 80% in both athlete groups and this finding adds to the existing body of knowledge in this field 
(Table 4.2.), 2) that only 3.4% of ultra-distance runners and 8.3% of triathletes had a self-reported 
diagnosis of asthma, 3) the diagnosis of asthma was most commonly made only by means of history 
taking and physical examination by a physician without any contributory special investigations, and 4) the 








































a PDA, Physician diagnosed asthma; bICS, Inhaled corticosteroids; c IBA, Inhaled beta 2-agonists;  dLDR, Long- 







































































































and 11% in 
controls 
Helenius  





















































































4.4. Summary: Allergic symptoms in endurance athletes 
 
In Chapter 2, (Table 2.5) the prevalence of allergy in the athletic population was reviewed. In this review, 
it was clear that allergies are common among athletes of all sports disciplines. It was also interesting to 
note that the most common reported allergic conditions were rhinitis and hay fever.   
 
In Chapter 3, the point prevalence of allergic symptoms including the nature and treatment of these 
symptoms was investigated in two groups of endurance athletes. The first main finding of this study was 
that allergies were common and were significantly more prevalent in triathletes than in ultra-distance 
runners. This finding has contributed to the body of knowledge of the prevalence of allergies in endurance 
athletes (Table 4.3). Other significant findings from this study were; 1) the majority of symptoms in both 
groups were confined to the upper respiratory tract, in particular nasal symptoms, 2) the Ironman 
triathlete group reported significantly more symptoms of post nasal drip, sneezing, nasal congestion, itchy 
eyes and headaches than ultra-distance runners, and 3) the first choice of medication used for allergic 
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4.5 Summary: Clinical implications 
 
The main clinical implications of the research presented in this dissertation are as follows: 
 For endurance athletes, the few weeks before the event is an important period of final preparation 
and is characterized by high volumes of intense training. This is therefore identified as a period in 
which illness is more likely to occur, but to date has not been well studied. It was evident from results 
of this study that in the 6 weeks before the event, respiratory symptoms are very common and 
athletes may present with these symptoms to the sports physician. The treating physician will need to 
have a sound clinical approach to managing these athletes, including an understanding of the 
aetiology of RTS. Finally, the sports physician requires a clinical approach to “return to play” in 
endurance athletes presenting with RTS in the pre-event period. 
 The novel finding that about 10% of ultra-distance runners experienced systemic symptoms in the 
one week before the event has significant clinical implications. Current guidelines indicate that any 
athlete with regional or systemic symptoms should not participate in exercise training (including 
events) because of the potential risk of associated systemic illness and complications that may 
negatively impact the health of the athlete. Both athletes and coaches therefore should be educated 
regarding the current clinical guidelines (“neck-check”) in the approach to training and competing 
under these circumstances. 
 Although we report a low prevalence of asthma in this study, there is a discrepancy between asthma-
like symptoms experienced and the actual diagnosis of asthma. This might indicate the under-
reporting and possible under-diagnosis of asthma in endurance athletes.  
 It was also of clinical relevance that the data from this study show that the diagnosis (by means of 
history taking and physical examination by the physician) was probably inadequate and special 
investigations should be implemented to confirm the diagnosis of asthma.  
 Data from this study indicated that; 1) inhaled corticosteroids are not consistently used as the first 
choice of treatment, and 2) bronchodilators (beta 2-agonists) are not used appropriately – therefore, 












 Data from this and other studies consistently show that there is a high prevalence of allergies, 
especially nasal symptoms in endurance athletes. Therefore, we recommend that athletes should 
undergo allergy screening as part of their periodic health assessment.  
 Athletes with allergies (particularly rhinitis) should also be investigated for asthma and asthmatic 
athletes should have allergy screening, as these conditions often co-exist.  
 Athletes in this study were under-treated for allergic symptoms and anti-histamine tablets were 
inappropriately used as the drug of choice. The use of intranasal corticosteroids should be 
encouraged in these athletes as it has been shown not only to relieve allergic symptoms, but also to 
improve sleep, performance and quality of life. 
 
4.6. Future studies 
 
This study was a descriptive cross-sectional study and was not aimed at determining the cause of RTS in 
athletes. Future studies are needed to further investigate the non-infectious hypothesis of the cause of 
respiratory symptoms experienced by athletes in periods of intense training or competition. These studies 
should also explore the relationship between allergies and respiratory symptoms in the pre-event period. 
The need to investigate the aetiology of respiratory tract symptoms is important in the prevention and 
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SUBJECT INFORMATION SHEET: 
COMPONENTS OF THE RESEARCH STUDY TO BE CONDUCTED AT THE 
2009 TWO OCEANS ULTRA-MARATHON 
 
The research study at the 2009 Two Oceans ultra-marathon will have five components. You will be free 
participate in all, or some of the components of the study. The detailed information on each of these 
components of the study is as follows:  
COMPONENT 1: CAUSES OF EXERCISE ASSOCIATED MUSCLE CRAMPING (EAMC) IN ULTRA-
MARATHON RUNNERS  
The purpose of this component of the study is to determine the possible causes of exercise associated 
muscle cramping (EAMC) in endurance athletes. At registration, athletes will be given the opportunity to 
volunteer to participate in this component of the study.  
Details of the study are as follows:  
 • Prior to, or at registration, a questionnaire detailing personal particulars, medical information, 
training information, and history of muscle cramping will be completed.  
 • At registration, a blood sample (5ml – 1 teaspoon) will be collected from the vein in the arm 
using standard procedures.  
 • In the 8 weeks after the race, you may be contacted by telephone r email, and asked to 
complete a short questionnaire so that the researchers can determine if you suffered from EAMC during 
or after the race  
 
Potential risks of this component of the study  
 • The completion of a questionnaire is not associated with any risk. Questionnaire and other 
clinical data (paper and electronic) will be kept confidential, will be kept secure, and will not be made 
available to any party other than the research team without the consent of the individual subjects.  
 • The potential risks to subjects of blood collection are minimal and are related to 1) blood sample 
collection technique, and 2) the volume of blood collected prior to racing and the potential risk of a 
decreased performance in the race. The potential risks associated with blood collection technique from 
the veins on my arm (ante-cubital veins) are: infection, delayed healing, blood clot (haematoma), physical 
pain, mental discomfort and injury to a nerve or a vessel. These risks are small and will be minimized by 
the use of staff that is trained to take blood samples (trained phlebotomists), use of sterile techniques and 
the use of disposable, single use materials. The risk of decreased performance as a result of blood 
collection will be reduced by not subjecting any participant to the collection of a blood volume exceeding 
15 ml prior to the race.  
 • The flexibility tests that will be used are standard tests that are used daily in clinics and are 
associated with minimal risk. The only risk is to overstretch, but (1) an experienced tester will be 
administering the tests, (2) all normal precautions will be taken to avoid over-stretching, (3) and you will 
be asked to indicate when the stretch becomes uncomfortable, which is the normal clinical end point for 
the test.  
 • All medical conditions, including EAMC, will be treated appropriately on the course and in the 
medical facility at the finish of the race. The most appropriate treatment will be initiated and administered 
by the medical staff at the event, and the patient will be transported to the local hospital if necessary. The 
support from the local hospital is part of the normal standard medical care associated with this event.  
 
Potential benefits of this component of the study  
 • The anticipated benefits of this component of the study are that the results will further our 
understanding of the possible cause/s of EAMC in endurance athletes. In particular, once the cause of 
EAMC is better understood, this will improve our ability to prevent this condition, and to treat it effectively 
if it does occur.  
 
Component 2: The genetic basis for common running related injuries, particularly the response of 












Data from our laboratory suggests that several genetic variants are associated with a number of tendon 
and ligament injuries. These genetic variants might also be associated with flexibility measurements and 
structural characteristics of the Achilles tendon. The purpose of this component of the study will be to (i) 
to determine what the effect of an endurance event (such as the Two Oceans) is on the structure of the 
Achilles tendon and (ii) to determine whether there is a higher frequency of the “susceptible” variants of 
the genes shown to be associated with tendon injury (pathology) in these athletes.  
At registration you will be required to complete a questionnaire with personal details, training details, past 
injury details, and details about family history. In addition, a 5ml (1 teaspoon) blood sample will be taken 
from a vein in your arm. 
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You can then volunteer that a qualified radiologist examines both your Achilles tendons using a soft tissue 
diagnostic ultrasound machine. This procedure entails putting a clear jelly on your skin, and then using a 
probe to examine the tendon by passing it over the skin. This is not associated with any discomfort. You 
will be given immediate feedback on the imaging results of this examination, and will be given any advice 
the management of any findings.  
After you complete the race, you may be asked to undergo the same procedure (ultrasound examination) 
in the medical facility at the finish. Finally, you may be asked to report to the Sports Science Institute of 
South Africa in Newlands for a final ultrasound examination approximately 6 weeks after the race. The 
cost of this will be free, but you will not receive any financial compensation to attend this centre.  
The blood sample will be used for the extraction and analysis of genetic material (DNA). The DNA will 
only be used for scientific research purposes relating to medical complaints during ultra-endurance 
events. All data will be analysed anonymously and DNA samples will be destroyed on completion of the 
study.  
Potential risks of this component of the study  
 • The completion of a questionnaire is not associated with any risk. Questionnaire and other 
clinical data (paper and electronic) will be kept confidential, will be kept secure, and will not be made 
available to any party other than the research team without the consent of the individual subjects.  
 • The potential risks to you during blood collection are minimal and are related to 1) blood sample 
collection technique, and 2) the volume of blood collected prior to racing and the potential risk of a 
decreased performance in the race. The potential risks associated with blood collection technique from 
the veins on my arm (ante-cubital veins) are: infection, delayed healing, blood clot (haematoma), physical 
pain, mental discomfort and injury to a nerve or a vessel. These risks are small and will be minimized by 
the use of staff that is trained to take blood samples (trained phlebotomists), use of sterile techniques and 
the use of disposable, single use materials. The risk of decreased performance as a result of blood 
collection will be reduced by not subjecting any participant to the collection of a blood volume exceeding 
15 ml prior to the race.  
 • Soft tissue diagnostic ultrasound is a well described and common clinical diagnostic procedure 
that is associated with no known risk. This procedure will be undertaken by a trained radiologist.  
 
Potential benefits of this component of the study  
 • The anticipated benefits of this component of the study are that the results will clarify why 
certain runners may be more or less prone to chronic tendon injuries, based on their genetic make-up. In 
future, this work may lead to the screening and early identification of an increased risk for tendon injuries, 
so that preventative measures can be undertaken.  
 
Component 3: Pre-race predictors (including training parameters, medical history, medication 
use, and psychological traits) of medical complications that may occur in runners during and 
immediately after the Two Oceans ultra-marathon  
This study will be conducted by the UCT/MRC Research Unit for Exercise Science and Sports Medicine 
at the University of Cape Town in Cape Town, South Africa. The main aim of this component is to 
determine if there are any factors that can be identified before the race that will predict whether a runner 
is likely to develop a medical problem during or after the race. The details of the study are as follows:  
 • Prior to, or at registration, a detailed questionnaire detailing personal particulars, medical 












 • In the 8 weeks after the race, you may be contacted by telephone or email, and asked to 
complete a short questionnaire so that the researchers can determine if you suffered from a medical 
problem during or after the race  
 
Potential risks of this component of the study  
 • The completion of a questionnaire is not associated with any risk. Questionnaire and other 
clinical data (paper and electronic) will be kept confidential, will be kept secure, and will not be made 
available to any party other than the research team without the consent of the individual subjects.  
 
Potential benefits of this component of the study  
 • There is not direct benefit to an individual in participating in this component of the study. 
However, the long term anticipated benefits of this component of the research study are to identify factors 
that may predispose an increased risk of medical consequences during running. This information will 
eventually assist runners in predicting and improving their performance, and decrease their risk of 
medical complications during running.  
 
Component 4: Factors associated with pre-race and post-race (up to 10 days) respiratory tract 
symptoms in runners  
Upper respiratory tract (URT) symptoms such as a sore throat, runny or blocked nose, and throat irritation 
are particularly common in ultra distance athletes including tri-athletes. These symptoms occur mostly in 
the 2 weeks after a race. It has been shown to occur in 30-50% of all athletes after endurance events. It is 
important to understanding the relationship between exercise and URT symptoms as it is known that 
infections have potential negative effects for the athlete. Having an infection or not may mean the 
difference between being able to compete safely, performing at a sub-optimum level at risk, or missing 
the event altogether because of illness. In recent years we have become aware that the symptoms of 
URT infections that endurance athlete suffer from after a race, may NOT be caused by an infection. 
Instead this may reflect an irritation of the inner cell lining of the nose and throat due to allergy or perhaps 
pollution. However, we still need more evidence to prove this. 
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The aim of this component of our research is to determine which factors may predict the development of 
upper respiratory tract symptoms that are commonly experienced by athletes after a race.  
The details of the study are as follows:  
 • Prior to, or at registration, a detailed questionnaire detailing personal particulars, medical 
information, training information, respiratory tract symptoms and psychological parameters will be 
completed.  
 • In the 8 weeks after the race, you may be contacted by telephone or email, and asked to 
complete a short questionnaire so that the researchers can determine if you suffered from respiratory 
tract symptoms during or after the race  
 
Potential risks of this component of the study  
 • The completion of a questionnaire is not associated with any risk. Questionnaire and other 
clinical data (paper and electronic) will be kept confidential, will be kept secure, and will not be made 
available to any party other than the research team without the consent of the individual subjects.  
 
Potential benefits of this component of the study  
 • The anticipated benefits to subjects participating in this component of the study are firstly that 
the knowledge of the cause of the symptoms of the URT after an endurance event will be known, 
secondly that runners can be given accurate and safe advice on training during the recovery period.  
 
Component 5: Neural Fatigue following the Two Oceans ultra-marathon  
The aim of this study is to increase our understanding of the extent of the nervous systems ability to 
manage information and whether it has become slowed down or tired (neural processing 
slowdown/changes and arousal changes) that occurs in athletes having just completed an exhaustive 
ultra-marathon. Since this component of the study requires completion of a familiarisation test 6 weeks 
prior to the event, in Newlands, Cape Town, only Cape Town based competitors will be considered for 












The way we will test for neural processing changes is by way of a repetitive reaction time cognitive test – 
a computer generated test similar to a computer game (Stroop tes)t – whereby participants have to 
respond to the colour of 4 different colour words presented in the centre of the laptop screen. The 4 
colour words, red, blue, green and yellow will be presented on the screen in a different colour to what the 
word says, e.g. red written in blue ink, or green written in yellow. To ensure that participants read the 
words, 20% of the 4 colour words will be presented in grey – in this case participants have to respond to 
the word (i.e. not the colour). Arousal changes will be determined from subtle variations in the heart rate 
(heart rate variability - HRV).  
A familiarisation test will be conducted 6 weeks prior to the Two Oceans in a laboratory at the MRC/UCT 
Research Unit for Exercise Science and Sports Medicine, which is located at the Sports Science Institute 
of South Africa. A further pre-event test will be conducted the day before the Two Oceans during 
registration in a separate testing area; and finally a post-event test will be done within 30 min of 
completing the Two Oceans in the medical tent.  
We will be using a portable Biopac MP150 W System to record the HRV data. The measurements are 
completely non-invasive and harmless and will be collected by way of 3 electrodes attached to both wrists 
and the left ankle to record HRV data.  
The anticipated benefits of this component of the study are that the results will further our understanding 
of the deterioration of neural processing in athletes completing extreme endurance exercise. If significant 
deterioration in brain processing is indeed found, strategies can be implemented to combat this, whether 
by dietary, training or psychological means.  
Potential risks of this component of the study  
 • The completion of a questionnaire is not associated with any risk. Completion of self-rated 
behavioural questionnaires has not previously been shown to be associated with risk. A potential risk is 
that people who have experienced significant past trauma will find questionnaires on this uncomfortable. 
The questions within the behavioural questionnaires are asking are about personality characteristics 
(temperament) and none of the scales are directed at picking up psychological abnormalities 
(psychopathology). Questionnaire and other clinical data (paper and electronic) will be kept confidential, 
will be kept secure, and will not be made available to any party other than the research team without the 
consent of the individual subjects.  
 • There is no risk associated with the recording of the heart rate variability.  
 • There is no risk associated with the recording of the Stroop test  
 
Potential benefits of this component of the study  
 • There is not direct benefit in participating in this component of the study. The long term 
anticipated benefits of this component of the research study are to identify genetic factors that may 
predispose to 1) improved performance or 2) increased risk of medical consequences (such as abnormal 
electrolyte imbalances). This information will eventually assist tri-athletes in predicting and improving their 
























TWO OCEANS RESEARCH STUDIES 2009 
           Race no: 
INFORMED CONSENT FORM 
 
I, _________________________________, agree voluntarily to participate in the following components 
(DELETE THOSE COMPONENTS YOU DO NOT AGREE TO PARTICIPATE IN) of the UCT/MRC 
Research Unit for Exercise Science and Sports Medicine‟s, University of Cape Town, research project 
titled:-  
 1. Causes of Exercise Associated Muscle Cramping (EAMC) in ultra-marathon runners  
 2. The genetic basis for common running related injuries, particularly the response of soft tissues 
(Achilles tendon) to repeated forces during running (mechanical loading)  
 3. Pre-race predictors (including training parameters, medical history, medication use, and 
psychological characteristics (traits) of medical complications that may occur in runners during and 
immediately after the Two Oceans ultra-marathon  
 4. Factors associated with pre-race and post-race (up to 10 days) respiratory tract symptoms in 
runners  
 5. Brain and nervous system tiredness (Neural Fatigue) following the T o Oceans ultra-marathon  
 
I understand that my participation in this research project has no direct benefits to me during the Two 
Oceans 2009 competition. However, I understand that my participation in the research project will 
advance the medical and scientific knowledge related to endurance sports. Therefore, information 
gathered through my participation in this project could advance the future medical care, training advice 
and performance of endurance athletes.  
I have read the subject information sheets and the following procedures and concepts have been 
explained to me in full:  
(DELETE THOSE COMPONENTS YOU DO NOT AGREE TO PARTICIPATE IN)  
1. Completion of a questionnaire: (all components)  
The completion of personal details, racing, training, equipment use, medical, supplement use, fluid use 
and lifestyle history questionnaires are not associated with any risk. Completion of self-rated behavioural 
questionnaires has not previously been shown to be associated with risk. A potential risk is that people 
who have experienced significant past trauma will find questionnaires on this uncomfortable. The 
questions within the behavioural questionnaires are asking are about personality characteristics 
(temperament) and none of the scales are directed at picking up psychological abnormalities 
(psychopathology). Any personal id ntification of subjects (names and surnames), questionnaire data and 
other clinical data (paper and electronic) will be kept confidential, will be kept secure, and will not be 
made available to any party other than the research team without the consent of the individual subjects.  
I agree that the all the questionnaire information, my performance during the Two Oceans marathon, 
together with all the other data collected from the various components of this trial may be used to answer 
scientific questions about the medical conditions, physiological responses and measures of performance 
associated with the participation in and completion of an ultramarathon.  
2. Blood sample collection for re- serum creatine kinase (marker of muscle damage) levels (only 
for the cramps component)  
I have agreed to donate 5 milliliters (1 teaspoon) of venous blood during registration. The sample will be 
used to measure my levels of a muscle enzyme that is released if muscle is damaged (serum creatine 
kinase levels). The potential risks associated with blood collection technique from the veins on my arm 
(ante-cubital veins) are: infection, delayed healing, blood clot (haematoma), physical pain, mental 
discomfort and injury to a nerve or a vessel. These risks are small and will be minimized by the use of 
staff that is trained to take blood samples (trained phlebotomists), use of sterile techniques and the use of 
disposable, single use materials. The risk of decreased performance as a result of blood collection will be 
reduced by not subjecting any participant to the collection of a blood volume exceeding 15 ml prior to the 
race.  













I have agreed to undergo measurements of my lower limb flexibility. I understand that the two tests are 
the straight-leg raise test, and the sit-and-reach test. In both these test my limbs will be relaxed and 
electrodes to measure muscle 
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activity will be attached to my skin (back of the thigh). A tester who is experienced in administering these 
test, will then perform the tests as follows: 1) my leg will be raised (with the knee straight) until it feels 
“tight” and a muscle activity signal is registered on a machine that measures electrical signals from the 
muscles (electromyographic machine - EMG) - the degree to which my leg is lifted will be measured. 2) I 
will be asked to sit on the floor and then reach forward with both hands until it feels tight – the distance 
from my fingertips to my toes will then be measured. These are standard tests that are used daily in 
clinics and are associated with minimal risk. The only risk is to overstretch, but I will have the freedom to 
stop the test at any time if the stretch becomes uncomfortable.  
 4. Recording of heart rate variability during stroop test: (only for the management of pain 
components)  
 
The stroop test is a simple, computer based test (similar to a computer game). The mental concentration 
that is required for the test is relevant for the data collection and not the outcome of the test. There is no 
risk associated with the recording of the heart rate variability  
 5. Soft tissue diagnostic ultrasound examination: (only for the Achilles tendon component)  
 
I understand that I will be subjected to a test where gel is applied to my skin and a special machine is 
used to see the Achilles tendon underneath the skin (soft tissue diagnostic ultrasound examination of my 
Achilles tendons) during the registration period, on completion of the race, and if possible 6 weeks after 
the race at a medical facility close to my home. I understand that I will not receive any direct financial 
compensation to attend this centre for the ultrasound, but that the investigation will be free of charge. I 
understand that these investigations are not associated with any risk, and will be performed by a trained 
radiologist.  
 6. Blood sample collection for genetic studies: (only for the genetics component)  
 
At one of the pre-race facilities or at race registration, I have agreed to donate ten milliliters (2 teaspoons) 
of venous blood. The sample will be used for the extraction and analysis of genetic material (DNA).  
The potential risks associated with blood collection technique from the veins on my arm (ante-cubital 
veins) are: infection, delayed healing, blood clot (haematoma), physical pain, mental discomfort and injury 
to a nerve or a vessel. These risks are small and will be minimized by the use of staff that is trained to 
take blood samples (trained phlebotomists), use of sterile techniques and the use of disposable, single 
use materials. The risk of decreased performance as a result of blood collection will be reduced by not 
subjecting any participant to the collection of a blood volume exceeding 15 ml prior to the race.  
The genetic material that is extracted from my blood (DNA) will only be used for scientific research 
purposes relating to the genetic basis of (1) athletic ability, (2) physiological response to (3) medical 
complications during ultra-endurance events. I have also agreed to complete personal particulars, 
training, sporting, measures of my inherent behaviour and responses (behavioural endophenotypes) and 
medical questionnaires and understand that all the information that is collected during the study will be 
treated with the strictest confidentiality and will only be used for scientific research purposes. 
Questionnaire and other clinical data (paper and electronic) will be kept confidential, will be kept secure, 
and will not be made available to any party other than the research team without the consent of the 
individual subjects. I also understand that all data will be analysed without revealing any of my personal 
details (anonymously) and my DNA sample will be destroyed on completion of the study.  
I understand that some of the DNA extracted from the donated blood sample will be sent to the Cyprus 
Institute of Neurology and Genetics in Cyprus for analysis. I understand that the DNA samples will be 
shipped to and analysed in Cyprus anonymously. I understand that the DNA will be genotyped (analysed) 
for variations (polymorphisms) within genes relating to the genetic basis of athletic ability, tendon and 
ligament overuse injuries and dysnatraemia during ultra-endurance events only.  
I understand that whilst there is no direct benefit to myself, if a genetic predisposition for (1) athletic 
ability, (2) physiological response to and (3) medical complications during ultra-endurance events can be 












better prevention and treatment options in the future. I understand that I will receive the overall results of 
the study.  
I have read (or, where appropriate, have had read to me) and understood the information about this 
study, and any questions I have asked have been answered to my satisfaction. I agree to participate in 
the study, realising that I have the right to request that my DNA sample be destroyed at anytime. I agree 
that research data provided by me or with my permission during the project may be included in a thesis, 
presented at conferences and published in journals on the condition that neither my name nor any other 
identifying information is used. 
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I have read the preceding subject information sheet and understand the testing procedures outlined 
therein. I understand any accompanying risks and discomforts. Knowing these risks and 
discomforts and having had the opportunity to pose questions answered to my satisfaction, I hereby 
consent to participate in this study. I understand that I may withdraw from this study at any time 
without further question. I have been informed that the individual data derived from my participation 
in these protocols will remain confidential. I understand that the medical staff and the research team 
have professional medical insurance.  
Name of the athlete: ____________________________  
Signature of athlete ____________________________  
Date: _________ April 2009  
Name of main investigator: Prof Martin Schwellnus  
Signature of main Investigator: ____________________________  
































Department of Human Biology 
UCT/MRC RESEARCH UNIT FOR EXERCISE SCIENCE & SPORTS MEDICINE 
Faculty of Health Sciences, University of Cape Town 
Private Bag, Rondebosch 7700, South Africa 
Tel: + 27 21 650 4561 
Fax: + 27 21 686 7530 
 
2007 IRONMAN – MEDICAL AND TRAINING QUESTIONNAIRES 
 
These questionnaires have been constructed by the Medical Research team, in 
conjunction with the Medical Director of the Ironman 2007.  The information 
obtained from these questionnaires is essential for the planning of medical care 
during events such as the Ironman. We acknowledge that the questionnaires are 
long, but we are asking about 30 minutes of your valuable time to complete them. 
The completion of the questionnaires is voluntary; all the information will be kept 
confidential and will only be used for research and medical care pla ning purposes. 
We suggest that you consider downloading and completing this before the event 
and handing in the completed questionnaire, at the research area during race 
registration.  
 
Prof Martin Schwellnus (Chairman, Research Team) 




Please answer each question by filling in the details in the allocated space or checking one or more 
of the option boxes. 
 
Please bring the completed forms together with the signed consent form to the research table at 
race registration. 
 
Please complete sections A, B, C, D, E and F 
Section A Personal Details Page 2 
Section B Racing, Training and Equipment Use History Pages 3-6 
Section C History of Medication, Supplement and Fluid Use as well as Lifestyle and Habits History Pages 7-8 
Section D Psychological and Behavioural Pages 9-13 
Section E Family Medical History Page 14 
Section F General Personal Medical History Pages 15-17 
Please complete only the relevant questions in the following section 































Section A: Personal details 
2007 Ironman Race Number       
Surname       
First Name       
Postal Address 
 




Postal/ Zip Code       
E-mail address       Phone (day time) code number 
Alternate E-mail address  
Date of birth y y y y - m m - d d  Cell (Mobile)       
Height       cm Gender Male  Female  
Weight       kg Age (on race day)        yrs 
Ethnic group 
(Only Required and 
Used for Research 
Purposes) 
Black/African    White  Indian  
Mixed Ancestry (Coloured)  Asian  Other  
Ancestry: Tribal or 
national 
background 
(eg Xhosa, Dutch, 
Zulu, German, Italian) 
Father:       Unknown   
Mother:       Unknown   
Country of Birth       
Dominant Hand Left     Right    Both  Dominant Leg Left    Right   Both  
Occupation       
What percentage 
of your working 
day is spent in the 
following activities? 
Sitting:      _____ % 
Standing:     _____ % 
Walking (Lower body activity)   _____ % 
Manual Labour (upper and body activity)  _____ % 
Did you participate in the research project conducted at the 2006 Ironman in 













Section B. Racing and training history 
Type of triathlon 
Standard 
(1.6, 40, 10) 
Ironman 
 
Which triathlons have you ever participated in? Yes  No  Yes  No  
Year of first event             
How many triathlon events have you ever 
participated in?             
How many triathlon races have you completed 
over the past 2 years?             
Personal best time ever _____ hrs:min _____ hrs:min 
What was your time for your last triathlon race 
during the past 12 months? _____ hrs:min _____ hrs:min 
Type of running event 10 km 21.1 km 42.2 km 
Which road running races have you ever 
participated in? Yes  No  Yes  No  Yes  No  
Year of first event                   
How many events have you ever participated 
in?                   
Personal best time ever _____ min _____ min _____ min 
What is your best time, in a running race, in 
the last 15 weeks? _____ min _____ min _____ min 






Which races have you ever participated in? Yes  No  Yes  No   
Year of first event              
How many events have you ever participated 
in?              
Personal best time _____ hrs:min _____ hrs:min  
What is your personal best cycling time in a race 
between 80 to 120 km in the last 15 weeks?  
Time:   _____   min  
Distance:  _____  km 
South African Ironman Triathlon racing history 
Did you enter any of the South African Ironman Triathlons? 
2000 (Gordon‟s Bay) Yes  No   Race No _______ 
2001 (Gordon‟s Bay) Yes  No   Race No _______ 
2005 (Port Elizabeth) Yes  No   Race No _______ 
2006 (Port Elizabeth) Yes  No   Race No _______ 
What is your predicted time for the entire 2007 
Ironman event and each of the three splits? 
Entire event: _____   min 
Swim:  _____   min 
Cycle:  _____   min 
Run:  _____   min 
 
 
Please answer the following questions, with your answers reflecting your average in the most 
recent 15 weeks i.e. beginning December 2006 to 18
th












Do you train with a heart rate monitor? Yes  No  
Do you race with a heart rate monitor? Yes  No  
Do you record, download and store your heart rate information? Yes  No  
Would you be willing to make your heart rate data available to the 
research team? Yes  No  
How many days a week did you train during the last 15 weeks?        days/week 
What distances did you train in an average week during the last 
15 weeks?    
Swim:  _____ km/week 
Cycle:  _____ km/week 
Run:  _____ km/week 
How many hours a week did you train in an average week during 
the last 15 weeks? 
Swim:  _____ hrs/week 
Cycle:  _____ hrs/week 
Run:  _____ hrs/week 
How many hours a week did you work in an average week during 
the last 15 weeks? _____ hrs/week 
What distances did you train in the week before the race?    
Swim:  _____ km 
Cycle:  _____ km 
Run:  _____ km 
How many hours did you train in the week before the race?    
Swim:  _____ hours 
Cycle:  _____ hours 
Run:  _____ hours 
How many fast/ hard sessions did you do per week in the last 8 
weeks? 
Swim:  _____ 
Cycle:  _____ 
Run:  _____ 
Describe briefly the session, including distance, time and recovery 
interval (if applicable) e.g. 10 x 400m in 75 sec with 60 sec jog 
recovery between each 
 
What percentage of your weekly training distance was done at 
race speed or faster (for each discipline)? 
Swim:  _____ % 
Cycle:  _____ % 
Run:  _____ % 
How many hours did you train 3 days before the race 
Swim:  _____ hours 
Cycle:  _____ hours 
Run:  _____ hours 
How many hours did you train 2 days before the race 
Swim:  _____ hours 
Cycle:  _____ hours 
Run:  _____ hours 
How many hours did you train the day before the race 
Swim:  _____ hours 
Cycle:  _____ hours 
Run:  _____ hours 
How did your training commitment affect your social life? 
 Not at all  
 A fair amount  


















Do you perform flexibility training (regular stretching exercises)? Yes    No  
If YES, please complete the rest of the flexibility training history section below:- 
If NO, continue completing the questionnaire from the top of page 5 (Equipment use history).  
On average, how many days a week do you perform a stretching 
session?        days/week 
On average, how times a day do you perform a stretching 
session?        times/day 
Please tick which muscle groups do you include 
in your stretching session? 
 Hamstrings 
 Quadriceps 
 Calf (gastrocnemius) 
 Calf (soleus)  
 Groin (inner thigh) 
 Upper body limbs 
 Other: _____________________________ 
Please tick when you stretch? (before, during and/or after 
exercising.  You can tick more than one box) 
 Before Exercise 
 During Exercise 
 After Exercise 
When you stretch an individual muscle group, on average, how 
long do you hold the stretch for?        seconds 
When you stretch an individual muscle group, on average, 
how many times do you stretch the muscle for? 
 Once  
 Twice 
 3 times  
 4 times 
 5 times 
 6 or more times  
 
Equipment use history 
Please indicate which 
type of bicycle you 
use? 
 Kuota   Kestrel   Trek 
 Aegis   Litespeed   Softride 
 Felt    Quintana Roo  Javelin 
 Cervelo   Argon 18   Scott 
 Elite   Specialized   Guru 
 Giant   Other: _______________________ 
Please indicate which 
type of handle bars 
you use? 
 Bontrager   HED   Zipp 
 Profile Design  Vision Tech   Oval Concepts 
 Deda   Easton   Syntace 
 Pedalsoft   Kestrel 
 Other: _______________________ 
Please indicate which 
type of saddle (Brand - 
model) you use? 
 Selle San Marco- Azoto TriathGel 
 Profile Design- Tri Stryke (with a groove) 
 Selle San Marco- Rever Profil 
 Fizik- Arione Tri 
 Terry 
 Koobi 












Please indicate which 
brand of helmet you 
use? 
 Trek   Bell    Giro 
 MET   Other: _______________________ 
Please indicate which 
type of cycling shorts 
you use? 
 Thin lycra (no padding)                               Padded cycling shorts 
 Triathlon shorts with some padding            Swimming  costume  
 Other: _______________________ 
Do you normally wear underwear together with cycling shorts?  Yes    No 
Please indicate which 
type of cycling shoes 
you use? 
 Olympic   Nike   Diadora 
 Shimano   Carnac   Sidi  
 Other: _______________________ 
Please indicate which 
type of kit you use? 
 Anatomic   Nike   Velo 
 Howzit   Adidas   Orca 
 De Soto   Louis Garneau  Quintana Roo 
 Zoot   Other: _______________________ 
Please indicate which 
brand of running 
shoe you use? 
 Adidas                       Asics                         Brooks                     
 New Balance             Nike                          Mizuno                     
 Puma                         Reebok                     Saucony                    
 Other: _______________________ 
Please indicate which 
type of running shoe 
you use? 
 Soft neutral shoe 
 Mild anti-pronation shoe 
 Motion control shoe 
 Light racing shoe 
 Unknown or not sure 













Section C. History of medication and supplement use 
What medication, if any, are you 
currently using? (please list) 
Name of medication Years taken 
            
            
            
            
Do you use protective skin 
sunscreen during training 
session or when competing? 
Yes  No  
 Every session  Most sessions 
 Some sessions  Very occasionally 
Are you currently taking dietary supplements/vitamins? Yes  No  
If yes to the above question, 
please list names of dietary, 
sports or vitamin supplements. 
Name of supplement Years taken 
 Multi-vitamins     _____ 
 Anti-oxidants     _____ 
 Immune boosters     _____ 
 Protein powders/supplements, Protein bars. BCAAs  _____ 
 Creatine       _____ 
 Caffeine      _____ 
 Fat cutters      _____ 
 Carbohydrate drinks/powders/gels   _____ 
 Other: _____________________________  _____ 
Have you ever used oral 
corticosteroids (cortisone 
tablets)? (If yes, how long ago?) 
Yes  No  
 3 months  6 months 
 12 months  24 or more months 
Have you ever been given an 
injection with corticosteroids? (If 
yes, how long ago?) 
Yes  No  
 3 months  6 months 
 12 months  24 or more months 
Have you ever been given an 
injection of corticosteroids in or 
around the Achilles tendon? (If 
yes, how many times?) 
Yes  No  
 Once  Twice 
 3 times  >3 times 
Have you ever used 
fluoroquinoline antibiotics? (refer 
to the following list) 
Yes  No  
 3 months  6 months 
 12 months  24 or more months 
 







































Lifestyle and habits history 
Please indicate your smoking 
status 
Current smoker   Ex smoker   Never smoked   
If you answered 
yes, (past or 
current smoker) 
please complete 
the section on the 
right 
Number of years of smoking:       If stopped, how many years ago:       
What is (was) the average number of cigarettes per day:       
On average, how much alcohol do you drink per week 
(tots, glasses) of spirits, wine or beer? 
_______  glasses beer/cider per week 
_______  glasses wine per week 
_______  tots of spirits per week 
 
Fluid Intake 
How do you best 
describe your fluid 
intake during an 
Ironman triathlon 
race? 
(a) I drink to thirst       
(b) I drink as much as tolerable      
(c) I drink according to a predetermined fluid intake schedule  
(d) I drink to prevent any weight loss during exercise   
(e) I combine (a) with (c)       
(f) I combine (b) with (c)       
(g) Other: _____________________________    
What percentage of 
your fluid intake will 
consist of these 
beverages? 
Water:   0-25%   26-50%   51-75%   76-100% 
Sports drink:  0-25%   26-50%   51-75%   76-100% 
Coke:   0-25%   26-51%   51-75%   76-100% 
Other:   0-25%   26-50%   51-75%   76-100% 
Specify other: _____________________________ 
What will be your estimated total fluid intake be (if at all) during the swim?       ml 
What will be your estimated total fluid intake be during the cycle?       ml 
What will be your estimated total fluid intake be during the run?       ml 
Rank the following 
sources of information 
on their importance in 
formulating your 
drinking strategy. (1 
being most influential 
and the lowest 
number being least 
influential) 
_____ Fellow triathletes  
_____ Coach / trainer 
_____ Magazines / books 
_____ Website (please specify: _____________________________) 
_____ Drinking guidelines from sports associations 
_____ Adverts 
_____ Self-experimentation 














Section D.  Psychological and Behavioural 
Connor-Davidson Resilience Scale (CD-RISC) 
Please indicate how much you agree with the following statements as they apply to you over the last 
















1. I am able to adapt when changes occur.      
2. I have at least one close and secure 
relationship which helps me when I am 
stressed. 
     
3. When there are no clear solutions to my 
problems, sometimes fate or God can help.      
4. I can deal with whatever comes my way.      
5. Past successes give me confidence in dealing 
with new challenges and difficulties.      
6. I try to see the humorous side of things when I 
am faced with problems.      
7. Having to cope with stress can make me 
stronger.      
8. I tend to bounce back after illness, injury, or 
other hardships.      
9. Good or bad, I believe that most things 
happen for a reason.      
10. I give my best effort, no matter what the 
outcome may be.      
11. I believe I can achieve my goals, even if there 
are obstacles.      
12. Even when things look hopeless, I don't give 
up.      
13. During times of stress/crisis, I know where to 
turn for help.      
14. Under pressure, I stay focused and think 
clearly.      
15. I prefer to take the lead in solving problems, 
rather than letting others make all the 
decisions. 
     
16. I am not easily discouraged by failure.      
17. I think of myself as a strong person when 
dealing with life's challenges and difficulties.      
18. I can make unpopular or difficult decisions 
that affect other people, if it is necessary.      
19. I am able to handle unpleasant or painful 
feelings like sadness, fear and anger.      
20. In dealing with life's problems, sometimes you 
have to act on a hunch, without knowing why.      
21. I have a strong sense of purpose in life.      
22. I feel in control of my life.      
23. I like challenges.      
24. I work to attain my goals, no matter what 
roadblocks I encounter along the way.      












TPQ / TCI (96 shared items) 
1. I usually am confident that everything will go ell, even in situations that 
worry most people. True  False  
2. I often try new things just for fun or thrills, even if most people think it is a 
waste of time. True  False  
3. I like to discuss my experiences and feelings openly with friends instead 
of keeping them to myself. True  False  
4. When nothing new is happening, I usually start looking for something that 
is thrilling or exciting. True  False  
5. Usually I am more worried about that most people that something might 
go wrong in the future. True  False  
6. I don‟t mind discussing my personal problems with people whom I have 
known briefly or slightly. True  False  
7. I would like to have warm and close friends with me most of the time. True  False  
8. I nearly always stay relaxed and carefree even when nearly everyone 
else is fearful. True  False  
9. I usually demand very good practical reasons before I am willing to 
change my old ways of doing things. True  False  
10. I often have to stop what I am doing because I start worrying that 
something might go wrong. True  False  
11. I hate to change the way I do things, even if many people tell me there is 
a new and better way to do it, True  False  
12. My friends find it hard to know my feelings because I seldom tell them 
about my private thoughts. True  False  
13. I like it when people can do exactly what they want without strict rules and 
regulations. True  False  
14. I often stop what I am doing because I get worried, even when my friends 
tell me everything will go well. True  False  
15. It wouldn‟t bother me to be alone all the time. True  False  
16. I like to be very organized and set up rules for people whenever I can. True  False  
17. I usually do things my own way, rather than giving in to the wishes of 
other people. True  False  
18. I usually feel tense and worried when I have to do something new and 
unfamiliar. True  False  
19. I often feel tense and worried in familiar situations, even when others feel 
there is little to worry about. True  False  
20. Other people often think that I am too independent because I won‟t so 
what they want. True  False  
21. Even when most people feel it is not important, I often insist on things 
being done in a strict and orderly way, True  False  
22. I often do things based on how I feel at the moment, without thinking 
about how they are done in the past. True  False  
23. I often feel tense and worried in unfamiliar situations, even when others 
feel there is no danger at all. True  False  
24. I often brake rules and regulations when I think I can get away with it. True  False  
25. I don‟t care very much whether other people like me or the way I do 
things. True  False  
26. I usually stay calm and secure in situations that most people would find 
physically dangerous. True  False  
27. I feel it is more important to be sympathetic and understanding of other 
people than to be practical and tough- minded. True  False  
28. I lose my temper more quickly than most people. True  False  
29. I am usually confident that I can easily do things that most people would 
consider dangerous (such as driving as automobile fast on a wet or icy 
road). 
True  False  
30. I often react so strongly to unexpected news that I say or do things that I 












31. People find it easy to come to me for help, sympathy, and warm 
understanding. True  False  
32. I am much more reserved and controlled than most people. True  False  
33. When I have to meet a group of strangers, I am more shy than most 
people. True  False  
34. I am strongly moved by sentimental appeals (like when asked to helped 
crippled people). True  False  
35. I almost never get so excited that I lose control of myself. True  False  
36. I have a reputation as someone who is practical and does not act on 
emotion. True  False  
37. I often avoid meeting strangers because I lack confidence with people I 
do not know. True  False  
38. I usually stay away from social situations where I would have to meet 
strangers, even if I am assured that they will be friendly. True  False  
39. I usually push myself harder than most people do because I want to do as 
well as I possibly can. True  False  
40. I often push myself to the point of exhaustion or try to do more than I 
really can. True  False  
41. I would probably stay relaxed and outgoing when meeting a group of 
strangers, even if I were told they were unfriendly. True  False  
42. It is difficult for me to keep the same interests for a long time because my 
attention often shifts to something else. True  False  
43. I think I would stay confident and relaxed when meeting strangers, even if 
I were told they are angry with me. True  False  
44. I could probably accomplish more than I do, but I don‟t see the point of 
pushing myself harder than is necessary to get by. True  False  
45. I like to think about things for a long time before I make a decision. True  False  
46. Most of the time I would prefer to do something a little risky (like riding in 
an automobile over steep hills and sharp turns), rather than having to stay 
quiet and inactive for a few hours. 
True  False  
47. I often follow my instincts, hunches, or intuition without thinking through all 
the details. True  False  
48. I try to do as little work as possible, even when other people expect more 
of me. True  False  
49. I often have to change my decisions because I had a wrong hunch or 
mistaken first impression. True  False  
50. Most of the time I would prefer to so something risky (like hang-gliding or 
parachute jumping(, rather than having to stay quiet and inactive for a few 
hours. 
True  False  
51. I am satisfied with my accomplishments and have little desire to do better. True  False  
52. I see no point in continuing to work on something unless there is a good 
chance of success. True  False  
53. I have less energy and get tired more quickly than most people. True  False  
54. I usually think about all the facts in detail before I make a decision. True  False  
55. I nearly always think about all the facts in detail before I make a decision, 
even when other people demand a quick decision. True  False  
56. I often need naps or extra rest periods because I get tired so easily. True  False  
57. I don‟t go out of my way to please other people. True  False  
58. I am more energetic and tire less quickly than most people. True  False  
59. I am usually able to get other people to believe me, even when I know 
that what I am saying is exaggerated or untrue. True  False  
60. I can usually do a good job of stretching the truth to tell a funnier story or 
to play a joke on someone. True  False  
61. I usually can stay “on the go” all day without having to push myself. True  False  
62. I am usually more upset than most people by the loss of a close friend. True  False  
63. I have trouble telling a lie, even when it is meant to spare someone else‟s 












64. I am better at saving money than most people. True  False  
65. Even after there are problems in a friendship, I nearly always try to keep it 
going anyway. True  False  
66. I recover more slowly than most people from minor illnesses or stress. True  False  
67. I need much extra rest, support, or reassurance to recover from minor 
illnesses or stress. True  False  
68. I often spend money until I run out of cash or get into debt from using too 
much credit. True  False  
69. Because I so often spend too much money on impulse, it is hard for me to 
save money, even for special plans like a vacation. True  False  
70. It is extremely difficult for me to adjust to changes in my usual way of 
doing things because I get so tense, tired or worried. True  False  
71. If I am feeling upset, I usually feel better around friends than when left 
alone. True  False  
72. I usually feel much more confident and energetic than most people, even 
after minor illnesses or stress. True  False  
73. Some people think I am too stingy or tight with my money. True  False  
74. I often keep trying the same thing over and over again, even when I have 
not had success in a long time. True  False  
75. It is hard for me to enjoy spending money on myself, even when I have 
saved plenty of money. True  False  
76. I recover more quickly than most people from minor illnesses or stress. True  False  
77. I hate to make decisions based only on my first impressions. True  False  
78. I think I will have very good luck in the future. True  False  
79. I am most often moved deeply by fine speech or poetry. True  False  
80. If I am embarassed or humiliated, I get over it very quickly. True  False  
81. I like old “tried and true” ways of doing things according to their priority of 
importance to me because of lack of time. True  False  
82. I like to keep my problems to myself. True  False  
83. I enjoy saving money more than spending it on entertainment or thrills. True  False  
84. Even when I am with friends, I prefer not to “open up” very much True  False  
85. I feel very confident and sure of myself in almost all social situations. True  False  
86. I usually like to stay cool and detached from other people. True  False  
87. I never worry about terrible things that might happen in the future. True  False  
88. I am more hard-working than most people. True  False  
89. In conversations I am much better as a listener than as a talker. True  False  
90. I like to please other people as much as I can. True  False  
91. Regardless of any temporary problem that I have to overcome, I always 
think it will turn out well. True  False  
92. I like to stay at home better than to travel and explore new places. True  False  
93. I am usually so determined that I continue to work long after other people 
have given up. True  False  
94. I usually have good luck in whatever I try to do. True  False  
95. I like to pay close attention to details in everything I do. True  False  




Instructions: The following questions ask about how you have been feeling during the past four 
weeks. For each question, please circle the number that best describes how often you have had this 
feeling. Your answers will be kept confidential. 


























1. About how often did you feel tired of for no 
good reason? 
1 2 3 4 5 
2. About how often did you feel nervous? 1 2 3 4 5 
3. About how often did you feel so nervous that 
nothing could calm you down? 
1 2 3 4 5 
4. About how often did you feel hopeless? 1 2 3 4 5 
5. About how often did you feel restless or 
fidgety? 
1 2 3 4 5 
6. About how often did you feel restless you could 
not sit still? 
1 2 3 4 5 
7. About how often did you feel depressed? 1 2 3 4 5 
8. About how often did you feel that everything is 
an effort? 
1 2 3 4 5 
9. About how often did you feel so sad that 
nothing could cheer you up? 
1 2 3 4 5 














Section E. Family medical history 
Have any of your blood (biological) relatives ever had the following?  
Please tick yes or no. If yes, please tick the relationship of that person to you (You may tick 
more than one of the relationship blocks).  
Description  If Yes, please indicate the relationship  
Exercise associated muscle 
cramps Yes  No  
 Father      Mother         Brother   
  Sister    Child 
 Grandfather   Grandmother  
Night muscle cramps Yes  No  
 Father      Mother         Brother   
  Sister    Child 
 Grandfather   Grandmother  
Chronic Achilles tendon 
injury  Yes  No  
 Father      Mother         Brother   
  Sister    Child 
 Grandfather   Grandmother  
Achilles tendon rupture Yes  No  
 Father      Mother         Brother   
  Sister    Child 
 Grandfather   Grandmother  
Any ligament injury Yes  No  
 Father      Mother         Brother   
  Sister    Child 
 Grandfather   Grandmother  
Asthma Yes  No  
Father      Mother         Brother   
  Sister    Child 
 Grandfather   Grandmother  
Allergies (in general) Yes  No  
 Father      Mother         Brother   
  Sister    Child 
 Grandfather   Grandmother  
Heart Disease Yes  No  
 Father      Mother         Brother   
  Sister    Child 
 Grandfather   Grandmother  
Diabetes Yes  No  
 Father      Mother         Brother   
  Sister    Child 
 Grandfather   Grandmother  
Depression, Anxiety attacks, 
Personality disorder Yes  No  
 Father      Mother         Brother   
  Sister    Child 
 Grandfather   Grandmother  
Gastro-intestinal (GIT) 
disease Yes  No  
 Father      Mother         Brother   
  Sister    Child 














Section F. Personal general medical history 
In this section, you are asked to read through 14 questions about your personal general medical 
history. If you answer “yes” to any of questions 1 to 12, please complete the additional questions 
at the end of the section (section G on page 18).  
1. In the 6 weeks before this race (from 1st February) did you suffer from any 
symptoms of flu (fever, sore throat, blocked or runny nose, cough, wheeze, 
muscle aches and pains)? 
Yes  No  
2. Have you ever in triathlon career suffered from muscle cramping (painful, 
spontaneous, sustained spasm of a muscle) during or immediately (within 6 
hours) after exercise (in training or competition)?  
Yes  No  
3. Have you ever in your triathlon career suffered from a tendon or ligament injury 
(pain, swelling, stiffness) in any tendon (including Achilles tendon, knee tendons, 
and shoulder tendons) or ligaments (partial or complete tear)? 
Yes  No  
4. Have you ever in your triathlon career used medicines to treat injuries in the 
week before or during a race – including anti-inflammatory drugs, cortisone 
(pills, or injection), or pain killers?  
Yes  No  
5. Have you ever in your triathlon career suffered gastrointestinal symptoms 
during exercise including heartburn, nausea, vomiting, abdominal pain, urge to 
defecate (pass a stool), diarrhoea, or blood in the stools? 
Yes  No  
6. Have you ever in your triathlon career suffered from symptoms of the nervous 
system including exercise induced headaches, nerve tingling or loss of 
sensation? 
Yes  No  
7. Have you ever in your triathlon or cycling career (in particular with cycling) 
suffered from injury to the genital area including genital numbness after cycling, 
genital pain after cycling, genital swelling or altered sexual function after cycling? 
Yes  No  
8. Have you ever in your triathlon career suffered from symptoms of allergies 
including nose allergies (hay fever), allergic sinusitis, allergic asthma, skin 
allergies, a past history of allergies to medication, plant material or animal 
material? 
Yes  No  
9. Do you currently suffer from asthma including exercise induced asthma, or 
symptoms of asthma such as shortness of breath, wheezing, or chronic 
coughing? 
Yes  No  
10. Have you ever collapsed (fell down not because of an accident, needing 
medical attention) during, at the finish or after a race or training session? Yes  No  
11. Do you currently suffer from any symptoms of injury in the muscles, tendons, 
bones, ligaments or joints? Yes  No  
12. Do you currently, or did you in the 
last year, suffer from any symptoms 
of exercise related skin disease? 
Sunburn:   Yes    No  
Skin cancer:   Yes    No  












13. Please tick in which anatomical area 
you ever had surgery performed. 
 Gastric (stomach)  Oesophageal (swallowing pipe) 
 Small bowel    Large bowel (colon) 
 Rectum                Gallbladder 
 Pancreas                Liver 
 Abdomen (general)   Wrist 
 Head    Finger 
 Neck   Lower back 
 Face   Hip  
 Front chest   Thigh 
 Back chest    Knee 
 Shoulder   Lower leg 
 Upper arm   Achilles 
 Elbow   Ankle 
 Forearm   Foot 
 Other (Specify: _____________________________) 
14. Management of pain during the last 3 months 
14a. Did you alter or stop your training schedule due to pain in any part 
of your body? Yes  No  
        If yes: For how long _____________ days 
              Did you adapt your training schedule for a while when 
       your injury/illness was healed? Yes  No  
14b. How do you feel when you 
experience pain? (you can tick more 
than one option) 






14c.When you experience pain, do 
you? (you can tick more than one 
option) 
 Adjust your training schedule 
 Stop training 
 Slowly get “back on track” of your training schedule 
 Train harder to make up for the missed training sessions 
 Ignore the pain and continue to train 
 Feel scared to do anything that could aggravate the pain  
 Think that the pain means that you have a severe injury 
 Tell everybody about it 
15. Female athletes only: 
Please complete the following questions (14a. to 14g.) related to your menstrual cycle and other 
gynaecological history 
15a. At what age did you start your periods (menstruating)?       (years) 
15b. In the last 12 months, how many menstrual cycles did you have?       
15c. Have you ever had irregular menstrual periods in the past? (excluding 












15d. Have you had a hysterectomy/ovarectomy? Yes  No  
15e. How many times have you been pregnant?        (times) 
15f. What form of contraception are you 
currently using? 
 None 
 Oral contraceptive pill 
 Injection 
 Intra-uterine device 
 Sterilization (tubes tied) 
 Other: _____________________________ 
15g. If yes to question 15f. above, for oral 
contraceptive pill, for what reason was the pill 
prescribed? 
 Not applicable 
 Dermatological 
 Contraception 
 Regulate period 
 Other: _____________________________ 
 
THANK YOU FOR COMPLETING THIS QUESTIONNAIRE 
 
If you have answered YES to any of the first 11 questions of the Personal General 
Medical History questionnaire (section F) please complete the relevant additional 
questions that follow in section G. 
 
Please bring the completed forms together with the signed consent form to the pre-













Section G. Additional detailed medical history  
(Please complete all the sections to which you answered “Yes” in the Personal general medical 
history) 
 
1. Flu symptoms in the last 6 weeks  
If you answered YES to question 1 in section F, please complete the following two questions related to 
flu symptoms in the last 6 weeks. 
(1a) Please tick which of these flu 
symptoms you suffered from in the 
last 6 weeks. 
 Fever   Cough  Joint pains 
 Blocked nose   Wheezing  Sore Throat 
 Runny nose   Muscle aches 
 Any other flu symptoms   
      (Specify: _____________________________) 
(1b) Please tick which of these flu 
symptoms you suffered from in the 
last 7 days. 
 Fever   Cough  Joint pains 
 Blocked nose   Wheezing  Sore Throat 
 Runny nose   Muscle aches 
 Any other flu symptoms   
      (Specify: _____________________________) 
 
2. Muscle cramping  
If you answered YES to question 2 in section F, please complete the following questions (2a. to 2m.) 
related to your cramping. 
(2a) For how many years have you suffered from cramping?        (years) 
(2b) Did you suffer from cramping during or after exercise in the last 12 months? Yes  No  
(2c) With what type of exercise is your cramping 
associated (You can tick more than one form of exercise)?  Swimming    Cycling     Running 
(2d) In the last 10 races or 
training sessions, how many 
times have you experienced 
cramping? 
Races:    _____/10 
Training sessions:  _____/10 
(2e) What treatment/s have you had that 
successfully relieved an acute cramp? 
(can tick more than one) 
 Stretching        Resting  
 Drinking fluid  Ice application 
 Massage          Magnesium 
 Salt (tablets or solution) 
 Other  (Specify: _____________________________) 
(2f) At what point in the race or training 
run do you usually first experience 
cramping? 
 First quarter   Second quarter  
 Third quarter  Fourth quarter 
 After the race   No pattern 
(2g) In which muscles do you usually 
cramp (please list the  muscle by the one 
which cramps most frequently (as 1) and 
the others after that (2-4)? 
 Calves   Hamstrings  
 Quadriceps (thigh)  Foot muscles 
 Other  (Specify: _____________________________) 












(2i) Have you ever been admitted to hospital following cramping? Yes  No  
(2j) Have you ever been confused or in a coma during or after a cramping 
episode? Yes  No  
(2k) Have you ever had “dark urine” in the 3 days following a cramping episode? Yes  No  
(2l) If you cramp, how long does the cramp usually last for (min)?      (minutes) 
(2m) If you cramp, how 
severe is the cramp usually? 
(please tick). 
 Mild: < 5 minutes and you are able to continue exercising 
 Moderate: 5-15 minutes and you are able to continue exercising 
 Severe: >15 minutes or if  you have to STOP exercising 
 
3. Past Tendon and Ligament Injury History 
If you answered YES to question 3 in section F, please complete the following questions (3a. to 3d.) 
related to your past history of tendon/ligament injury/ies.  
(3a) Please tick which 
tendon/s you have 
injured? (next column 
on the tright) 
 
Also indicate (tick) if 
your injured tendon 
was longsatnding pain 
(tendinopathy) or an 







Foot and ankle: 
 
 Achilles tendon 
 Tibialis posterior 







Knee:  Patellar tendon   
Elbow and wrist:  Wrist extensor tendon   
Shoulder:  Rotator cuff                     
Other: _____________________________   
(3b) Please tick which 
ligament/s you have 
injured? (next column 
on the tright) 
 
Also indicate if your 
sprained or completely 
tore the ligamant.  
Ligament Sprain Complete Tear 
 Shoulder ligaments 
 Elbow ligaments 
 Wrist ligaments   
 Finger ligaments 
 Knee (ACL)  
 Knee (MCL) 
 Knee (PCL) 
 Knee (LCL) 
 Ankle lateral ligaments 
 Ankle medial ligaments   
 Spinal  ligaments  

























(3c) Please tick if you have you ever 
suffered from any of the following joint 
capsule injuries? 
 Acute shoulder dislocation 
 Chronic shoulder instability 
 Other: _____________________________ 
(3d) Do you suffer from any other connective 
tissue or rheumatological diseases or 
disorders? (If yes, please specify which one) 
Yes    No   (refer to the list on the next page) 



















Discoid Lupus Erythematosus 
Ehlers-Danlos syndrome (EDS) 
Eosinophilic Fascitis 
Giant Cell (Temporal) Arthritis 
Gout 
Hypersentive Vasulatis 
Lipid Storage Diseases 
Marfan Syndrome 
Menkes Kinky Hair Syndrome 
Mucopolysaccharidoses 
Myopathies and Dystrophies  
Ochronosis (Homocystinuria) 
Osteogenesis imperfecta (OI) 
Polyarteritis Nodosa 
Polymyalgia Rheumatica 











4. Use of medicines to treat an injury before or during participation 
If you answered YES to question 4 in section F, please complete the following two questions related to 
medicine use for injuries before or during races. 
(4a) Which of the following 
medicines have you used in 
the past to treat an injury in 
the week just before a 
race? 
 Paracetamol (e.g. Panado, Tylenol)  
 Non-steroidal anti-inflammatories (e.g. Voltaren, Cataflam) 
 Cortisone (pills) 
 Cortisone injection 
 Codeine 
 Anti-inflammatory gels/creams/patches 
 Any other pain killers  (Specify: _____________________________) 
(4b) Which of the following 
medicines have you used in 
the past to treat an injury 
during a race? 
 Paracetamol (e.g. Panado, Tylenol)  
 Non-steroidal anti-inflammatories (e.g. Voltaren, Cataflam) 
 Cortisone (pills) 
 Cortisone injection 
 Codeine 
 Anti-inflammatory gels/creams/patches 














5. Gastrointestinal symptoms during exercise 
If you answered YES to question 5 in section F, please indicate which gastrointestinal symptoms you have ever suffered from during 
exercise and, how frequently (in the last 12 months and in the last 10 races), and in which type of exercise. 
Symptom 
Number of times 
you experienced 
the GIT symptom 
in the last 12 
months (during 
exercise) 
Number of times 
you experienced 
the GIT 
symptom in the 
last 10 races 
(during races) 
Please indicate 






Please indicate the “severity” of the GIT symptom 
during exercise 




 Does not affect training or racing 
 Affects training/racing (slow down or reduce time) 
 Prevents training/racing 




 Does not affect training or racing 
 Affects training/racing (slow down or reduce time) 
 Prevents training/racing 




 Does not affect training or racing 
 Affects training/racing (slow down or reduce time) 
 Prevents training/racing 
Abdominal 




 Does not affect training or racing 
 Affects training/racing (slow down or reduce time) 
 Prevents training/racing 
Urge to pass 
a stool 
(defecate) 




 Does not affect training or racing 
 Affects training/racing (slow down or reduce time) 
 Prevents training/racing 




 Does not affect training or racing 
 Affects training/racing (slow down or reduce time) 
 Prevents training/racing 
Passing 
blood in the 
stool 




 Does not affect training or racing 
 Affects training/racing (slow down or reduce time) 
 Prevents training/racing 
Please indicate if you previously suffered from or had any of the following 
(you may tick more than one)? 
 History of heartburn  
 Gastroscopy 
 Ulcer (gastric, duodenal) 
 Irritable bowel syndrome 
 Allergy to milk products 
 Other past history of GIT disease 
 
6. Diseases of the nervous system 
If you answered YES to question 6 in section F, please indicate which nervous disease symptoms you have ever suffered from 
during exercise and, how frequently (in the last 12 months and in the last 10 races), and in which type of exercise. 
Symptom 
Number of times in 
the last 12 months 
(during exercise) 
Number of times 
in last 10 races 
(during races) 
Tick type of exercise 
Headaches              Swimming,  Cycling,  Running 
Nerve tingling in 
the hands              Swimming,  Cycling,  Running 
Loss of sensation 














7. Genital tract injury during cycling 
If you answered YES to question 7 in section F, please indicate which symptoms of genital tract injury 
have you suffered from during or after cycling, how frequently (in the last 10 sessions), how long 








when the symptoms 
occur 
Please indicate if any of the following reduce or 
prevent the symptoms (can tick more than one) 
Genital 
numbness       
 Only during 
cycling 
 During and up to 
1 hour after cycling 
 During and 1-24 
hours after cycling 
 During and > 24 
hours after cycling  
 Changing the saddle type 
 Changing the saddle position 
 Using padded cycling shorts 
 Wearing no underwear 
 Wearing additional underwear  
 Other (Specify:  ________________________) 
Genital 
pain        
 Only during 
cycling 
 During and up to 
1 hour after cycling 
 During and 1-24 
hours after cycling 
 During and > 24 
hours after cycling  
 Changing the saddle type 
 Changing the saddle position 
 Using padded cycling shorts 
 Wearing no underwear 
 Wearing additional underwear  
 Other (Specify:  ________________________) 
Genital 
bruising       
 Only during 
cycling 
 During and up to 
1 hour after cycling 
 During and 1-24 
hours after cycling 
 During and > 24 
hours after cycling  
 Changing the saddle type 
 Changing the saddle position 
 Using padded cycling shorts 
 Wearing no underwear 
 Wearing additional underwear  







      
 Up to 1 hour after 
cycling 
 1-24 hours after 
cycling 
 > 24 hours after 
cycling  
 Changing the saddle type 
 Changing the saddle position 
 Using padded cycling shorts 
 Wearing no underwear 
 Wearing additional underwear  














8. Allergy history 
If you answered YES to question 8 in section F, please complete the following questions (8a. to 8e.) 
related to your current and past history of allergies. 
(8a) Please indicate how long (years) have you been suffering from allergies?         years 
(8b) Please tick which type of allergy do you currently suffer from 
Nose (hay fever) Yes  No  Sinusitis Yes  No  Asthma (allergic) Yes  No  
Skin allergies Yes  No  Eye allergies Yes  No  Allergy to plant material Yes  No  
Allergy to foods Yes  No  Allergy to animals Yes  No  
Allergy to 
medication Yes  No  
(8c) Please tick which type of allergy do you currently take medication for 
Nose (hay fever) Yes  No  Sinusitis Yes  No  Asthma (allergic) Yes  No  
Skin allergies Yes  No  Eye allergies Yes  No  Allergy to plant material Yes  No  
Allergy to foods Yes  No  Allergy to animals Yes  No  
Allergy to 
medication Yes  No  
(8d) Please tick which type of medication do you currently take 
Cortisone nose 
spray Yes  No  
Cortisone nose 




Yes  No  
Cortisone cream Yes  No  Anti-histamine cream Yes  No  
Other inhaler 
/ tablets or 
cream 
Yes  No  
(8e) Please tick which symptoms of allergy do you currently suffer from  
Sneezing Yes  No  Itchy runny nose Yes  No  Headache Yes  No  
Itchy palate Yes  No  Streaming eyes Yes  No  Fatigue Yes  No  
Itchy eyes Yes  No  Blocked nose Yes  No  Poor sleep Yes  No  
Post nasal drip Yes  No  Coughing Yes  No  Wheezing Yes  No  
In which months of the year do 
you currently have symptoms of 
allergies? (You tick more than 
one) 
 Jan   Feb     March    April  May    June    
 July    Aug    Sept      Oct  Nov     Dec 
(8f) Please tick which type of allergy did you suffer from in the past (NOT currently) 
Nose (hay fever) Yes  No  Sinusitis Yes  No  Asthma (allergic) Yes  No  
Skin allergies Yes  No  Eye allergies Yes  No  Allergy to plant material Yes  No  
Allergy to foods Yes  No  Allergy to animals Yes  No  
Allergy to 














9. Asthma history 
If you answered YES to question 9 in section F, please complete the following questions (9a. to 9k.) 
related to your current history of asthma 
(9a) Do you currently suffer from asthma? Yes  No  
(9b) How many years have you suffered from asthma?        (years) 
(9c) How was your asthma 
diagnosed?  
 A doctor taking a history and performing an examination 
 Lung function test (blow test) but no exercise 
 Lung function test (blow test) before and after exercise 
 Metacholine challenge test 
 Eucapnic hyperventilation test (rebreathing test) 
 Other test  (Specify:  ________________________) 
(9d) Which type of asthma 
do you currently suffer 
from? 
 Asthma that occurs at any time but not during exercise 
 Asthma that occurs at any time including during exercise 
 Asthma that only occurs during exercise 
(9e) Please indicate how 
frequently do you 
currently experience the 
symptoms of asthma 
(shortness of breath, 
wheezing, coughing or 
coughing after exercise)? 
Daytime symptoms (per week) 
 < 2 / week       2-4 / week        >4 / week          All the time 
Night time symptoms (per month) 
 < 1 / month       2-3 / month        >4 / month        All the time 
Exercise related symptoms (per 10 exercise sessions) 
 <1 per 10 sessions    2-3 per 10 sessions    >4 per 10 sessions 
(9f) Please indicate if you 
had symptoms of asthma 
that were severe enough to 
necessitate hospital 
admission in the last 12 
months 
 No hospital admission for asthma in the last 12 months  
 1-2 hospital admissions for asthma in the last 12 months  
 3-4 hospital admissions for asthma in the last 12 months  
 >4 hospital admissions for asthma in the last 12 months  
(9g) Which symptoms of 
asthma do you currently 
suffer from? 
 Wheezing   Dry cough   Shortness of breath 
 Tight chest   Chest pain  












(9h) What medication do 
you currently use for your 
asthma? (you may tick more 
than one option) 
 Cortisone inhaler (e.g. Beclate, Becloforte, Becodisks, Becotide, 
Budeflam, Flixotide, Inflammide, Pulmicort, Qvar, etc)   
 Salbutamol (bronchodilator) inhaler (e.g. Ventolin, Venteze, Vomax, 
Airomir, Asthavent etc.) 
 Salmeterol (bronchodilator) inhaler (Serevent) 
 Fenoterol (bronchodilator) inhaler (Berotec) 
 Terbutaline (bronchodilator) inhaler (Bricanyl) 
 Formoterol (bronchodilator) inhaler (e.g. Foradil, Foratec, Oxis) 
 Ipratropium (bronchodilator) inhaler (Atrovent) 
 Tiotropium (bronchodilator) inhaler (Spiriva) 
 Combined cortisone and bronchodilator  inhaler (e.g. Atrovent, 
Berodual, Combivent, Duolin, Duovent, Seretide, Symbicord)  
 Cortisone tablets 
 Bronchodilator tablets 
 Leukotriene receptor antagonist tablets (e.g. Acccolate, Singulair) 
 Other inhaler  
 Other medication (Specify: ________________________) 
(9i) When do you use your 
medication for your 
asthma? 
 Daily (irrespective of exercise)  Only before exercise 
 Other (Specify: ________________________) 
(9j) How long before an 
exercise session do you 
use your medication for 
asthma? 
      min 
(9k) Have you obtained TUE (therapeutic use exemption forms) for your asthma 














10. History of previous collapse 
If you answered YES to question 10 in section F, please complete the following questions (10a. to 10d.) 
related to your current history of asthma 
(10a) Have you ever collapsed during training or racing? 
 Training     
 Racing     
 Training and racing     
(10b) How many times have you collapsed in training session 
or races during the last five years? 
_____  training session 
_____  races 
(10c) How many times have you collapsed in training session 
or races during the last 12 months (1 year)? 
 
(10d) When you collapse, does it mostly occur before of after 
the finish line / completion of the training session? 
 Before the finish 
 After the finish 
(10e) What is the cause of you 
collapse?  
 Dehydration 
 Heat illness 
 Hyponatremia 
 Low blood pressure  
 Low blood sugar 
 Other condition  (Specify:  ________________________) 












11. History of any current injury that you suffer from  
If you answered YES to question 11 in section F, please complete the following questions (11a. to 11g.) 
related to each of your current injury/ies (Space is provided for two injuries) 
 
Injury 1 
(11a) What was the approximate date when you first became aware of 
the injury?         Month             Year 
(11b) Please indicate which side of your body is injured (if applicable)  Right  Left 
(11c) Please indicate which anatomical area 
is currently injured 
 Head   Elbow  Hamstring  
 Neck   Forearm  Quadriceps 
 Face   Wrist  Knee 
 Front chest   Finger  Shin 
 Back chest    Lower back  Achilles 
 Shoulder   Hip   Ankle 
 Upper arm   Thigh  Foot 
Other (Specify:  ________________________) 
(11d) Please indicate the type of structure 
that was injured 
 Muscle   Ligament 
 Tendon   Joint 
 Bone 
Other (Specify:  ________________________) 
(11e) Please indicate in which sport 
(discipline) the injury occurred 
 Running   Cycling 
 Swimming 
Other (Specify:  ________________________) 
(11f) Please indicate 
the severity of the 
injury (tick one box 
please) 
 I only experience symptoms after exercise - Grade 1  
 I experience symptoms during exercise, but it does not interfere with exercise 
      - Grade 2    
 I experience symptoms during exercise that may interfere with my training/ 
      competition - Grade 3 
 I am so painful that I may not be able to train or compete - Grade 4 
(11g) Please indicate how your injury was 
treated to date (you can tick more than 
one)? 
 Rest   Tablets  
 Stretches    Cortisone injection 
 Physiotherapy  Other injection 
 Surgery   Orthotics 
 Strengthening exercises 
 Equipment change 














(11a) What was the approximate date when you first became aware of 
the injury?         Month             Year 
(11b) Please indicate which side of your body is injured (if applicable)  Right  Left 
(11c) Please indicate which anatomical area 
is currently injured 
 Head   Elbow  Hamstring  
 Neck   Forearm  Quadriceps 
 Face   Wrist  Knee 
 Front chest   Finger  Shin 
 Back chest    Lower back  Achilles 
 Shoulder   Hip   Ankle 
 Upper arm   Thigh  Foot 
Other (Specify:  ________________________) 
(11d) Please indicate the type of structure 
that was injured 
 Muscle   Ligament 
 Tendon   Joint 
 Bone 
Other (Specify:  ________________________) 
(11e) Please indicate in which sport 
(discipline) the injury occurred 
 Running   Cycling 
 Swimming 
Other (Specify:  ________________________) 
(11f) Please indicate 
the severity of the 
injury (tick one box 
please) 
 I only experience symptoms after exercise - Grade 1  
 I experience symptoms during exercise, but it does not interfere with exercise 
      - Grade 2    
 I experience symptoms during exercise that may interfere with my training/ 
      competition - Grade 3 
 I am so painful that I may not be able to train or compete - Grade 4 
(11g) Please indicate how your injury was 
treated to date (you can tick more than 
one)? 
 Rest   Tablets  
 Stretches    Cortisone injection 
 Physiotherapy  Other injection 
 Surgery   Orthotics 
 Strengthening exercises 
 Equipment change 
























Department of Human Biology 
UCT/MRC RESEARCH UNIT FOR EXERCISE SCIENCE & SPORTS MEDICINE 
Faculty of Health Sciences, University of Cape Town 
Private Bag, Rondebosch 7700, South Africa 
Tel: + 27 21 650 4561 
Fax: + 27 21 686 7530 
 
2009 TWO OCEANS ULTRA-MARATHON – MEDICAL AND 
TRAINING QUESTIONNAIRES 
 
These questionnaires have been constructed by the Medical Research team, in 
conjunction with the Medical Director of the 2008 Two Oceans Ultra-Marathon.  The 
information obtained from these questionnaires is essential for the planning of 
medical care during events such as the Two Oceans. We acknowledge that the 
questionnaires are long, but we are asking about 30 minutes of your valuable time 
to complete them. The completion of the questionnaires is voluntary; all the 
information will be kept confidential and will only be used for research and medical 
care planning purposes. We suggest that you consider downloading and completing 
this before the event and handing in the completed questionnaire, at the research 
area during race registration.  
 
Prof Martin Schwellnus (Chairman, Research Team) 
Dr Karen Schwabe (Medical Officer, Two Oceans 2009) 
 
Instructions 
Please answer each question by filling in the details in the allocated space or checking one or more of the 
option boxes. 
Please bring the completed forms together with the signed consent form to the research table at race 
registration. 
 
Please complete sections A, B, C, D, E and F 
Section A Personal Details Page 2 
Section B Racing, Training and Equipment Use History Pages 3-4 
Section C History of Medication, Supplement and Fluid Use as well as Lifestyle and Habits History Pages 5-6 
Section D Psychological and Behavioural Pages 7-11 
Section E Family Medical History Page 12 













Please complete only the relevant questions in the following section 
Section G Additional Detailed Medical History Pages 16-28 
 
Section A: Personal details 
2008 Two Oceans Race Number       
Surname       
First Name       
Postal Address 
 




Postal/ Zip Code       
E-mail address       Phone (day time) code number 
Alternate E-mail address  
Date of birth y y y y - m m - d d  Cell (Mobile)       
Height       cm Gender Male  Female  
Weight       kg Age (on race day)        yrs 
Ethnic group 
(Only Required and 
Used for Research 
Purposes) 
Black/African    White  Indian  
Mixed Ancestry (Coloured)  Asian  Other  
Ancestry: Tribal or 
national background 
 
Father:       
Unknown   
Mother:       Unknown   
Country of Birth       
Dominant Hand Left     Right    Both  Dominant Leg Left    Right   Both  
Occupation       
What percentage of 
your working day is 
spent in the following 
activities? 
Sitting:      _____ % 
Standing:     _____ % 
Walking (Lower body activity)   _____ % 














Section B. Racing and training history 
Type of running event 
10 km 21.1 km 42.2 km 
Which road running races have you ever 
participated in? 
Yes  No  Yes  No  Yes  No  
Year of first event                   
How many of these events have you ever 
participated in? 
                  
Personal best time ever _____ min _____ min _____ min 
What is your best time, in a running race, in the last 
15 weeks? 
_____ min _____ min _____ min 






Which races have you ever participated in? Yes  No  Yes  No   
Year of first event              
How many events have you ever participated in?              
Personal best time _____ hrs:min _____ hrs:min  
What is your predicted time for the 2008 Two Oceans ultra-
marathon? ______________ hrs ___________  min 
What is your predicted time for the through the marath n mark 
during the 2008 Two Oceans ultra-marathon? ______________ hrs ___________  min 
 
Please answer the following questions, with your answers reflecting your average in the most recent 15 weeks 
i.e. beginning January 2009 to 11
th
 April, 2009. 
Do you train with a heart rate monitor? Yes  No  
Do you race with a heart rate monitor? Yes  No  
Do you use heart rate information to control your training pace? Yes  No  
Do you use heart rate information to control your racing pace? Yes  No  
Do you record, download and store your heart rate information? Yes  No  
Would you be willing to make your heart rate data available to the research team? Yes  No  
How many days a week did you train during the last 15 weeks?  days/wk 












How many hours a week did you train in an average week during the last 15 weeks?  hrs/wk 
How many hours a week did you work in an average week during the last 15 weeks?  hrs/wk 
What distances did you train in the week before the race?     Km 
How many hours did you train in the week before the race?     Hours 
How many fast/ hard sessions did you do per week in the last 8 weeks?  
Describe briefly the session, including distance, time and recovery interval (if applicable) e.g. 
10 x 400m in 75 sec with 60 sec jog recovery between each 
 
What percentage of your weekly training distance was done at race 42.2 km speed or faster?  % 
How many hours did you train 3 days before the race  Hours 
How many hours did you train 2 days before the race  Hours 
How many hours did you train the day before the race  Hours 
How did your training commitment affect your social life? 
 Not at all  
 A fair amount  
 A lot  
 
 
Flexibility training history 
Do you perform flexibility training (regular stretching exercises)? Yes    No  
If YES, please complete the rest of the flexibility training history section below:- 
If NO, continue completing the questionnaire from the top of page 5 (Equipment use history).  
On average, how many days a week do you perform a stretching session?        days/week 
On average, how times a day do you perform a stretching session?        times/day 
Please tick which muscle groups do you include in 
your stretching session? 
 Hamstrings 
 Quadriceps 
 Calf (gastrocnemius) 
 Calf (soleus)  
 Groin (inner thigh) 
 Upper body limbs 












Please tick when you stretch? (before, during and/or after exercising.  You 
can tick more than one box) 
 Before Exercise 
 During Exercise 
 After Exercise 
When you stretch an individual muscle group, on average, how long do 
you hold the stretch for? 
       seconds 
When you stretch an individual muscle group, on average, how many 
times do you stretch the muscle for? 
 Once  
 Twice 
 3 times  
 4 times 
 5 times 
 6 or more times  
 
Equipment use history 
Please indicate which brand of 
running shoe you use? 
 Adidas                       Asics                         Brooks                     
 New Balance             Nike                          Mizuno                      
Puma                         Reebok                     Saucony                    
 Other: _______________________ 
Please indicate which type of 
running shoe you use? 
 Soft neutral shoe 
 Mild anti-pronation shoe 
 Motion control shoe 
 Light racing shoe 
 Unknown or not sure 













Section C. History of medication and supplement use 
What medication, if any, are you 
currently using? (please list) 
Name of medication Years taken 
            
            
            
            
Do you use protective skin 
sunscreen during training session or 
when competing? 
Yes  No   Every session  Most sessions 
 Some sessions  Very occasionally 
Are you currently taking dietary supplements/vitamins? Yes  No  
If yes to the above question, please 
list names of dietary, sports or 
vitamin supplements. 
Name of supplement Years taken 
 Multi-vitamins    _____ 
 Anti-oxidants     _____ 
 Immune boosters     _____ 
 Protein powders/supplements, Protein bars. BCAAs  _____ 
 Creatine       _____ 
 Caffeine      _____ 
 Fat cutters      _____ 
 Carbohydrate drinks/powders/gels   _____ 
 Other: _____________________________  _____ 
Have you ever used oral 
corticosteroids (cortisone 
tablets)? (If yes, how long ago?) 
Yes  No   3 months  6 months 
 12 months  24 or more months 
Have you ever been given an 
injection with corticosteroids? (If 
yes, how long ago?) 
Yes  No   3 months  6 months 
 12 months  24 or more months 
Have you ever been given an 
injection of corticosteroids in or 
around the Achilles tendon? (If 
yes, how many times?) 
Yes  No  
 Once  Twice 
 3 times  >3 times 
Have you ever used fluoroquinoline 
antibiotics? (refer to the following 
list) 
Yes  No   3 months  6 months 
 12 months  24 or more months 
 

















































Lifestyle and habits history 
Please indicate your smoking status Current smoker   Ex smoker   Never smoked   
If you answered yes, 
(past or current 
smoker) please 
complete the section 
on the right 
Number of years of smoking:       If stopped, how many years ago:       
What is (was) the average number of cigarettes per day:       
On average, how much alcohol do you drink per week (tots, 
glasses) of spirits, wine or beer? 
_______  glasses beer/cider per week 
_______  glasses wine per week 
_______  tots of spirits per week 
 
Fluid Intake 
How do you best 
describe your fluid intake 
during an Ironman 
triathlon race? 
(a) I drink to thirst       
(b) I drink as much as tolerable      
(c) I drink according to a predetermined fluid intake schedule  
(d) I drink to prevent any weight loss during exercise   
(e) I combine (a) with (c)       
(f) I combine (b) with (c)       
(g) Other: _____________________________    
What percentage of your 
fluid intake will consist of 
these beverages? 
Water:   0-25%   26-50%   51-75%   76-100% 
Sports drink:  0-25%   26-50%   51-75%   76-100% 
Coke:   0-25%   26-51%   51-75%   76-100% 
Other:   0-25%   26-50%   51-75%   76-100% 
Specify other: _____________________________ 
What will be your estimated total fluid intake be (if at all) during the swim?       ml 
What will be your estimated total fluid intake be during the cycle?       ml 












Rank the following 
sources of information 
on their importance in 
formulating your drinking 
strategy. (1 being most 
influential and the lowest 
number being least 
influential) 
_____ Fellow triathletes  
_____ Coach / trainer 
_____ Magazines / books 
_____ Website (please specify: _____________________________) 
_____ Drinking guidelines from sports associations 
_____ Adverts 
_____ Self-experimentation 














Section D.  Psychological and Behavioural 
Connor-Davidson Resilience Scale (CD-RISC) 
Please indicate how much you agree with the following statements as they apply to you over the last month. If a 















26. I am able to adapt when changes occur.      
27. I have at least one close and secure relationship 
which helps me when I am stressed. 
     
28. When there are no clear solutions to my problems, 
sometimes fate or God can help. 
     
29. I can deal with whatever comes my way.      
30. Past successes give me confidence in dealing with 
new challenges and difficulties. 
     
31. I try to see the humorous side of things when I am 
faced with problems. 
     
32. Having to cope with stress can make me stronger.      
33. I tend to bounce back after illness, injury, or other 
hardships. 
     
34. Good or bad, I believe that most things happen for 
a reason. 
     
35. I give my best effort, no matter what the outcome 
may be. 
     
36. I believe I can achieve my goals, even if there are 
obstacles. 
     
37. Even when things look hopeless, I don't give up.      
38. During times of stress/crisis, I know where to turn 
for help. 
     
39. Under pressure, I stay focused and think clearly.      
40. I prefer to take the lead in solving problems, rather 
than letting others make all the decisions. 
     
41. I am not easily discouraged by failure.      
42. I think of myself as a strong person when dealing 
with life's challenges and difficulties. 
     
43. I can make unpopular or difficult decisions that 
affect other people, if it is necessary. 
     
44. I am able to handle unpleasant or painful feelings 
like sadness, fear and anger. 
     
45. In dealing with life's problems, sometimes you have 
to act on a hunch, without knowing why. 
     
46. I have a strong sense of purpose in life.      












48. I like challenges.      
49. I work to attain my goals, no matter what 
roadblocks I encounter along the way. 
     
50. I take pride in my achievements.      
TPQ / TCI (96 shared items) 
97. I usually am confident that everything will go ell, even in situations that worry most 
people. 
True  False  
98. I often try new things just for fun or thrills, even if most people think it is a waste of 
time. 
True  False  
99. I like to discuss my experiences and feelings openly with friends instead of 
keeping them to myself. 
True  False  
100. When nothing new is happening, I usually start looking for something that is 
thrilling or exciting. 
True  False  
101. Usually I am more worried about that most people that something might go wrong 
in the future. 
True  False  
102. I don‟t mind discussing my personal problems with people whom I have known 
briefly or slightly. 
True  False  
103. I would like to have warm and close friends with me most of the time. True  False  
104. I nearly always stay relaxed and carefree even when nearly everyone else is 
fearful. 
True  False  
105. I usually demand very good practical reasons before I am willing to change my old 
ways of doing things. 
True  False  
106. I often have to stop what I am doing because I start worrying that something might 
go wrong. 
True  False  
107. I hate to change the way I do things, even if many people tell me there is a new 
and better way to do it, 
True  False  
108. My friends find it hard to know my feelings because I seldom tell them about my 
private thoughts. 
True  False  
109. I like it when people can do exactly what they want without strict rules and 
regulations. 
True  False  
110. I often stop what I am doing because I get worried, even when my friends tell me 
everything will go well. 
True  False  
111. It wouldn‟t bother me to be alone all the time. True  False  
112. I like to be very organized and set up rules for people whenever I can. True  False  
113. I usually do things my own way, rather than giving in to the wishes of other 
people. 
True  False  
114. I usually feel tense and worried when I have to do something new and unfamiliar. True  False  
115. I often feel tense and worried in familiar situations, even when others feel there is 
little to worry about. 
True  False  
116. Other people often think that I am too independent because I won‟t so what they 
want. 
True  False  
117. Even when most people feel it is not important, I often insist on things being done 
in a strict and orderly way, 
True  False  
118. I often do things based on how I feel at the moment, without thinking about how 
they are done in the past. 












119. I often feel tense and worried in unfamiliar situations, even when others feel there 
is no danger at all. 
True  False  
120. I often brake rules and regulations when I think I can get away with it. True  False  
121. I don‟t care very much whether other people like me or the way I do things. True  False  
122. I usually stay calm and secure in situations that most people would find physically 
dangerous. 
True  False  
123. I feel it is more important to be sympathetic and understanding of other people 
than to be practical and tough- minded. 
True  False  
124. I lose my temper more quickly than most people. True  False  
125. I am usually confident that I can easily do things that most people would consider 
dangerous (such as driving as automobile fast on a wet or icy road). 
True  False  
126. I often react so strongly to unexpected news that I say or do things that I regret. True  False  
127. People find it easy to come to me for help, sympathy, and warm understanding. True  False  
128. I am much more reserved and controlled than most people. True  False  
129. When I have to meet a group of strangers, I am more shy than most people. True  False  
130. I am strongly moved by sentimental appeals (like when asked to helped crippled 
people). 
True  False  
131. I almost never get so excited that I lose control of myself. True  False  
132. I have a reputation as someone who is practical and does not act on emotion. True  False  
133. I often avoid meeting strangers because I lack confidence with people I do not 
know. 
True  False  
134. I usually stay away from social situations where I would have to meet strangers, 
even if I am assured that they will be friendly. 
True  False  
135. I usually push myself harder than most people do because I want to do as well as 
I possibly can. 
True  False  
136. I often push myself to the point of exhaustion or try to do more than I really can. True  False  
137. I would probably stay relaxed and outgoing when meeting a group of strangers, 
even if I were told they were unfriendly. 
True  False  
138. It is difficult for me to keep the same interests for a long time because my 
attention often shifts to something else. 
True  False  
139. I think I would stay confident and relaxed when meeting strangers, even if I were 
told they are angry with me. 
True  False  
140. I could probably accomplish more than I do, but I don‟t see the point of pushing 
myself harder than is necessary to get by. 
True  False  
141. I like to think about things for a long time before I make a decision. True  False  
142. Most of the time I would prefer to do something a little risky (like riding in an 
automobile over steep hills and sharp turns), rather than having to stay quiet and 
inactive for a few hours. 
True  False  
143. I often follow my instincts, hunches, or intuition without thinking through all the 
details. 












144. I try to do as little work as possible, even when other people expect more of me. True  False  
145. I often have to change my decisions because I had a wrong hunch or mistaken 
first impression. 
True  False  
146. Most of the time I would prefer to so something risky (like hang-gliding or 
parachute jumping(, rather than having to stay quiet and inactive for a few hours. 
True  False  
147. I am satisfied with my accomplishments and have little desire to do better. True  False  
148. I see no point in continuing to work on something unless there is a good chance of 
success. 
True  False  
149. I have less energy and get tired more quickly than most people. True  False  
150. I usually think about all the facts in detail before I make a decision. True  False  
151. I nearly always think about all the facts in detail before I make a decision, even 
when other people demand a quick decision. 
True  False  
152. I often need naps or extra rest periods because I get tired so easily. True  False  
153. I don‟t go out of my way to please other people. True  False  
154. I am more energetic and tire less quickly than most people. True  False  
155. I am usually able to get other people to believe me, even when I know that what I 
am saying is exaggerated or untrue. 
True  False  
156. I can usually do a good job of stretching the truth to tell a funnier story or to play a 
joke on someone. 
True  False  
157. I usually can stay “on the go” all day without having to push myself. True  False  
158. I am usually more upset than most people by the loss of a close friend. True  False  
159. I have trouble telling a lie, even when it is meant to spare someone else‟s 
feelings. 
True  False  
160. I am better at saving money than most people. True  False  
161. Even after there are problems in a friendship, I nearly always try to keep it going 
anyway. 
True  False  
162. I recover more slowly than most people from minor illnesses or stress. True  False  
163. I need much extra rest, support, or reassurance to recover from minor illnesses or 
stress. 
True  False  
164. I often spend money until I run out of cash or get into debt from using too much 
credit. 
True  False  
165. Because I so often spend too much money on impulse, it is hard for me to save 
money, even for special plans like a vacation. 
True  False  
166. It is extremely difficult for me to adjust to changes in my usual way of doing things 
because I get so tense, tired or worried. 
True  False  
167. If I am feeling upset, I usually feel better around friends than when left alone. True  False  
168. I usually feel much more confident and energetic than most people, even after 
minor illnesses or stress. 












169. Some people think I am too stingy or tight with my money. True  False  
170. I often keep trying the same thing over and over again, even when I have not had 
success in a long time. 
True  False  
171. It is hard for me to enjoy spending money on myself, even when I have saved 
plenty of money. 
True  False  
172. I recover more quickly than most people from minor illnesses or stress. True  False  
173. I hate to make decisions based only on my first impressions. True  False  
174. I think I will have very good luck in the future. True  False  
175. I am most often moved deeply by fine speech or poetry. True  False  
176. If I am embarassed or humiliated, I get over it very quickly. True  False  
177. I like old “tried and true” ways of doing things according to their priority of 
importance to me because of lack of time. 
True  False  
178. I like to keep my problems to myself. True  False  
179. I enjoy saving money more than spending it on entertainment or thrills. True  False  
180. Even when I am with friends, I prefer not to “open up” very much True  False  
181. I feel very confident and sure of myself in almost all social situ tions. True  False  
182. I usually like to stay cool and detached from other people. True  False  
183. I never worry about terrible things that might happen in the future. True  False  
184. I am more hard-working than most people. True  False  
185. In conversations I am much better as a listener than as a talker. True  False  
186. I like to please other people as much as I can. True  False  
187. Regardless of any temporary problem that I have to overcome, I always think it 
will turn out well. 
True  False  
188. I like to stay at home better than to travel and explore new places. True  False  
189. I am usually so determined that I continue to work long after other people have 
given up. 
True  False  
190. I usually have good luck in whatever I try to do. True  False  
191. I like to pay close attention to details in everything I do. True  False  















Instructions: The following questions ask about how you have been feeling during the past four weeks. For each 
question, please circle the number that best describes how often you have had this feeling. Your answers will be 
kept confidential. 














1. About how often did you feel tired of for no 
good reason? 
1 2 3 4 5 
2. About how often did you feel nervous? 1 2 3 4 5 
3.About how often did you feel so nervous that nothing 
could calm you down? 
1 2 3 4 5 
4. About how often did you feel hopeless? 1 2 3 4 5 
5. About how often did you feel restless or fidgety? 1 2 3 4 5 
6. About how often did you feel restless you could not 
sit still? 
1 2 3 4 5 
7. About how often did you feel depressed? 1 2 3 4 5 
8. About how often did you feel that everything is an 
effort? 1 2 3 4 5 
9. About how often did you feel so sad that nothing 
could cheer you up? 1 2 3 4 5 














Section E. Family medical history 
Have any of your blood (biological) relatives ever had the following?  
Please tick yes or no. If yes, please tick the relationship of that person to you (You may tick more than 
one of the relationship blocks).  
Description 
 If Yes, please indicate the relationship  
Exercise associated muscle 
cramps 
Yes  No  
 Father      Mother         Brother   
  Sister    Child 
 Grandfather   Grandmother  
Night muscle cramps Yes  No  
 Father      Mother         Brother   
  Sister    Child 
 Grandfather   Grandmother  
Chronic Achilles tendon injury  Yes  No  
 Father      Mother         Brother   
  Sister    Child 
 Grandfather   Grandmother  
Achilles tendon rupture Yes  No  
 Father      Mother         Brother   
  Sister    Child 
 Grandfather   Grandmother  
Any ligament injury Yes  No  
 Father      Mother         Brother   
  Sister    Child 
 Grandfather   Grandmother  
Asthma Yes  No  
 Father      Mother         Brother   
  Sister    Child 
 Grandfather   Grandmother  
Allergies (in general) Yes  No  
 Father      Mother         Brother   
  Sister    Child 












Heart Disease Yes  No  
 Father      Mother         Brother   
  Sister    Child 
 Grandfather   Grandmother  
Diabetes Yes  No  
 Father      Mother         Brother   
  Sister    Child 
 Grandfather   Grandmother  
Depression, Anxiety attacks, 
Personality disorder 
Yes  No  
 Father      Mother         Brother   
  Sister    Child 
 Grandfather   Grandmother  
Gastro-intestinal (GIT) disease Yes  No  
 Father      Mother         Brother   
  Sister    Child 














Section F. Personal general medical history 
In this section, you are asked to read through 14 questions about your personal general medical history. If 
you answer “yes” to any of questions 1 to 12, please complete the additional questions at the end of the 
section (section G on page 18).  
16. In the 6 weeks before this race (from 1st February) did you suffer from any symptoms of 
flu (fever, sore throat, blocked or runny nose, cough, wheeze, muscle aches and pains)? 
Yes  No  
17. Have you ever in triathlon career suffered from muscle cramping (painful, spontaneous, 
sustained spasm of a muscle) during or immediately (within 6 hours) after exercise (in 
training or competition)?  
Yes  No  
18. Have you ever in your triathlon career suffered from a tendon or ligament injury (pain, 
swelling, stiffness) in any tendon (including Achilles tendon, knee tendons, and shoulder 
tendons) or ligaments (partial or complete tear)? 
Yes  No  
19. Have you ever in your triathlon career used medicines to treat injuries in the week 
before or during a race – including anti-inflammatory drugs, cortisone (pills, or injection), 
or pain killers?  
Yes  No  
20. Have you ever in your triathlon career suffered gastrointestinal symptoms during 
exercise including heartburn, nausea, vomiting, abdominal pain, urge to defecate (pass a 
stool), diarrhoea, or blood in the stools? 
Yes  No  
21. Have you ever in your triathlon career suffered from symptoms of the nervous system 
including exercise induced headaches, nerve tingling or loss of sensation? 
Yes  No  
22. Have you ever in your triathlon career suffered from symptoms of allergies including 
nose allergies (hay fever), allergic sinusitis, allergic asthma, skin allergies, a past history of 
allergies to medication, plant material or animal material? 
Yes  No  
23. Do you currently suffer from asthma including exercise induced asthma, or symptoms of 
asthma such as shortness of breath, wheezing, or chronic coughing? 
Yes  No  
24. Have you ever collapsed (fell down not because of an accident, needing medical 
attention) during, at the finish or after a race or training session? 
Yes  No  
25. Do you currently suffer from any symptoms of injury in the muscles, tendons, bones, 
ligaments or joints? 
Yes  No  
26. Do you currently, or did you in the last 
year, suffer from any symptoms of 
exercise related skin disease? 
Sunburn:   Yes    No  
Skin cancer:   Yes    No  












27. Please tick in which anatomical area you 
ever had surgery performed. 
 Gastric (stomach)  Oesophageal (swallowing pipe) 
 Small bowel    Large bowel (colon) 
 Rectum                Gallbladder 
 Pancreas                Liver 
 Abdomen (general)   Wrist 
 Head    Finger 
 Neck   Lower back 
 Face   Hip  
 Front chest   Thigh 
 Back chest    Knee 
 Shoulder   Lower leg 
 Upper arm   Achilles 
 Elbow   Ankle 
 Forearm   Foot 
 Other (Specify: _____________________________) 
28. Management of pain during the last 3 months 
14a. Did you alter or stop your training schedule due to pain in any part of 
your body? Yes  No  
        If yes: For how long _____________ days 
              Did you adapt your training schedule for a while when 
       your injury/illness was healed? 












14b. How do you feel when you 
experience pain? (you can tick 
more than one option) 






14c.When you experience pain, do 
you? (you can tick more than one 
option) 
 Adjust your training schedule 
 Stop training 
 Slowly get “back on track” of your training schedule 
 Train harder to make up for the missed training sessions 
 Ignore the pain and continue to train 
 Feel scared to do anything that could aggravate the pain  
 Think that the pain means that you have a severe injury 
 Tell everybody about it 
29. Female athletes only: 
Please complete the following questions (14a. to 14g.) related to your menstrual cycle and other gynaecological 
history 
15a. At what age did you start your periods (menstruating)?       (years) 
15b. In the last 12 months, how many menstrual cycles did you have?       
15c. Have you ever had irregular menstrual periods in the past? (excluding 
pregnancy)? Yes  No  
15d. Have you had a hysterectomy/ovarectomy? Yes  No  












15f. What form of contraception are you 
currently using? 
 None 
 Oral contraceptive pill 
 Injection 
 Intra-uterine device 
 Sterilization (tubes tied) 
 Other: _____________________________ 
15g. If yes to question 15f. above, for oral 
contraceptive pill, for what reason was the 
pill prescribed? 
 Not applicable 
 Dermatological 
 Contraception 
 Regulate period 
 Other: _____________________________ 
 
THANK YOU FOR COMPLETING THIS QUESTIONNAIRE 
 
If you have answered YES to any of the first 11 questions of the Personal General 
Medical History questionnaire (section F) please complete the relevant additional 
questions that follow in section G. 
 
Please bring the completed forms together with the signed consent form to the pre-race 













Section G. Additional detailed medical history  
(Please complete all the sections to which you answered “Yes” in the Personal general medical history) 
 
1. Flu symptoms in the last 6 weeks  
If you answered YES to question 1 in section F, please complete the following two questions related to flu 
symptoms in the last 6 weeks. 
(1a) Please tick which of these flu 
symptoms you suffered from in the last 6 
weeks. 
 Fever   Cough  Joint pains 
 Blocked nose   Wheezing  Sore Throat 
 Runny nose   Muscle aches 
 Any other flu symptoms   
      (Specify: _____________________________) 
(1b) Please tick which of these flu 
symptoms you suffered from in the last 7 
days. 
 Fever   Cough  Joint pains 
 Blocked nose   Wheezing  Sore Throat 
 Runny nose   Muscle aches 
 Any other flu symptoms   
      (Specify: _____________________________) 
 
2. Muscle cramping  
If you answered YES to question 2 in section F, please complete the following questions (2a. to 2m.) related to your 
cramping. 
(2a) For how many years have you suffered from cramping?        (years) 
(2b) Did you suffer from cramping during or after exercise in the last 12 months? Yes  No  
(2c) With what type of exercise is your cramping associated 
(You can tick more than one form of exercise)? 
 Swimming    Cycling     Running 
(2d) In the last 10 races or 
training sessions, how many 
times have you experienced 
cramping? 
Races:    _____/10 












(2e) What treatment/s have you had that 
successfully relieved an acute cramp? (can 
tick more than one) 
 Stretching        Resting  
 Drinking fluid  Ice application 
 Massage          Magnesium 
 Salt (tablets or solution) 
 Other  (Specify: _____________________________) 
(2f) At what point in the race or training run 
do you usually first experience cramping? 
 First quarter   Second quarter  
 Third quarter  Fourth quarter 
 After the race   No pattern 
(2g) In which muscles do you usually cramp 
(please list the  muscle by the one which 
cramps most frequently (as 1) and the others 
after that (2-4)? 
 Calves   Hamstrings  
 Quadriceps (thigh)  Foot muscles 
 Other  (Specify: _____________________________) 
(2h) Have you ever suffered from cramping in your whole body (arms and legs)? Yes  No  
(2i) Have you ever been admitted to hospital following cramping? Yes  No  
(2j) Have you ever been confused or in a coma during or after a cramping episode? Yes  No  
(2k) Have you ever had “dark urine” in the 3 days following a cramping episode? Yes  No  
(2l) If you cramp, how long does the cramp usually last for (min)?      (minutes) 
(2m) If you cramp, how severe is 
the cramp usually? (please tick). 
 Mild: < 5 minutes and you are able to continue exercising 
 Moderate: 5-15 minutes and you are able to continue exercising 
 Severe: >15 minutes or if  you have to STOP exercising 
 
3. Past Tendon and Ligament Injury History 
If you answered YES to question 3 in section F, please complete the following questions (3a. to 3d.) related to your 
past history of tendon/ligament injury/ies.  
(3a) Please tick which 
tendon/s you have 




















Also indicate (tick) if your 
injured tendon was 
longsatnding pain 
(tendinopathy) or an 
acute tear/rupture  
Foot and ankle: 
 
 Achilles tendon 
 Tibialis posterior 








 Patellar tendon 
  
Elbow and wrist:  Wrist extensor tendon 
  
Shoulder: 
 Rotator cuff                     
Other: _____________________________   
(3b) Please tick which 
ligament/s you have 
injured? (next column on 
the tright) 
 
Also indicate if your 
sprained or completely 




 Shoulder ligaments 
 Elbow ligaments 
 Wrist ligaments   
 Finger ligaments 
 Knee (ACL)  
 Knee (MCL) 
 Knee (PCL) 
 Knee (LCL) 
 Ankle lateral ligaments 
 Ankle medial ligaments   
 Spinal  ligaments  




































(3c) Please tick if you have you ever 
suffered from any of the following joint 
capsule injuries? 
 Acute shoulder dislocation 
 Chronic shoulder instability 
 Other: _____________________________ 
(3d) Do you suffer from any other connective tissue 
or rheumatological diseases or disorders? (If yes, 
please specify which one) 
Yes    No   (refer to the list on the next page) 



















Discoid Lupus Erythematosus 
Ehlers-Danlos syndrome (EDS) 
Eosinophilic Fascitis 
Giant Cell (Temporal) Arthritis 
Gout 
Hypersentive Vasulatis 
Lipid Storage Diseases 
Marfan Syndrome 
Menkes Kinky Hair Syndrome 
Mucopolysaccharidoses 
Myopathies and Dystrophies  
Ochronosis (Homocystinuria) 
Osteogenesis imperfecta (OI) 
Polyarteritis Nodosa 
Polymyalgia Rheumatica 











4. Use of medicines to treat an injury before or during participation 
If you answered YES to question 4 in section F, please complete the following two questions related to medicine use 
for injuries before or during races. 
(4a) Which of the following 
medicines have you used in the 
past to treat an injury in the 
week just before a race? 
 Paracetamol (e.g. Panado, Tylenol)  
 Non-steroidal anti-inflammatories (e.g. Voltaren, Cataflam) 
 Cortisone (pills) 
 Cortisone injection 
 Codeine 
 Anti-inflammatory gels/creams/patches 
 Any other pain killers  (Specify: _____________________________) 
(4b) Which of the following 
medicines have you used in the 
past to treat an injury during a 
race? 
 Paracetamol (e.g. Panado, Tylenol)  
 Non-steroidal anti-inflammatories (e.g. Voltaren, Cataflam) 
 Cortisone (pills) 
 Cortisone injection 
 Codeine 
 Anti-inflammatory gels/creams/patches 














5. Gastrointestinal symptoms during exercise 
If you answered YES to question 5 in section F, please indicate which gastrointestinal symptoms you have ever suffered from during 
exercise and, how frequently (in the last 12 months and in the last 10 races), and in which type of exercise. 
Symptom 
Number of times 
you experienced 
the GIT symptom 
in the last 12 
months (during 
exercise) 
Number of times 
you experienced 
the GIT 
symptom in the 
last 10 races 
(during races) 
Please indicate 






Please indicate the “severity” of the GIT symptom 
during exercise 




 Does not affect training or racing 
 Affects training/racing (slow down or reduce time) 
 Prevents training/racing 




 Does not affect training or racing 
 Affects training/racing (slow down or reduce time) 
 Prevents training/racing 




 Does not affect training or racing 
 Affects training/racing (slow down or reduce time) 
 Prevents training/racing 




 Does not affect training or racing 
 Affects training/racing (slow down or reduce time) 
 Prevents training/racing 
Urge to pass a 




 Does not affect training or racing 
 Affects training/racing (slow down or reduce time) 
 Prevents training/racing 




 Does not affect training or racing 
 Affects training/racing (slow down or reduce time) 

















 Does not affect training or racing 
 Affects training/racing (slow down or reduce time) 
 Prevents training/racing 
Please indicate if you previously suffered from or had any of the following (you 
may tick more than one)? 
 History of heartburn  
 Gastroscopy 
 Ulcer (gastric, duodenal) 
 Irritable bowel syndrome 
 Allergy to milk products 
 Other past history of GIT disease 
 
6. Diseases of the nervous system 
If you answered YES to question 6 in section F, please indicate which nervous disease symptoms you have ever suffered from 
during exercise and, how frequently (in the last 12 months and in the last 10 races), and in which type of exercise. 
Symptom 
Number of times in 
the last 12 months 
(during exercise) 
Number of times in 
last 10 races 
(during races) 
Tick type of exercise 
Headaches              Swimming,  Cycling,  Running 
Nerve tingling in the 
hands 
             Swimming,  Cycling,  Running 
Loss of sensation in 















7. Allergy history 
If you answered YES to question 7 in section F, please complete the following questions (7a. to 7e.) related to your 
current and past history of allergies. 
(7a) Please indicate how long (years) have you been suffering from allergies? 
        years 
(7b) Please tick which type of allergy do you currently suffer from 
Nose (hay fever) Yes  No  Sinusitis Yes  No  
Asthma 
(allergic) Yes  No  
Skin allergies Yes  No  Eye allergies Yes  No  
Allergy to plant 
material Yes  No  
Allergy to foods Yes  No  Allergy to animals Yes  No  
Allergy to 
medication Yes  No  
(7c) Please tick which type of allergy do you currently take medication for 
Nose (hay fever) Yes  No  Sinusitis Yes  No  
Asthma 
(allergic) Yes  No  
Skin allergies Yes  No  Eye allergies Yes  No  
Allergy to plant 
material Yes  No  
Allergy to foods Yes  No  Allergy to animals Yes  No  
Allergy to 
medication Yes  No  
(7d) Please tick which type of medication do you currently take 
Cortisone nose 
spray 
Yes  No  
Cortisone nose 
inhaler Yes  No  
Anti-histamine 
tablets Yes  No  
Cortisone cream Yes  No  
Anti-histamine 
cream Yes  No  
Other inhaler / 
tablets or 
cream 
Yes  No  
(7e) Please tick which symptoms of allergy do you currently suffer from  
Sneezing Yes  No  Itchy runny nose Yes  No  Headache Yes  No  
Itchy palate Yes  No  Streaming eyes Yes  No  Fatigue Yes  No  
Itchy eyes Yes  No  Blocked nose Yes  No  Poor sleep Yes  No  
Post nasal drip Yes  No  Coughing Yes  No  Wheezing Yes  No  
In which months of the year do you 
currently have symptoms of allergies? 
(You tick more than one) 
 Jan   Feb     March    April  May     June    












(7f) Please tick which type of allergy did you suffer from in the past (NOT currently) 
Nose (hay fever) Yes  No  Sinusitis Yes  No  
Asthma 
(allergic) Yes  No  
Skin allergies Yes  No  Eye allergies Yes  No  
Allergy to plant 
material Yes  No  
Allergy to foods Yes  No  Allergy to animals Yes  No  
Allergy to 














8. Asthma history 
If you answered YES to question 8 in section F, please complete the following questions (8a. to 8k.) related to your 
current history of asthma 
(9a) Do you currently suffer from asthma? Yes  No  
(8b) How many years have you suffered from asthma?        (years) 
(8c) How was your asthma 
diagnosed?  
 A doctor taking a history and performing an examination 
 Lung function test (blow test) but no exercise 
 Lung function test (blow test) before and after exercise 
 Metacholine challenge test 
 Eucapnic hyperventilation test (rebreathing test) 
 Other test  (Specify:  ________________________) 
(8d) Which type of asthma do 
you currently suffer from? 
 Asthma that occurs at any time but not during exercise 
 Asthma that occurs at any time including during exercise 
 Asthma that only occurs during exercise 
(8e) Please indicate how 
frequently do you currently 
experience the symptoms of 
asthma (shortness of breath, 
wheezing, coughing or 
coughing after exercise)? 
Daytime symptoms (per week) 
 < 2 / week       2-4 / week        >4 / week          All the time 
Night time symptoms (per month) 
 < 1 / month       2-3 / month        >4 / month        All the time 
Exercise related symptoms (per 10 exercise sessions) 
 <1 per 10 sessions    2-3 per 10 sessions    >4 per 10 sessions 
(8f) Please indicate if you had 
symptoms of asthma that were 
severe enough to necessitate 
hospital admission in the last 
12 months 
 No hospital admission for asthma in the last 12 months  
 1-2 hospital admissions for asthma in the last 12 months  
 3-4 hospital admissions for asthma in the last 12 months  












(8g) Which symptoms of 
asthma do you currently suffer 
from? 
 Wheezing   Dry cough   Shortness of breath 
 Tight chest   Chest pain  
 Other (Specify: ________________________) 
(8h) What medication do you 
currently use for your asthma? 
(you may tick more than one 
option) 
 Cortisone inhaler (e.g. Beclate, Becloforte, Becodisks, Becotide, Budeflam, 
Flixotide, Inflammide, Pulmicort, Qvar, etc)   
 Salbutamol (bronchodilator) inhaler (e.g. Ventolin, Venteze, Vomax, Airomir, 
Asthavent etc.) 
 Salmeterol (bronchodilator) inhaler (Serevent) 
 Fenoterol (bronchodilator) inhaler (Berotec) 
 Terbutaline (bronchodilator) inhaler (Bricanyl) 
 Formoterol (bronchodilator) inhaler (e.g. Foradil, Foratec, Oxis) 
 Ipratropium (bronchodilator) inhaler (Atrovent) 
 Tiotropium (bronchodilator) inhaler (Spiriva) 
 Combined cortisone and bronchodilator  inhaler (e.g. Atrovent, Berodual, 
Combivent, Duolin, Duovent, Seretide, Symbicord)  
 Cortisone tablets 
 Bronchodilator tablets 
 Leukotriene receptor antagonist tablets (e.g. Acccolate, Singulair) 
 Other inhaler  
 Other medication (Specify: ________________________) 
(8i) When do you use your 
medication for your asthma? 
 Daily (irrespective of exercise)  Only before exercise 
 Other (Specify: ________________________) 
(8j) How long before an 
exercise session do you use 
your medication for asthma? 
      min 
(8k) Have you obtained TUE (therapeutic use exemption forms) for your asthma 
medication? 














9. History of previous collapse 
If you answered YES to question 9 in section F, please complete the following questions (9a. to 9d.) related to your 
current history of asthma 
(9a) Have you ever collapsed during training or racing? 
 Training     
 Racing     
 Training and racing     
(9b) How many times have you collapsed in training session or races 
during the last five years? 
_____  training session 
_____  races 
(9c) How many times have you collapsed in training session or races 
during the last 12 months (1 year)? 
 
(9d) When you collapse, does it mostly occur before of after the finish 
line / completion of the training session? 
 Before the finish 
 After the finish 
(9e) What is the cause of you 
collapse?  
 Dehydration 
 Heat illness 
 Hyponatremia 
 Low blood pressure  
 Low blood sugar 
 Other condition  (Specify:  ________________________) 












10. History of any current injury that you suffer from  
If you answered YES to question 11 in section F, please complete the following questions (10a. to 10g.) related to 
each of your current injury/ies (Space is provided for two injuries) 
 
Injury 1 
(10a) What was the approximate date when you first became aware of the 
injury?   
      Month             Year 
(10b) Please indicate which side of your body is injured (if applicable)  Right  Left 
(10c) Please indicate which anatomical area is 
currently injured 
 Head   Elbow  Hamstring  
 Neck   Forearm  Quadriceps 
 Face   Wrist  Knee 
 Front chest   Finger  Shin 
 Back chest    Lower back  Achilles 
 Shoulder   Hip   Ankle 
 Upper arm   Thigh  Foot 
Other (Specify:  ________________________) 
(10d) Please indicate the type of structure that 
was injured 
 Muscle   Ligament 
 Tendon   Joint 
 Bone 
Other (Specify:  ________________________) 
(10e) Please indicate in which sport (discipline) 
the injury occurred 
 Running   Cycling 
 Swimming 
Other (Specify:  ________________________) 
(10f) Please indicate 
the severity of the 
injury (tick one box 
please) 
 I only experience symptoms after exercise - Grade 1  
 I experience symptoms during exercise, but it does not interfere with exercise 
      - Grade 2    
 I experience symptoms during exercise that may interfere with my training/ 
      competition - Grade 3 












(10g) Please indicate how your injury was treated 
to date (you can tick more than one)? 
 Rest   Tablets  
 Stretches    Cortisone injection 
 Physiotherapy  Other injection 
 Surgery   Orthotics 
 Strengthening exercises 
 Equipment change 














(10a) What was the approximate date when you first became aware of the 
injury?   
      Month             Year 
(10b) Please indicate which side of your body is injured (if applicable)  Right  Left 
(10c) Please indicate which anatomical area is 
currently injured 
 Head   Elbow  Hamstring  
 Neck   Forearm  Quadriceps 
 Face   Wrist  Knee 
 Front chest   Finger  Shin 
 Back chest    Lower back  Achilles 
 Shoulder   Hip   Ankle 
 Upper arm   Thigh  Foot 
Other (Specify:  ________________________) 
(10d) Please indicate the type of structure that 
was injured 
 Muscle   Ligament 
 Tendon   Joint 
 Bone 
Other (Specify:  ________________________) 
(10e) Please indicate in which sport (discipline) 
the injury occurred 
 Running   Cycling 
 Swimming 
Other (Specify:  ________________________) 
(10f) Please indicate 
the severity of the 
injury (tick one box 
please) 
 I only experience symptoms after exercise - Grade 1  
 I experience symptoms during exercise, but it does not interfere with exercise 
      - Grade 2    
 I experience symptoms during exercise that may interfere with my training/ 
      competition - Grade 3 












(11g) Please indicate how your injury was treated 
to date (you can tick more than one)? 
 Rest   Tablets  
 Stretches    Cortisone injection 
 Physiotherapy  Other injection 
 Surgery   Orthotics 
 Strengthening exercises 
 Equipment change 





























UNIVERSITY OF CAPE TOWN 
• 
13 January 2006 
REC REF: 42512005 
Assoc Prof MP Schwellnus 
Department of Human Biology 
Health Sciences Faculty 
Research Ethics Committee 
Room E53-24 Groote Schuur Hospital Old Main Building 
Observatory 7925 
Telephone [021]406 6338 • Facsimile [021]406 6411 
e-mail: preaward@curie .uct. .ac.za 
UCTIMRC Research Unit for Exercise Science and Sports Medicine 
Medical School 
Dear Prof Schwellnus 
THE PORT ELIZABETH IRONMAN TRIATHLON 2006: MEDICAL CONSEQUENCES FOLLOWING 
ENDURANCE SPORTS. 
Thank you for your letter to the Research Ethics Committee dated 14 December 2005, addressing the 
issues raised by the committee. It is a pleasure to inform you that the Ethics Committee has formally 
approved the above mentioned study. 
















UNIVERSITY OF C\J>E TOWN , 
09 February 21107 
REC REF: 002/2007 
Prof M Schwellnu. 
Human Biology 
Dear Prof Schwellirus 
Health Sciences F acWry 
Research Ethics Committee 
Room E52-24 Groote Schuu. Hospital Old Main Building 
Obsenatoty 7925 
Telepboae (021)406 6338 • Facsimile [021) 406 Mll 
e-mail: rJrca.wanI@curic-.un .. ac.?3 
PROjECI' TITLE: THE PORT ELIZABETH mONMAN TRIATIn.ON 2007: MEDICAL 
CONSEQUENCES FOILOWING ENDURANCE SPORTS 
Thank you for your letter In the Resean:h Ethics Committee dated 07 February 2007. 
It is a pleasure to infonn yon that the Ethics Committee has fonaaJly approved the above-mentioned study. 
Your comments to the queries ru.ed are noted With thanks. 
This serve. to confinn that the University of Cape Town Researcb Ethics Cotntnittee complies to the Ethics 
Standards for Clinical Reseattb with a new drug in paU=ts, based on the Medical Research Council (J.'IRC-
SA), Food and Drug Administration (FDA-USA), International Convention 00 
Harmonisation Good Clinical Practice (lCH Gcp) and Droaratinn of Helsinki guidelines. 
The Reseatth Ethics Committee granting this approval is in compl:iauce with the ICH Hannonised Tripartite 
Guiddines E6: Note for Guidance on Good Clinical Pmctice (CPMP/ICH/13S/95) and FDA Code Federal 
Regulation Part 50,56 and 312 
Please note that ongoing ethical conduct of the study remains the resporunl>!lity of the principal invesrigator. 
Please quote the REe. REF in ail your ~ce. 
Youts sincerely 
A/PROF. M. BLOCKMAN 
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